var title_f5_45_5840="Hemostats applied to foreskin";
var content_f5_45_5840=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemostats applied to foreskin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_45_5840=[""].join("\n");
var outline_f5_45_5840=null;
var title_f5_45_5841="Type II AC joint sprain PI";
var content_f5_45_5841=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F67478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F67478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Type II acromioclavicular joint sprain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 440px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_45_5841=[""].join("\n");
var outline_f5_45_5841=null;
var title_f5_45_5842="Contents: HIV infection";
var content_f5_45_5842=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?15/21/15710\">",
"       Infectious Diseases",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       HIV infection",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			HIV infection",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/55/20345\">",
"           Diagnostic assays for HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/20/16712\">",
"           Screening laboratory tests in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/34/10793\">",
"           Serologic screening for HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/44/39623\">",
"           Techniques and interpretation of HIV-1 RNA quantitation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/52/21320\">",
"           Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug resistance",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/46/3814\">",
"           Clinical trials of HIV drug resistance testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/42/32424\">",
"           Drug resistance testing in the clinical management of HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/48/4873\">",
"           Overview of HIV drug resistance testing assays",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/26/34218\">",
"           Primer on interpretation of HIV drug resistance testing",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/46/13030\">",
"           Clinical manifestations and diagnosis of HIV-2 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/61/12249\">",
"           Dementia and delirium in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/13/12504\">",
"           Depression, mania, and schizophrenia in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/26/39332\">",
"           Electrolyte disturbances with HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/28/38343\">",
"           Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/61/24538\">",
"           Fever and rash in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/44/26313\">",
"           HIV and the older patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/25/37273\">",
"           Immunizations in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/34/5674\">",
"           Immunology of HIV-1 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/37/42584\">",
"           Management of tissue wasting in patients with HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/44/5831\">",
"           Overview of the neuropsychiatric aspects of HIV infection and AIDS",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/50/11047\">",
"           Pneumococcal immunization in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/54/26474\">",
"           Primary care of HIV-infected adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/42/33450\">",
"           Primary prevention of opportunistic infections in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/61/15321\">",
"           Solid organ transplantation in HIV-infected individuals",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/31/2551\">",
"           Substance abuse and addiction in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/29/42456\">",
"           Surgical issues in HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/5/26713\">",
"           Treatment of HIV-2 infection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         HIV and malignancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/52/12103\">",
"           AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/37/18009\">",
"           AIDS-related Kaposi sarcoma: Staging and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/4/7242\">",
"           AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/36/20042\">",
"           AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/9/7321\">",
"           AIDS-related lymphomas: Primary central nervous system lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/15/30969\">",
"           AIDS-related lymphomas: Primary effusion lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/28/38346\">",
"           AIDS-related lymphomas: Treatment of systemic lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/36/27206\">",
"           HIV infection and malignancy: Epidemiology and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/14/18665\">",
"           Preinvasive and invasive cervical neoplasia in HIV-infected women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/7/21623\">",
"           Pulmonary involvement in AIDS-related Kaposi sarcoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/33/9750\">",
"           Pulmonary manifestations of HIV-associated lymphoma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         HIV and specific organisms",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/62/22504\">",
"           AIDS-related cytomegalovirus gastrointestinal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/28/7623\">",
"           AIDS-related cytomegalovirus neurologic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/5/15449\">",
"           Bacterial pulmonary infections in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/42/38568\">",
"           Clinical management and monitoring during antifungal therapy of the HIV-infected patient with cryptococcal meningoencephalitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/25/7577\">",
"           Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/41/19093\">",
"           Cytomegalovirus infection as a cause of pulmonary disease in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/58/11178\">",
"           Diagnosis and treatment of invasive pulmonary aspergillosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/46/12009\">",
"           Diagnosis of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/63/39924\">",
"           Epidemiology and clinical manifestations of histoplasmosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/28/35270\">",
"           Epidemiology and clinical manifestations of pulmonary aspergillosis and invasive disease in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/13/18649\">",
"           Epidemiology of tuberculosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/61/40919\">",
"           Epidemiology, clinical manifestations, and diagnosis of cryptococcal meningoencephalitis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/55/7033\">",
"           Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/10/1194\">",
"           Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/8/3209\">",
"           HIV and malaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/55/38777\">",
"           Mycobacterium avium complex (MAC) infections in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/9/15512\">",
"           Overview of nontuberculous mycobacteria (excluding MAC) in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/29/36310\">",
"           Parasitic pulmonary infections in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/51/37688\">",
"           Pathogenesis, clinical manifestations, and diagnosis of AIDS-related cytomegalovirus retinitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/52/2889\">",
"           Prophylaxis against Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/22/33129\">",
"           Toxoplasmosis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/1/13337\">",
"           Treatment of AIDS-related cytomegalovirus retinitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/60/27593\">",
"           Treatment of Pneumocystis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/23/23929\">",
"           Treatment of cryptococcal meningoencephalitis in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/12/4298\">",
"           Treatment of latent tuberculosis infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/35/19002\">",
"           Treatment of pulmonary tuberculosis in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/47/22261\">",
"           Tuberculous pleural effusions in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         HIV and specific organs/tissues",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/29/26069\">",
"           AIDS cholangiopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/10/41128\">",
"           Approach to HIV-infected patients with central nervous system lesions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/43/20154\">",
"           Approach to the HIV-infected patient with pulmonary symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/35/32313\">",
"           Bone and calcium disorders in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/40/25226\">",
"           Cardiac involvement in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/40/38536\">",
"           Clinical trials in treatment of chronic hepatitis C virus infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/12/27848\">",
"           Diagnosis, treatment and prognosis of HIV-associated neuropathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/44/37575\">",
"           Emphysema-like disease in HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/1/26650\">",
"           Epidemiology of cardiovascular disease and risk factors in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/43/26298\">",
"           Epidemiology, clinical manifestations, and diagnosis of HIV-associated lipodystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/56/29577\">",
"           Epidemiology, clinical manifestations, diagnosis, and treatment of HIV-associated peripheral neuropathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/32/30218\">",
"           Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/1/35864\">",
"           Epidemiology, pathogenesis and clinical features of HIV-associated neuropathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/3/63\">",
"           Evaluation of abdominal pain in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/25/11670\">",
"           Evaluation of the HIV-infected patient with anorectal symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/36/11848\">",
"           Evaluation of the HIV-infected patient with chronic hepatitis C virus infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/41/38551\">",
"           Evaluation of the HIV-infected patient with diarrhea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/62/21480\">",
"           Evaluation of the HIV-infected patient with hepatobiliary complaints",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/38/4707\">",
"           Evaluation of the HIV-infected patient with odynophagia and dysphagia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/50/24359\">",
"           HIV-associated eosinophilic folliculitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/1/3098\">",
"           Hematologic manifestations of HIV infection: Anemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/0/44039\">",
"           Hematologic manifestations of HIV infection: Neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/11/14522\">",
"           Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/34/34344\">",
"           Human immunodeficiency virus and dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/26/30120\">",
"           Hypogonadism in HIV-infected males",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/3/49\">",
"           Management of dyslipidemia and cardiovascular risk in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/31/36345\">",
"           Monitoring the HIV-infected patient taking hepatitis C therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/37/4695\">",
"           Muscle disease in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/28/40392\">",
"           Pathogenesis and biomarkers of cardiovascular disease in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/50/22312\">",
"           Pituitary and adrenal gland dysfunction in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/27/23993\">",
"           Pleural effusions in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/58/40870\">",
"           Predictors of response to hepatitis C treatment in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/31/38388\">",
"           Thyroid gland dysfunction in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/36/44617\">",
"           Treatment of HIV-associated lipodystrophy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/38/18026\">",
"           Treatment of hepatitis C virus infection in the HIV-infected patient",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Natural history and epidemiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/39/24186\">",
"           Factors affecting HIV progression",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/35/16954\">",
"           HIV and women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/44/1737\">",
"           The adolescent with HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/2/21546\">",
"           The global human immunodeficiency virus pandemic",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/2/13353\">",
"           The stages and natural history of HIV infection",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prevention",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/21/29016\">",
"           Effect of herpes simplex virus on HIV infection: Implications for HIV prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/12/28872\">",
"           Epidemiology, clinical manifestations, and diagnosis of genital herpes simplex virus in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/24/19848\">",
"           HIV treatment as prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/47/7930\">",
"           Management of healthcare personnel exposed to HIV",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/4/13384\">",
"           Non-antiretroviral interventions to reduce perinatal HIV transmission in the developing world",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/50/26410\">",
"           Nonoccupational exposure to HIV in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/15/34041\">",
"           Pre-exposure prophylaxis against HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/23/29050\">",
"           Prevention of HIV transmission during breastfeeding in resource-limited settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/14/34024\">",
"           Treatment of drug-resistant genital herpes simplex virus infection in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/52/41799\">",
"           Treatment of genital herpes simplex virus type 2 in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Primary HIV infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/7/43129\">",
"           Acute and early HIV infection: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/46/18151\">",
"           Acute and early HIV infection: Pathogenesis and epidemiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/17/22808\">",
"           Acute and early HIV infection: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Transmission",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/29/42456\">",
"           Surgical issues in HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/28/31175\">",
"           Transfusion transmitted HIV infection and AIDS",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/34/10794\">",
"           Adverse effects of antiretroviral therapy in developing countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/30/24037\">",
"           Antiretroviral medications in pregnancy: Entry and integrase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/60/16328\">",
"           Antiretroviral medications in pregnancy: Non-nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/53/42841\">",
"           Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/24/18825\">",
"           Antiretroviral medications in pregnancy: Protease inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/13/31956\">",
"           Clinical trials of HIV antiretroviral therapy: Agents in advanced stages of development",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/19/37173\">",
"           Clinical trials of HIV antiretroviral therapy: Boosted protease inhibitor monotherapy studies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/9/32918\">",
"           Clinical trials of HIV antiretroviral therapy: CCR5 antagonists",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/1/11286\">",
"           Clinical trials of HIV antiretroviral therapy: Early clinical trials (1987 to 1996)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/34/7720\">",
"           Clinical trials of HIV antiretroviral therapy: Integrase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/4/9287\">",
"           Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/16/17672\">",
"           Clinical trials of HIV antiretroviral therapy: Protease inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/27/14774\">",
"           Clinical trials of HIV antiretroviral therapy: Protease inhibitors versus non-nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/57/33682\">",
"           Clinical trials of HIV antiretroviral therapy: Three versus four-drug regimens",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/5/10325\">",
"           Clinical trials of HIV antiretroviral therapy: Triple regimens using nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/46/3814\">",
"           Clinical trials of HIV drug resistance testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/18/3370\">",
"           Considerations prior to initiating antiretroviral therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/61/986\">",
"           Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/29/12759\">",
"           Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/42/32424\">",
"           Drug resistance testing in the clinical management of HIV infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/32/40458\">",
"           HIV protease inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/35/23098\">",
"           Immune reconstitution inflammatory syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/40/30345\">",
"           Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/26/36265\">",
"           Modifying HIV antiretroviral therapy regimens",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/48/4873\">",
"           Overview of HIV drug resistance testing assays",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/17/38167\">",
"           Patient monitoring during HIV antiretroviral therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/56/11144\">",
"           Pharmacology of integrase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/18/37162\">",
"           Pharmacology of non-nucleoside reverse transcriptase inhibitors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/4/15433\">",
"           Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/24/36234\">",
"           Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/51/10039\">",
"           Structured treatment interruptions in the HIV-infected patient",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/6/39018\">",
"           The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-limited settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/12/29898\">",
"           The impact of antiretroviral therapy on morbidity and mortality of HIV infection in resource-rich countries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/45/33494\">",
"           Treatment and prevention of mitochondrial toxicity in HIV-infected patients",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/5/26713\">",
"           Treatment of HIV-2 infection",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/39/37495\">",
"           Treatment of HIV-infected adults who have trouble swallowing pills: Liquid, chewable, and crushable formulations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/44/25290\">",
"           Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/35/9786\">",
"           When to initiate antiretroviral therapy in HIV-infected patients",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-757E74A1CE-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f5_45_5842=[""].join("\n");
var outline_f5_45_5842=null;
var title_f5_45_5843="Rosacea papules and pustules PI";
var content_f5_45_5843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F60054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F60054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rosacea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This person with rosacea has raised, red bumps (called \"papules\") and raised, red bumps with pus in them (called \"pustules\") on the nose and cheeks.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_45_5843=[""].join("\n");
var outline_f5_45_5843=null;
var title_f5_45_5844="Lumbar burst fracture";
var content_f5_45_5844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 503px\">",
"   <div class=\"ttl\">",
"    Lumbar burst fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 483px; height: 512px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anteroposterior (A) and lateral (B) radiographs demonstrating a L3 burst fracture with retropulsion of bony fragments into the spinal canal noted on an axial CT image (C).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Whang PW, Vaccaro AR. Fractures and dislocations of the thoracolumbar spine. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RB, (ed), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_45_5844=[""].join("\n");
var outline_f5_45_5844=null;
var title_f5_45_5845="Nadroparin: Patient drug information";
var content_f5_45_5845=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nadroparin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/41/27286?source=see_link\">",
"     see \"Nadroparin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F199025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Fraxiparine&trade;;",
"     </li>",
"     <li>",
"      Fraxiparine&trade; Forte",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700437",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       People who have had recent spinal anesthesia, epidurals, or spinal taps are more likely to have bleeding problems when started on this drug. This bleeding rarely happens, but can be very bad. Tell your doctor if you have had any spinal care. Do not take any other blood-thinner drugs including nonsteroidal anti-inflammatory drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705929",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor you use this drug before you get spinal anesthesia or a spinal treatment.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to thin the blood so that clots will not form.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nadroparin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703348",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding problems, a heart infection called endocarditis, low platelet count, recent surgery of the eye or brain, very bad kidney disease, or very high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you know that you will not take the drug as you have been told.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697216",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have eye problems from high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697760",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care to stop injury and avoid falls or crashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697901",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fall or crash when you hit your head. Talk with your doctor even if you feel fine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Move the site where you give the shot with each shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12037 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-122.72.76.133-791DB7C3D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_45_5845=[""].join("\n");
var outline_f5_45_5845=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199025\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028789\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028791\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028790\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028795\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028796\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028798\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028793\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028794\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028799\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028800\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?26/41/27286?source=related_link\">",
"      Nadroparin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_45_5846="Rotigotine: Drug information";
var content_f5_45_5846=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rotigotine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/54/18277?source=see_link\">",
"    see \"Rotigotine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14699479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neupro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F4801855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-Parkinson's Agent, Dopamine Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F4801889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Parkinson&rsquo;s disease:",
"     </b>",
"     Topical: Transdermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Early-stage:",
"     </i>",
"     Initial: Apply 2 mg/24 hours patch once daily; may increase by 2 mg/24 hours weekly, based on clinical response and tolerability; lowest effective dose: 4 mg/24 hours (maximum dose: 6 mg/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Advanced-stage:",
"     </i>",
"     Initial: Apply 4 mg/24 hours patch once daily; may increase by 2 mg/24 hours weekly, based on clinical response and tolerability (maximum dose: 8 mg/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Discontinuation of treatment in Parkinson&rsquo;s disease:",
"     </i>",
"     Decrease by &le;2 mg/24 hours preferably every other day until withdrawal complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Restless legs syndrome (RLS):",
"     </b>",
"     Topical: Transdermal: Initial: Apply 1 mg/24 hours patch once daily; may increase by 1 mg/24 hours weekly, based on clinical response and tolerability; lowest effective dose: 1 mg/24 hours (maximum dose: 3 mg/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Discontinuation of treatment for RLS:",
"     </i>",
"     Decrease by 1 mg/24 hours preferably every other day until withdrawal complete",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F4801890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F4801891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mild-to-severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;15 mL/minute): No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F4801892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Mild-to-moderate hepatic impairment (Child-Pugh class A or B): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Severe hepatic impairment: No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F14699480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal [once-daily patch]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neupro&reg;: 1 mg/24 hours (30s) [contains metal, sodium metabisulfite; 5 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total rotigotine 2.25 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neupro&reg;: 2 mg/24 hours (30s) [contains metal, sodium metabisulfite; 10 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total rotigotine 4.5 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neupro&reg;: 3 mg/24 hours (30s) [contains metal, sodium metabisulfite; 15 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total rotigotine 6.75 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neupro&reg;: 4 mg/24 hours (30s) [contains metal, sodium metabisulfite; 20 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total rotigotine 9 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neupro&reg;: 6 mg/24 hours (30s) [contains metal, sodium metabisulfite; 30 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total rotigotine 13.5 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neupro&reg;: 8 mg/24 hours (30s) [contains metal, sodium metabisulfite; 40 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total rotigotine 18 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F4801854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4801893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Transdermal patch: Apply patch to clean, dry, hairless area of intact healthy skin on the front of the abdomen, thigh, hip, flank, shoulder, or upper arm at approximately the same time daily. Remove from pouch immediately before use and press patch firmly in place on skin for 30 seconds. Application sites should be rotated on a daily basis. Do not apply to same application site more than once every 14 days or apply patch to oily, irritated or damaged skin. Avoid exposing patch to external heat sources (eg, heating pad, electric blanket, heat lamp, hot tub, direct sunlight). If applied to hairy area, shave &ge;3 days prior to applying patch. If patch falls off, immediately apply a new one to a new site.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3335289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of the signs and symptoms of idiopathic Parkinson's disease (early-stage to advanced-stage disease); treatment of moderate-to-severe primary restless legs syndrome (RLS)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4801851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sound-alike/look-alike issues:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neupro&reg; may be confused with Neupogen&reg;",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Transdermal patch contains metal (eg, aluminum); remove patch prior to MRI or cardioversion",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F4801866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (dose related; 2% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Somnolence (dose related; 5% to 32%), dizziness (5% to 23%), headache (8% to 18%), fatigue (6% to 18%), orthostatic hypotension (1% to 18%), sleep disorder (disturbance in initiating/maintaining sleep; dose related; 2% to 14%), hallucinations (dose related; 7% to 14%), insomnia (5% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Application site reactions (dose related; 27% to 46%), hyperhidrosis (dose related; 1% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (dose related; 15% to 48%), vomiting (dose related; 2% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Dyskinesia (dose related; 14% to 17%), arthralgia (8% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (dose related; 1% to 5%), T-wave abnormalities on ECG (&le;3%), syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Abnormal dreams (dose related; 1% to 7%), nightmare (dose related; 3% to 5%), depression (&le;5%), vertigo (1% to 4%), early morning awakening (dose related; &le;3%), balance disorder (2% to 3%), lethargy (1% to 2%), postural dizziness (1% to 2%), sleep attacks (dose related; &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (3% to 7%), erythema (dose related; &le;6%), pruritic rash (dose related; &le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hot flash (&le;3%), serum ferritin decreased (dose related; 1% to 2%); serum glucose decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Constipation (2% to 9%), weight gain (2% to 9%), diarrhea (5% to 7%), anorexia (&le;8%), xerostomia (dose related; 3% to 7%), appetite decreased (&le;3%), dyspepsia (dose related; &le;3%), weight loss (dose related; &le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Erectile dysfunction (dose related; &le;3%), urinary WBC positive (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Contusion (dose related; &le;4%), hemoglobin decreased, hematocrit decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (dose related 5% to 6%), tremor (3% to 4%), weakness (3% to 4%), muscle spasms (dose related; 1% to 4%), musculoskeletal pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Vision changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Otic: Tinnitus (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: BUN increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasopharyngitis (7% to 10%), upper respiratory tract infection (&le;5%), cough (3%), nasal congestion (3%), sinus congestion (2% to 3%), sinusitis (dose related; &le;3%), pharyngolaryngeal pain (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Hiccups (dose related; 2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Agitation, aggression, confusion, delirium, delusions, disorientation, generalized skin reaction, impulsive/compulsive behaviors (eg, binge eating, hypersexuality, pathological gambling, shopping), paranoid ideation, psychotic-like behavior",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F4801861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to rotigotine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4801862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Application site reactions: Dose-dependent application site reactions, potentially severe, have been observed; daily rotation of application sites has been shown to decrease incidence of reactions. If a generalized (nonapplication site) skin reaction occurs; discontinue therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Fibrosis: Rare cases of pleural effusion, pleural thickening, pulmonary infiltrates, retroperitoneal fibrosis, pericarditis and/or cardiac valvulopathy have been reported in patients treated with ergot-derived dopamine agonists, generally with prolonged use. The potential of rotigotine, a nonergot derived dopamine agonist, to cause similar fibrotic complications is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Fluid retention: Weight gain and fluid retention have been reported, primarily associated with development of peripheral edema in Parkinson&rsquo;s disease patients; use caution in patients with heart failure or renal insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hallucinations/psychotic-like behavior: May cause hallucinations (dose-related) and other psychotic-like behaviors (eg, agitation, delirium, delusions, aggression). In general, avoid use in patients with pre-existing major psychotic disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impulse control disorders: Dopamine agonists used for Parkinson&rsquo;s disease or restless legs syndrome have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), and/or binge eating. Causality has not been established, and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/addictions and/or drug therapy. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Melanoma: Risk for melanoma development is increased in Parkinson&rsquo;s disease patients; drug causation or factors contributing to risk have not been established. Patients receiving therapy for any indication should be monitored closely and periodic skin examinations should be performed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Orthostatic hypotension: Dopamine agonists may cause orthostatic hypotension and syncope; Parkinson&rsquo;s disease patients appear to have an impaired capacity to respond to a postural challenge. Use with caution in patients at risk of hypotension (such as those receiving antihypertensive drugs) or where transient hypotensive episodes would be poorly tolerated (cardiovascular disease or cerebrovascular disease). Parkinson&rsquo;s and RLS patients being treated with dopaminergic agonists ordinarily require careful monitoring for signs and symptoms of postural hypotension, especially during dose escalation, and should be informed of this risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Somnolence: Use is commonly associated with somnolence. In addition, falling asleep during activities of daily living, including while driving, has also been reported and may occur without significant warning signs. Monitor for daytime somnolence or pre-existing sleep disorder. Patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Use with caution in patients receiving other CNS depressants or psychoactive agents; discontinue if significant daytime sleepiness or episodes of falling asleep occur. Effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with pre-existing cardiovascular disease; therapy has been associated with  increases in blood pressure (as well as orthostatic hypotension), which may be significant (&gt;40 mm Hg or &ge;20 mm Hg increase in systolic or diastolic measurements, respectively), increased heart rate, syncope, and weight gain/fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dyskinesia: Use with caution in patients with pre-existing dyskinesia; therapy may exacerbate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Restless legs syndrome (RLS): Augmentation (earlier onset of symptoms each day and/or an overall increase in symptom severity) or rebound (considered to be an end of dose effect) may occur in some patients with RLS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Aluminum: Patch contains aluminum; remove patch prior to magnetic resonance imaging or cardioversion to avoid skin burns.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Heat application: Avoid exposure of application site to any direct external heat sources (eg, hair dryers, heating pads, electric blankets, saunas, hot tubs, direct sunlight); heat exposure has not been studied with the rotigotine patch, but an increase in the rate and extent of absorption has been observed with other transdermal products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sulfites: Patch contains sodium metabisulfite which may cause allergic reaction in susceptible individuals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Discontinuation of therapy: Taper treatment when discontinuing therapy; do not stop abruptly. Other dopaminergic agents have been associated with a syndrome resembling neuroleptic malignant syndrome on withdrawal and/or significant dosage reduction.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F14192539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F4801872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Atypical): May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist). Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics (Typical): Anti-Parkinson's Agents (Dopamine Agonist) may diminish the therapeutic effect of Antipsychotics (Typical). Antipsychotics (Typical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Avoid concomitant therapy if possible and monitor for decreased effects of both agents when these combinations cannot be avoided. Atypical antipsychotics such as clozapine and quetiapine may be less likely to reduce the effects of anti-Parkinson's agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4801875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F4801856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4801857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F4801859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4801860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolactin secretion is decreased and lactation may be inhibited.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570474\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch, 24-hour",
"     </b>",
"     (Neupro Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/24 hrs (30): $153.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/24 hrs (30): $153.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg/24 hrs (30): $153.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg/24 hrs (30): $450.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg/24 hrs (30): $450.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg/24 hrs (30): $450.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F4801895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure (including orthostatic); daytime alertness; periodic skin evaluations (melanoma development)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Neupro (AT, AU, BE, CH, CZ, DE, DK, EE, ES, FR, GB, GR, HK, IE, IT, KP, MY, NL, NO, PL, PT, SE, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F4801878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rotigotine is a nonergot dopamine agonist with specificity for D",
"     <sub>",
"      3",
"     </sub>",
"     -, D",
"     <sub>",
"      2",
"     </sub>",
"     -, and D",
"     <sub>",
"      1",
"     </sub>",
"     -dopamine receptors. Although the precise mechanism of action of rotigotine is unknown, it is believed to be due to stimulation of postsynaptic dopamine D",
"     <sub>",
"      2",
"     </sub>",
"     -type auto receptors within the substantia nigra in the brain, leading to improved dopaminergic transmission in the motor areas of the basal ganglia, notably the caudate nucleus/putamen regions.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4801880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 84 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensive via conjugation and N-dealkylation; multiple CYP isoenzymes, sulfotransferases, and two UDP-glucuronosyltransferases involved in catalyzing the metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: After removal of patch: ~5-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 15-18 hours; can occur 4-27 hours post application",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (~71% as inactive conjugates and metabolites, &lt;1% as unchanged drug); feces (~23%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Factor SA, &ldquo;Current Status of Symptomatic Medical Therapy in Parkinson&rsquo;s Disease,&rdquo;",
"      <i>",
"       Neurotherapeutics",
"      </i>",
"      , 2008, 5(2):164-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/45/5846/abstract-text/18394561/pubmed\" id=\"18394561\" target=\"_blank\">",
"        18394561",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Molina JA, S&agrave;inz-Artiga MJ, Fraile A, et al, &ldquo;Pathologic Gambling in Parkinson's Disease: A Behavioral Manifestation of Pharmacologic Treatment,&rdquo;",
"      <i>",
"       Mov Disord",
"      </i>",
"      , 2000, 15(5):869-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/45/5846/abstract-text/11009192/pubmed\" id=\"11009192\" target=\"_blank\">",
"        11009192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reichmann H, Bilsing A, Ehret R, et al, &ldquo;Ergoline and Non-Ergoline Derivatives in the Treatment of Parkinson&rsquo;s Disease,&rdquo;",
"      <i>",
"       J Neurol",
"      </i>",
"      , 2006, 253(Suppl 4):36-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/45/5846/abstract-text/16944356/pubmed\" id=\"16944356\" target=\"_blank\">",
"        16944356",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reynolds NA, Wellington K, and Easthope SE, &ldquo;Rotigotine in Parkinson&rsquo;s Disease,&rdquo;",
"      <i>",
"       CNS Drugs",
"      </i>",
"      , 2005, 19(11):973-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/45/5846/abstract-text/16268667/pubmed\" id=\"16268667\" target=\"_blank\">",
"        16268667",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weintraub D, Siderowf AD, Potenza MN, et al, &ldquo;Association of Dopamine Agonist Use With Impulse Control Disorders in Parkinson Disease,&rdquo;",
"      <i>",
"       Arch Neurol",
"      </i>",
"      , 2006, 63(7):969-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/45/5846/abstract-text/16831966/pubmed\" id=\"16831966\" target=\"_blank\">",
"        16831966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83322 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-F7CC41E664-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_45_5846=[""].join("\n");
var outline_f5_45_5846=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14699479\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801855\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801889\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801890\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801891\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801892\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14699480\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801854\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801893\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3335289\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801851\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801866\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801861\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801862\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14192539\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801872\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801875\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801856\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801857\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801859\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801860\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570474\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801895\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302646\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801878\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4801880\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83322\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/83322|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/54/18277?source=related_link\">",
"      Rotigotine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_45_5847="Acetaminophen, caffeine, and dihydrocodeine: Drug information";
var content_f5_45_5847=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetaminophen, caffeine, and dihydrocodeine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/43/3765?source=see_link\">",
"    see \"Acetaminophen, caffeine, and dihydrocodeine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13136418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Trezix&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F129452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic Combination (Opioid)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F129443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Relief of pain:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule (acetaminophen 356.4 mg, caffeine 30 mg, and dihydrocodeine bitartrate 16 mg): Two capsules every 4 hours as needed; adjust dose based on severity of pain (maximum dose: 10 capsules/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet (acetaminophen 712.8 mg, caffeine 60 mg, and dihydrocodeine bitartrate 32 mg): One tablet every 4 hours as needed; adjust dose based on severity of pain (maximum dose: 5 tablets/24 hours)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2525228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F129429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trezix&trade;: Acetaminophen 356.4 mg, caffeine 30 mg, and dihydrocodeine bitartrate 16 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: Acetaminophen 712.8 mg, caffeine 60 mg, and dihydrocodeine bitartrate 32 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F129419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F129454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F129430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of moderate to moderately-severe pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5118568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Panlor&reg; may be confused with Pamelor&trade;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F129450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined. Most common reactions with this combination include:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, lightheadedness, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, skin reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F129432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acetaminophen, caffeine, dihydrocodeine, codeine, or any component of the formulation; significant respiratory depression (in unmonitored settings); acute or severe bronchial asthma; hypercapnia; paralytic ileus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F129421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Acetaminophen may cause severe hepatotoxicity, potentially requiring liver transplant or resulting in death; hepatotoxicity is usually associated with excessive acetaminophen intake (&gt;4 g/day).",
"     </b>",
"     Risk is increased with alcohol use, pre-existing liver disease, and intake of more than one source of acetaminophen-containing medications. Chronic daily dosing in adults has also resulted in liver damage in some patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactic reactions: Hypersensitivity and anaphylactic reactions have been reported with acetaminophen use; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur. Use with caution in patients with hypersensitivity reactions to other phenanthrene-derivative opioid agonists (hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Use with caution in patients with alcoholic liver disease; consuming &ge;3 alcoholic drinks/day may increase the risk of liver damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with known G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Use with caution in patients with hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory diseases including asthma, emphysema, and/or COPD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; MAO inhibitors: Use with caution with concurrent use of MAO inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Caffeine: May cause CNS and cardiovascular stimulation, as well as GI irritation in high doses. Use with caution in patients with a history of peptic ulcer or GERD; avoid in patients with symptomatic cardiac arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dosage limit: Limit acetaminophen dose from all sources (prescription and OTC) to &lt;4 g/day.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F129448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F129424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: Caffeine may diminish the therapeutic effect of Adenosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Acetaminophen may increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Formoterol: Caffeine may enhance the adverse/toxic effect of Formoterol. Caffeine may enhance the hypokalemic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: Caffeine may enhance the adverse/toxic effect of Indacaterol. Caffeine may enhance the hypokalemic effect of Indacaterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May diminish the analgesic effect of Dihydrocodeine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May decrease the metabolism of Caffeine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Gemifloxacin; Levofloxacin (Systemic); Lomefloxacin; Moxifloxacin (Systemic); Nalidixic Acid; Ofloxacin (Systemic); Sparfloxacin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regadenoson: Caffeine may diminish the vasodilatory effect of Regadenoson.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Teriflunomide: May decrease the serum concentration of Caffeine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F129438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Ethanol: Excessive intake of ethanol may increase the risk of acetaminophen-induced toxicity. Ethanol may also increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F129426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F129434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. Birth defects, including some heart defects, have been associated with maternal use of opioid analgesics during the first trimester of pregnancy (Broussard, 2011). Use of opioids during pregnancy may produce physical dependence in the neonate (Rathmell, 1997). Dihydrocodeine is a semisynthetic analogue of codeine; it has been shown to cause respiratory depression in the fetus when administered to women during labor (Leppert, 2010; Myers, 1958; Sliom, 1970). Also refer to the acetaminophen and caffeine monographs for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F129444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F129435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acetaminophen, caffeine, and dihydrocodeine are excreted in breast milk. Also refer to the acetaminophen and caffeine monographs for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F129433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Trezix Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     356.4-30-16 mg (100): $262.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (APAP-Caff-Dihydrocodeine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     712.8-60-32 mg (30): $52.08",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F129420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acetaminophen inhibits the synthesis of prostaglandins in the central nervous system and peripherally blocks pain impulse generation; produces antipyresis from inhibition of hypothalamic heat-regulating center.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caffeine is a CNS stimulant; use with acetaminophen and dihydrocodeine increases the level of analgesia provided by each agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dihydrocodeine binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; produces generalized CNS depression.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, &ldquo;Potentiation of Oral Anticoagulant Therapy by Acetaminophen,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/45/5847/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, &ldquo;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/45/5847/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, &ldquo;Potentiation of Warfarin Anticoagulation by Acetaminophen,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/45/5847/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, &ldquo;Interaction Between Paracetamol and Coumarin Anticoagulants,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/45/5847/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Broussard CS, Rasmussen SA, Reefhuis J, et al, \"Maternal Treatment With Opioid Analgesics and Risk for Birth Defects,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      ,  2011, 204(4):314.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/45/5847/abstract-text/21345403/pubmed\" id=\"21345403\" target=\"_blank\">",
"        21345403",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &ldquo;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&rdquo;",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/45/5847/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &ldquo;Warfarin and Acetaminophen Interaction,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/45/5847/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, &ldquo;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/45/5847/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, &ldquo;The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leppert W, \"Dihydrocodeine as an Opioid Analgesic for the Treatment of Moderate to Severe Chronic Pain,\"",
"      <i>",
"       Curr Drug Metab",
"      </i>",
"      , 2010, 11(6):494-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/45/5847/abstract-text/20540693/pubmed\" id=\"20540693\" target=\"_blank\">",
"        20540693",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Myers JD, \"A Preliminary Clinical Evaluation of Dihydrocodeine Bitartrate in Normal Parturition,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1958, 75(5):1096-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/45/5847/abstract-text/13520835/pubmed\" id=\"13520835\" target=\"_blank\">",
"        13520835",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rathmell JP, Viscomi CM, and Ashburn MA, \"Management of Nonobstetric Pain During Pregnancy and Lactation,\"",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1997, 85(5):1074-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/45/5847/abstract-text/9356103/pubmed\" id=\"9356103\" target=\"_blank\">",
"        9356103",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, \"Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),\"",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sliom CM, \"Analgesia During Labour: A Comparison Between Dihydrocodeine and Pethidine,\"",
"      <i>",
"       S Afr Med J",
"      </i>",
"      , 1970, 44(11):317-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/45/5847/abstract-text/4907758/pubmed\" id=\"4907758\" target=\"_blank\">",
"        4907758",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, \"The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,\"",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/45/5847/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8661 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_45_5847=[""].join("\n");
var outline_f5_45_5847=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13136418\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129440\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129452\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129443\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2525228\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129429\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129419\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129454\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129430\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5118568\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129450\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129432\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129421\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129448\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129424\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129438\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129426\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129434\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129444\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129435\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129433\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129420\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8661\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8661|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/43/3765?source=related_link\">",
"      Acetaminophen, caffeine, and dihydrocodeine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_45_5848="Giant molluscum contagiosum";
var content_f5_45_5848=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Molluscum contagiosum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDlr7SG0bXjHpupyzK+Y5lYZfKjOAByPrW3falJZWtmos7kGRSvnTrsRj1OX6mtfxvfabpSWJ0m3jl1CJ/NVbaRfNyo/eZ46Y9azZtbbxTokcdxZNJeyMrJIMrtRem0AY2+rHrWbjFHoKT2Rk65YXd54f8A7R1meGDTLhlNvBC2JpF6bxn+EHtXe+BdP07TtOg1Nyk9sYvs8VxJnzQ6jJIH8K5/OsT4mbV0bTdKs4WSOONPnHzEE8k5HTJ6Cti30WK4srdNae5hWKL90iIQpYdAw9/zpp20ihNNu8ncefES6xaJpGn3jWlmVJvbxozIev3Yx+harulWklpE6aY7RLb/ACiSJTu8s9XPofrWtpSQW0ECywRwzQOqorYEbK2cZ9qiHiS7GpnRprVJJ5Yth25BKBuGOOv19KWi1ZeuyRLDpwh0GX7LI6wuSBuUHew5Iz1LdxUFqRp0exfNlmADN02YI5zj+VbJigtJ3hjuFk8qMG3LElGkbv8ApUVi8F1DcW4lAu8shCqDEeMkMfXrx9KGg5u+xDp8sFysF5Zu3nW2T5UoJMmOqr/SsHT9Qub7xBqa2/mrb2jAI8mRjdyWwfukjitia/8A7NSP7RbE2UmY0uGHzxHvtHHPsawvC6z6g15JHetO9/cujiZtvmgH5Sw9ABQ9yktLnQXckzw3EaxxPb7w7gHhCR7dR71mHzZbV5i28ufK5BYcenp6VoR3N5aW87WscWFjZJVXHrtJGOccU7weovLW/srq386+uJfkfJVI1xwvr2z70tHZBflTdhIpnfTVe+hYxliEkU7ZI3yAM+oAHFUYLOK41af7U32RXyxnjAAXjKk/XHWsnxybzQY49OuXjnupRm32HcxzwBn0HU1tvNJfaOIZbGyUpCkDshOX2jkoPU5zR5MdrarqctqWuSLIzXCyCCNNpmjHbP8AEev40+88TpqFtHFZw2xeVQVWEDflRjdnqq9z6mta40Se/s7WF2t41Yfu9w+6f4fMxz05xVDS9F06wku5rqwF++xkeQgqQ54zx246VnyyuU5J9CG1itrVPIieXy54wQ7Fclj1LegJzV3S7CRPPRkRmZRsBOAR3IPbHFU9K0f7MZ/svlNK0JkUO5cFMcgZ6HvVq1uIZVRllOnzxQ7fNClw/wBR79KFvqNsjud0srRRJ5jE7lcHJ4/pUsT/AOhSBpRnduKPz14zWfcXos7oRQwTy3anLImdyqfU+mK2r+SGK7tncyoSm85XBC9gR06UIp9irbxSRRP9qcPG7bomAICcYx7mkupCbMTF2mhxtjYnlWBwc0XUsU1nshZvLhkO2TaRkN69s8dKhiureW5jtmlMqQEnYq4P1PseKPIPMkjcy2xlZy0eQFwMbT9e9SaeJri7nkhXEYXfEu37xHDE1DeQukRuIUC2kjfKoPT8Kjt2aCVVh3KQuGwcHnrU6oY1J4hL12SA4Ys3Gc8fQCnL5Vm4d/LmVy8blOeCPlqm8MRW4Z9+VwVHbHvSW93EI/szklgoZcfwnufy71KuUyx5kli6eWBzGVkAOQwI6EVXgVTaRtJxMjkrjG0qP61oRwpNC5kI8yNAy54LAdR9apPIA0xZlVG+YHHQk/4UPQE7hPEbUg48sF/MB/HOfanys13C90OVdyGyfmB6/lRMVngVvPDKp2gNySOoP0pLY5heFgmN24N3U4/lSW43oiKCbLxxuGLYIJzyPSmIyfaYvOAdFODu79amEcUZzIzbnBBAXkHsc1XaFDHuU5kyQVJ/WjWw7DHULufcfLYlR+FJLiMFVX925BIPOaa0zeQIwzGJNzFT29cfWmzK4jVmKrvwVIPah6alDIJGmWZhG2YgCWA4xnHNJEm3gtw/U+lIdyN5fzFmbA2nAP1qm0UovXcSHAxuUnuD+lK/USjctvcBXLAFUxyF71HMyTBAmB65pt0MNyAFBwSvYVTj3LuEfIx8oqmxJD/LaCYNu+YnIY9MUpCGNmBzk4z70yVXkjUSks2eo6CnMCYm2gADgD196ZLI0iEQwSQc7vY01pDu+bGc0rMz4EhywGM1D/CWJ6cUCFkH7o5wTmmqCmBjg9acxLAbeOKaoYEg9D+lAWCTaRnAqC4wFG0n6VYZQM1WkwF9+gpisVWYnjoat6PffZ7ocYIPWoCh2lmIznGKrTDbyByKtCPTre532yTA9eoq8ZVkxlxnFed6XqR+zKrSEEHpniug0zUEbhsbulac1ylsdCZ8/KB0phnZX7VSnnyh2kCqxlLKAW5rKW5cUa5ueOT19KZ5m0g55FZhfA5NI84ArNlGlJdDbx1qr9qxktjNZ0l1tHJFZ9zeFwQh/GmkQ5JF6/v1UEZwe/NYFzdyyXAVcke1MmhllIdmJWrVraktHJ3HamkZNtm9orvJgSDAHr3reUiUhY8Z9ay7KIugwcDua2LPbE+QBn19a1QiW3iMT7WHUZOOlZOuoWbYnVu9b8sylOOD61npGrybpO3Sm2NXMyOyZLUbxzjvRW25EgwBwOlFTctSPOPGVs/9qyRQaUml20MfmKoRi90GHALHk8HOa3NI1u407wdLazNFb3FmfKaR5B50qHG1UHpjrV288AQ3uhteSTanqNzGpRrh7lgF44UL6DGOap3Hhq1tJbGexs3TMe+/lXMzRxEDoD/P3rRp2ucSet7G14evc29qLd3uS0P2i4EbbhbPG+UGCMHjk1102p6zcaRcXOvIraVMPMtpIsF0kJ+XnHUHrjtXN+BLtNPgj1F4ne3ut6KNwVBEOArccY75rsLvW7Sz0i9tMRwSvm5SJ8COIAdFJ4bI5oT0E077HFxPdWF6FbMttdgiaVxlVB+8w/HHTmtOTw/Notkb5dQN7e5DyuQwby8cDd2UDoKEkebw1bX1zClvG0w3eQxYOrcgEdFwByBU2pX/APaBtrCb/R4RJiWczZUoRx7cDpSsknc05m2i1LYzXNtBbw+Y0sMXmxY7lucKayNPsby7v5721jnW6sSCY4yFN05J2kn/AGSOuOelPvdfvbbWWWKR1jhhTy/tQERjjX7pfH+ea53xB4wt9QR1sXJuYp98TxFo0O7kxhfvHBzg96HZPQFe2p2GveKItKk0rUfEen4sbrEryy7ZCzBSHCqOB2468V554J1BZLl5bq9Fpbnf5KAkMIySeD6kUmrW93qHhjXZL2K+LWrJNbwqFWNGkOGYgknH0pPDnhjQ7rwZcXt4Lj7eZAkPl3IUAAdcAcjNTLmbsEXGOtr+h18WrWk94lnY27RG6CxqUJLs+eME4AJ71UvdT1PR4IprO8CyzzMrEHBjKnB3P0/AZrmDo2mWkA+2WWsyaiH+SSK586PGBtIxyT1rav7TR7GOw827sphKMtCJWZoT64boeeQKnWxakr2NbSbJ7cXt9JdyT3k0eWMtvliCc/u8/dXuTSvLOsSjTWnka5ZVJwD5j5zwO2OelJf389swtftsjxJgxITghGHT247VU8S3iSxqmlKsTQkSqsMhLb1/u98n2qrpaIdtDZjNwVmWxjEfmHa9uG3OCmMsc0kbwwiaByyyPyrKMZYkHaKyU1WTUkjmjmjCAARuRtJKjoe+evXvWlGkp8PW0l9JcSzCcuszDhwf4SexFJPoh9Ctd3cdlJ5ttdYZQcqYz8wxyM9yeRgUjaJ5UUk0ls7HyvO8iaUnEbdiMjBHpVqYT30enm8EGyMNFCwAzyec45BHrU7wJJCZ9VhvI1cFYpoASknpn6UrCv3Mi1aKGGeOPfCGUSYVQCSvTJPOOayNX1d4rQXV0sSxlRDnGGbHcDqT7109pMl5DaiWdR5fmI0joFwCvy89SaztYD6ijLZW6La2cQL9N5AIBIb1J7VLjoaJ67GHpN7qGpoba0L2tpKADNOBk88bV/qatxeGprASMiO8gLGeVjl2I65P9KdoKtDNcrcQDL5WGMnmI54J9Wrd1CSZlSRlCCbCthuSw+8SO1TFe7qOTd9DPkvF3WdtDlpp08pUI4zycYP4Gma7dqrobOBxPFEqyxydBIODj2p1+IC0dzMHa4aPYCwxtAPAX3PGTVN9UkmuZ8LFLJtHmAEb+nHHqe1N6Ak9zK8RXs+n3EVnbxLNezriNTyNp6sSOiirXh7SvsQLTEzXcr5mdsgu3YfT2qDR7J7R5bm7l33lx/rX9s8Io7AVrRmSadZA8Ue4HYCeMj+RqR6su3aSTRvtwgTIMPoCeAO5rNlt5HleFhzj7uexpf8ATZpleOdVaBlG5uuM9AfzpbtRLKW4ByQGxjd7+1J9xrQWGO3ktirxiPyojHGUz8zL0z71Haym1eQFg3mjDEc/SpIEMC+Wj7wGyMDinThishTBDEGTjuPSjoO/QjdiQM8nG3cTwPpUcMBito2bc4yQWPUmo4WklnKldo2kjHcetOZyYnbOVH3c0J3KaGODhi6knGRjpVW7gMTPG2AVwcdc5GamtnaSHayhHOe/p0pq/ebLZc8HdxTsmF7EJmbYA3DAYI64pjBnQjjPUk9hUNvxPckMCok2r7YHP6mpVCrIxwwDLyetAtyGdWUCEbgDnJqCFfK+UkN2B9atJNLLG+5QCG4wOWGOtV3ZQxVkO7GRnvSaGnYSZ1TqxGTgcZxSREFWx+dRybmQhV2kc4NNZ9qyKfbBpiYEGPqRuz0PpTcFwQx4z0FGSZVMnJxncKUAFNxzuFMkBlBtJ6d8ZoKtkbsU2VSAhJzmiLc8bAglgelACbjuwcgelQyABiW/Kp5LeSKNZHAUNyvNQz8AfNz9KBEUiqcMo571DKVJwBzVnZlMg1Wl+U9MGqTE1oUgyxy4YkD0rQju8KGRsY71l3AzLz6ULkLhTkU7kp2Z09trS4VJDzWhDdpJ91xXDhmAz6VIl48bDaTn60bl8525uucZzVWe6Nc9Fqj7gGIqzHfB3AJFHImJzL5MszkdKfBbYkGc5FSwlTGpDCnrcoJcVTVtDNasJUAHHrRbjBpZ5FJz29BUaNgn0rNmiNy0l2qDkA45rQS6Vk6/SuZiuCGxnrUv2nYPvEg00x2OhS7GeakEgboa55bgsRg8VeilIA5pFaG7bHkCiqcEpAGTzRVpkNNj7jUrzU5EtNHuBBaklmlKERKBzk5+/wA9629LESafYLbxiG5jASeaLLmYgcbh3BPp0rG8SXqE2qNcwyiRFAiPzAA4Bxj2HSrkOsQW8jzW7NbxlAVXBVofZgf6Vujk3tc2bnTdKu13XFom5pf309uxRGY8hOuB75Fc58QXW9FhptpDJBGzCJDKQWcDliG7DHSqreNdCFjqFlbvuuzL5kV2wKpkdj13Z5rgH8WSNrct7pm9pkTyUDgSnJPzbR0Hpk1EpK1giuXVnqOrailzaR22ju0enWkUfmOqlHyeHAP3dxHr2rnLp9Ou9RFlbD7HFhUnB/eJbqcAYPc45PpVbw++oGOCyiuLcyX7/wCkIzsRASflLgfKTnt+da1z4Q07SykU+pG+vnuBGIpQY4pHY4yAMAjvzSs5K5Sl0RnWsGlzeLf7EsZbjUB5gD3MS+ZPOOmEycKAOea2bDTJtM1C+s7q2OnvHIslqWIa4aTPDMw4GQfXArqNMs59G8R32o6dYRxC0VEuIQqxLhV5Ix69fer81hDrOt3jQyGS6uIfNhXPCPwfmb+7iqSI5u+x5d43sbn/AEy08zOpTSeTJIsmF555I6961/CumSR6fcW/kwuUWOKC5kkEapk87s9j6is3VbvToZb4XMEh1G0udkDCQsXYjBXjjjrmun0u4vV0MQ3elE/Z7UuZPQSN/rMHr6cVC3szR7XRlWw+z6pHeme1kEGUVS2VLjqwx1Hp9Ki8RzSS68tlqMIlnnXzy8qAAoejY7ZqDV7+KG9g+x2L/wBkW5BuTA4d2JHzOvtjgip9L1m2mi1XxTeG2uzOfstpAw+Yovyqdo6fj1NLyQ2+palt/DE3h42aQQR64AZHB3kvGGxlWzgHnp7VHoXh5or6PUdGhhM0D4SaaUbgem4bvTPWr2m6TbWmn2usNKLq9uJPOuYNm7yYwcBSfQD9TTvEM2nRX9wLGB4LOTbswxDc88A9TntQ9dxw3sjnLzT7jQtUX+0YWjtblzJ83RX9c+jfzrpdPu7e+ubqCyDMmzc0Uj/IkuPmBP05rmv7XvtZnksbWCR3OLZrmXPkxD0J6dB0qV7a28NvBBaXM01rMuDIVO5GbGdx/iU9vSpTtqi/Jl3S9cgS5u3Q7fJHJPAZsfcGRz+FXLA3d+jrqU0kECwiezsvMyGB53Mv8OD2PPc0WHh8Bbi9Cte6nG6vE4G1Ih3EY6E+vfipri5+0XSzyLbCeWTzXKryrZAJxjn6U1sS9XoUtLMGpa1HZoheQqflh6MwHTPqa03heGC4cpHD9lkUhWPQkHgY69M1ZvLOJVMkcJWdJts4XAXB5DBeozmsrU0gmWS0DPFHIoUjft5B79xgUWsVe7HGNbyGW6jYGQycyFSAAR19s1TvJUtoLgNhwMN5gJOD3/CrOi6pHHHdw2k2QF+VSu4HAxwR3FUJroP9+MAMAvu3ual90XFWdilZLJNcI6yyZZdiq33dxPUDsabFpkcV5LcytJFclhGWJ+TAByCOu7NWpApjkPlhNpDBl/h+v5U1V83zZirNj5j83K/n2rO3Rl37EsNpJFMstySyYwYgegznr24NQPaCVkW2CKXOBvPQZ/XA5p9xNbi4dYZZJoEADsBgjjOM+1VrC5W7i8yPlFchDj7y/wB4GnpsLzLRQ2908EmzdESjkdDg9aoXd+LS4t4lLebcOUQEZHTJP0xV1lMK/vBuIO7JGDn1NYVxINR8UWiooP2W1aQEdy5wP0BovYT1Ohgd+UXByOCOc460ySVQoRRhl43D+tQeasSptYgjpz901Fv2YkmYbi2RuHJ9qSfYqxNvw+7b07+9Rh2LlcDy/vDBzTsYBY4YY6DiomdQ524B6bTVBzEQBRm8ssQW/ipwILMGb58ZOehrO1S4eCMTwFmWFgzp6r3qZZ4prVnQ+ZHIMgr6ZqUrC5kLFGkESpGS7kkkt3yc08l5DiEKVb1zUSOQRgHA4yfSkMuGYxqdp4x6+9DBMUsqsVGT71XuGUHd1DdjQz7lYdCOB9ajRy/DoOOxoQ0JMcMGDbgO1VJH+cjnbViZcjptTOKhmQdQBn3NNFAMk4jIAxyCaRGJwAcH371G8bMAcbSeuKREOdqnBHr3oJZO79F5AHanoCXIGUz606RRtUdcUr/KvJ3E9M9qYiKQDGGzxwOeKjkfOPbg1MMSuwYkYH4VEQOUPbnI70xEbMM8UyROfnzTyoVsgUkp3YPOAaAM64UYJxx2qGH5QeODVyUK5IXpTDA8a5I+X1oJtcryKSOKrspHb5h2rRIAXAGe9VSuS/HBpomRU3AuMdaUb/MwtTeWAD8vPtSKNp44JpmZaW6lQbdxx61NFcM0nJ71nHcxGTxUibmbANBSkb32gDqRn60puuOaxFVy+WPHarcKFjtBJPrRuPmLLXp3U+K9ywyx57elUnCwDbJ29aqvKFcGPFLlKUzqYpR8uSetbNqylRz2rj7S4cqCfWtu0uMlcHFNaFJnSRHAG7HtRWfHdjp0oqirnn9zq+rf2q7/AGO5mSBsbWIXaW78dePSl1a4ivoBDBc3l5eMUaSK2jIMfqGJ5rrbPR/7X1q4l1G5eaaURYgh6FAduGI6DjFdHpFv/aOpaimgxwaPZ2S4lnYb2lccbS3rxWnJ/McHN2Z5tf6Nolsjm7s9SMvkkJEwIUSY45r07wjYzWmhpaWtnFBCYFMgaJSXOP4e/rzVVtJsovEOkrp5n1NpiZ97nMgKrxgdNoJrd1fUL9La0ljuo9scW+IRsFB5wQBgZ4zmiK5RqKuUTo1hFqERiguIriP99cyQ8LAw4VcE4bcCPeqY10av4nn1PxBZSXWlhGSFYQUVHGBvPYYHAPvV2wtE1EtJf6nBYaNhp5LnODOzD7qZ646Z/AVu+DPNvtM1G4ZbG00xh9niSUcyBfm3hP8AawPl70lroEtA05TJpx1Ka6tWsYzmaOclmKjozD+L04NZOqeJW0fRkg0sXDahqJ3xWaYkYj+CRCOVP+yegrC1PR9b1DV59N0+N5YLnawQvsjhUnOxccDPofu1FY6dM9xd3l2z6be2qYhkIL7tvAXePut1o1sVp1MfwOJ7me5k1CBLqWW7L/Z5H2hH5DZP9a7G1vjpkxlYT+WIjGVd8ZHQqD3HtWBdx2nh/RdOvILyGb+05PMk8gb1SQsfvE/dIPFXNXji1DwvBHPNEt3dX4RWklCiONV3v8vbJ71NrFR2NXx1JYaV4EljsvKNzb7ZYpI2ABEvRfViD1x0xXE+HNA1KFbO4sUTCxl3SSTb5hIyZcn5QewHce9Ykj3XiXxRb2COGtbZt8kZGdzHgKB3OO1eou1jBoskt6HN/CyRQW5UJHjOFHuf5UfEhbO1zBm8TWkVnaQK9xbF38qdwSzPkjIEfXgdvWtXVnn1tjLsltLKMFI5pW3XEybvlB7Jx+NJp3giW5k1PUNRV/7bDDyZopQAp6BR2ftk1Xmttd0y+ktpLNZZs4kVJMDp3DdKhprzNIyTfY1poYYbaFNOLwadtz9mLEASjqVz19fxpHvY7ya3t765+6m05Ubmx6Adfqan0NL6/gebWLFpoI0ZF+yON8QHduxzyKy9LsbS7vLnVXliEFsTDFas5Dtz83OOcnih9LD02Nm41mG2sWmv3lS3Mywq8cf3SRtyuOe/SqkU8lorRRKLoIzxqVOHI/h59Bwf0rLnsbjVb+48h1+waaBdzxZ3bZG4Rcewyae9+0d5FFcRqWugE80LkQIOS2BQ5dyoxW5q3Vyr6eLiYzzXsJKyIu1S4xk4z/FnHWsAzTeKLrapkhtNv7x8/PKT1UH09SK2721t9a06wjEJBiJWeSJvnmAOeR2GPxo22ltdRXFqq+VHKNsUYIKIO/sf60pK++w4tdA0+BNLjuFhd4JoV27Ik+WSPHzHJ5FUUeC6sop7OVn3feB7A9CParWoTNPJcuZJWDZZPNIclT2J9a5jw02pzNLbackCPZ7lMl04RMZ4Uf3jgjik2tkFraj7uSe31i2XzN0M8UnmQoTgFcEFv1OaINe2RzGyk84vGYQCN3mN2UetJd6PIdesP7bkuGimV22omyPG3khRyRnHWtew01beWO9ETskH7suiYWMnrgDoan0HdWMvT9NuUj8q8JS2fJdEYM8zHnDEdB7VrrsWFoo0XYpyQqY29vyrQtkMiExIE+zgh2/iIJ647kVzGozC71trS2nV4ImDzzKCA5PRPX3NU1YNzY1RYLmYT24CxSYHllsshAHJ+tc1oavNqWsXRDBmmW3jOMYVB/iTXSXDRThWgiaNdg4BJxgVlz2t0t8ZnkWG1VBtUkDLH1pPUa03JTFEsu5dpYcFSeM1nTyB7y3j+QRR7pth6Z6Zqvc38aOw+1QBiSNokHH41x+qa/NPf3IswN2RGCuOFHX8zQkkDZ3817FBHl5EGOOTXMah4otEAMLuJFGGDHIJz1HoMVyNxcX1yQtxKVjAzyckfhUR0xXQuWldcZ4/+tQ3fYk173xazgiBQM1Q07xJNZb4SR5YOQmOnqKli0uF4VZEUSDJzu6VWvdOzc73VJA/G7bjt3oCzOji8T2zIpwfpurYj1JJocwMG9hxivOJNNTztkTlCRwM5FP8vUbOJnhDyRIBvPpnoaaZF7bno8U6yp2LHt3pGdGXP8QOCfSuI0nXdzopO0jjB65rporyKdV2uM9xUlxncvNny2fcGXPQc0SlQgIHzkAjPXBqpbLIF8uVgMHjHPHarJQsUBO45IyO1Bo2LGdifNksaeGVsGMDPekhJWQErvweVqSNE81nTgE520wF53YK4JOac2AzdyeKkZ1ZicAfQ1GVPIGSeopCKsgYNg5BJ6GnqV4ywBHU02YGQls4PeljiVkOOe+DVAxQi7WZj8pqpMJA2OT7VZKeYoXJU5qINktvbpwCKCblZl3E+WMZqvMzglGLcdquk4U5HIPFMkHmEHAGOtAiucPFleo9aYyYUEE1M8ca2zMrkPn7tMV/3ZG0ZFCJZWIMRIHIPvRs3RE5ww7VLI6uw4wahYdWJ6dqolkW/wBakEi8EHBFV+d3AyaifcsgjLDe3Qd6CWaPn5TpVixnZH3nNUYfkj5FWIvnJPWmg3G6iDc3HmZIFQDCcGrE6nB5/CqkjBBg09yfhLUFxtbbitOK52p1Irn7e7VvlA59atNLkgg8elFi4zN/7bmPIbkUVgvdbYiOM47UU0gdRJndjVLRtdX+xJLi1t7g/Z7+4gjAXeeURfQ9QT71Nc6imhWLyWqObTcUSPIwHz/EP4q0r3SNJubGKxW0htZpIP8AQjG23yyDxNL3Jz61neGp447K5tYYhLe27MkscGGeZzkFt3Ze9aNX3ME9TnNH1zUE1JtSWRlhttqLOkRfyiTkqoHTPpWn4hOqeJ9XFpYuRFNH580kqGMjJ5UKOQPbvVKCb7HLqE0luXuI5IyrAgLGQPu47k9q6Lw9fmGe5utS1O3tmDb3j3YB44Xd32g/nUWvoV5suw6NaWFjY6hHq0V3exAL9iOdsAORhF5zgcnuKvXWqadATHpcV2dVSNfNmI3QIOmFHqRzntmsrw5q9p4h1ua7+2WOkaTpsRHm/cNwemSvVs5OatW/jC0s9B1Sx0xoRbrIVEy7v3qvgCOFcYJz3PFVyrcly00CfxB/wg3iuFYLYhhamZ4o8AEuOA2TyM9xVfU9S8Ry6FeTw2h05dRcRmN5EWJ07sR97dyDnuKyBoOpW8Fq50yc69Of3jXcilguflTZ1Bxj2rrPFV9rNw9umtWe5QqrthXZtcKM5BGc4HPak3certqedQaNqUui3WmQ3dq9tG7RwCGNpBM5PzAZwVx1z3rn57HX/sltd3uowQpGJdo3ckodhB7qee9ei/DvxKlhHqf2a2KStdlVvDhnijP3ggPG73rD8OaRJ4t8Ua3o2lW6SebdCd7+5fDRwqfulc4OSQTjmp5U7aCba3ZreDPDlxo+jQ6pa63AuquWxDDCJJ2PUN8388cUtvo17quyTWL2eaTcWSPOxcj1x6Dmun1HTn0Y2phnU3CNzvTbKjgcgDsn161Zv/EexhcWkzh5jvuI5QrAsAAeMYGeelKT7msY2Whr2Xie4h02PSbDTrdZMJGDFltwPU57E1BqE6rqE2qSWt0rhnSSNiG8t9uACT1FV5NRQ+FbW2b7FFGZPnVV/ek9Qx/2cHqKyZPEem2Gn3ixTyXk8bHfaRxl1ZQMjPf8ulO/mCjZ81i1aatqGm2d1Np8EMczRR4jZhiRWyu7GeT/AIVS8Px/YTKotoJo3jCxRzRlmDZyzJjqSTnFUNPsbmO6j1LW4fLa6h8yK3ifBjjbpyOAfb0FbVjcXMmjTWKQsW3b4JwxzE4HKqR3I7VGuiLdnqVfADymDUroXNqs088p2T/LuVTgLnoe/WpRbXsf2i3tY0Hnp5kgKcqnXIJ7VhaFJFb6fBb3qTxBY3+XHLPk8kH3rdvF1R7SLU7rbJHsC5cYLJj5T7jj8KXSxSXVdR1jbpIl15Up8pGCLe7CqDg9ee/p61FDdWrT2yEssk0mwqmAGHYAHvWNorNCZblLmO+iupG2Qru+QL8oOPXOTQ8bS6ob+9LpKF2xgZ4/28+pov2KsaV3atF5ssbo0attYK2e/Ue1UbW1MGqahFM3yvIrAsMkEoMfWtGK5khZmkKqjRlsSpw+OcZrD8TyTW1lHBbzRC5umWNNkgYrnktn2GaVluDvtc29cDrdWlze27LbwRPGzzMVKscYyfz4NYb+IrPYywXCsmcN8xKkj+dSXtxHdaVLa3F0zWZKlxI2FkA7knvWer3F6Ej0ayQRZ2q4XyolwOo7t+FKUr6oIrl0ZFrPiCSARR2oY3s4UxbVKggnAfJ64rUs9KfT7VI1CiVwWldzvYuT97jjmq+l+HltZ2vryV7q+JLZfJWP2RewrYG2GLccbD79KPUdmVhayIMz30rFTtPlAJn+tUtSXT4vNklAlVSSZJCSW/PpVu5uFjhd2j+TaTycH615b4k1uS6vFDuwtwc49cUOVlYahcTXLo6jKVjQJGSUjUIBkev0p+l6RbxFgxVcjkkcfjVOwuJruXeDFGgPy5HNdLaQyP5ciZw3ysQMqT61mpa2LdO+pVWyxIqMgTJyJOu4VPLC9vE5iYxyNwxHT8a2X0+WCb503BVxlRlSfWqktjdTTJJFGjKGJZXB5FXdgo6FKWyhWBZCSpPTjg1BFZtdSmBy+wjIx61cktJre1livFInibfgHcoU9O9XdGgilzcuXWRsbNowMdwalNtj5Va5k2+jrDqRtbsNsYgeaFyyj6UvifQTp6gWm64s3+eN24JA65rq7K0a4vLhnkGwR7t3qPTPqag1iDyZitjlogo+8MjPoM1oo2VzOS1seYajpfnoJIVdWPfOCDUFlfTadJ5d0pD44J7j1rurvTxHJFt2sHTgY+7jqKwNftI5oxCQrvztcdUHoaaRjKLjqjR028FxwWxuHX0rVRW2ZBzjvXBaTdSWsxt5G5xwTXZ2dyXQbegHNRY0jK5oQEnDJwacgyNoT5gc5z1quGy3yg8elSLIVUliAe2KCzQFuE5AHTI561CUyhKsd1IpIAIJzjNSqPMBKgEj+GgaKjMcgjBK9RioWYl9xYLjqBVuYMGDoFDN09qgeHlt/DH16GmIjkkLRFWPyjhWAqtCN8RZj8oOM1aUqQECZ7bahIWFjsHyk5NMljN/l8ONy091M0XmIoGOKWTFxtBIDgZB7VGjjlS2MfrQhMrSrkA8mmkjZwcN6VYupItqgLgjrVZgA+SPlPSmSAaMq5I+btULFcc4xSXdvIfmiYCoBvA+cZpkXHOAvIPNMlYMgJXB71M8TBQy457VGdq7twoJYxJFHXp24qzbgyHCHnris6Rm4xgCo3uzC3yHnpTIbNWadQGR+3GaxL65YN+7Aaq95qMjqwbIPrWZHK+4nkg9qpGcpGjaSEPucH6VpG5Tjaee49KybYCROSAfTNV5ZxDIQaqxCnY2ri4xGcHmisFroSHqMUUA56nsOhWGuXeo6nqEUtpmIeYJbpsxhBkEqP4iOvFWjCulxvfaXM15PeYjvZGjwd2fvD0HsK5XTdW8zV4b2a6g+x26DMcjfIQD9zH/ANatrWdR1O40m4ns40h0+TaRM7DJZ+BsUc01JdDW19WzL1ay0xdQuZNUlaOSJQTbDObiY/dxjuM/rXQ+ENKnn017TWbGz+y20wd7Mjc0sjDhmfrgcfKO9clo8cEGpm2uRFMbHDTTmQ7rhj0PPceldQPEsWn6dBZQwh7qeTe0p5MaE/eOO460c2u4lHTY7vxYdJulwgiWzsRsklgjUNcTkZ8sR44QEc0zRms9VgyZkGnW6tKsCLtX7Sf+WaZ6qP51zujW1u2sR3Wkyi8LH7PbxDhwMZa4ZT1zzye5rovEet+GPDPhpEtYJhc78W8qSFtr553HoD7c03q7j0WheWO11GMxqt2LzzCRJjdJIuOmM5BXBqhfXWpJuW3luJb6JPKlYnc6xtw23IPIU556VkWS6jfRW+uQm4NxbAgokZDQ5zh2PckZx9alttbI1iMT3VxZxiJo2jP+shhP3lx3LGockaNN3Ofu7a50nR9YFja3A0iKZJA74wNy4XcB/EcVf+C+m2Or6VcC2uJrW/muZHDzt8kcYA49yx79sVnfEPxHZTTJp9lH9gt7e1Z1Gdxds5V37FiCc+laPhh9U0TwTpkEVzZxabehnN7Cu4tE330ZvVe47E07W1Ibcml2NXx+LnR4tMMyRyz3pKxXKS7xIFPJJ9ABxXN3Op3Op289hbRia1tU3zy5AMKk87fUnv7Vga7qMFxrt1babf3t/plodlrIsZbC9WIXoMniqkqSW4t0uFubO0dfMWFR+9lQnqW9zx61lK7ZrBpLudxql9Pa2sOnyadHHPeoskHynzmQdwOip6mtHwt4PTTr6a5ubxtRRiPPe0+U4boqA8sPUVZ8O6NIdEm1GS1ju720Cq06PkJGOfJkyckqO4HXiupt7ZB4J86O2ePUhdgnbjeWPRfUDbVKGuopTukZ085sta04i6huY4doVoiTtXPQ56H1FX/GpGkiOC32RHzDKyRKyJvOCHXnjGcfrWZLbPHqdpK1tbzNNh0t4gShbPQ/X61l+LJ7VWumstUdYniz9ndWYyTZwsY645/AAUm2kyktUZdi51dzi9nur5XOIZx8kYBOdrdxnkmrHj/xDoq+FJJbFEttcWTyBbxOWRkIwXJ7DPNcJqety6ZBDaWMzSzRweXNGcYKZ3Mc9gG596ai6K18sQuH1W4uSk+8jCQ7Rll2qDlewzUqeoNWWhqaBc3jWC2mj2Mt9NaxFpZlGxEUdSWPHftW1pVnqoSObV5ogmAVjiGditk5znk02PxADFOkq6jHIighVtWUNwAU6cDGCPpTrLU7i80/yYhNBay3OGWZNoDBfvewxSSLvoi7rmpr/ZIs5xO727s0bK+AqHrx2NcF4eg1K6me+kh8yZ2KwtcHEaRk+g5LdOB6VsawpvDZ6VZRnzprgRTXYcEYzyEB6HHJNdM1rFbxiLzDMqjC7CQIz6H1pW0KV722KOm6bYvMsl7PLe3EZwzOvyp7Rr0H1rRt7q3a9u4oekMhiPmrkoByOnsetEcMhYLs+Qn5AT19ax9SU6frMM/Cw3GIZ2HaQfcY/UZH5Uk3YppXN8yfwKPujmq1x+8cIivsChiOufX6CkaaFLaQtJh8jAx8zc9qydRv2EzQQoz3LKMRqecHux/hWi4zH8Z6r9k04xJlppj5aKD19SfQAV5lcpvDszjdnAHqfSup8XEwXMD3DiW6LASMOijptA9KpHT1uryJCqjcS7k9PYChlRsyax0CLyIS80hcr8wLcFu5HtXR6bH/AGVcxiCSWSA4IQnO0+9X9I0zYjbiGfG0buoHtViytvIv0hupBAHBZSRkEdjWbT3NU+hu6PLtUEnzGbOU65/Oq+ow+ZeEW5YR5HB4I9qZbKjXohidkXGdw4we5rVsbSWW+mzKzKqbg4XJBraPvKxm4qOtzlPEOnyPYO0cjLJjB461QtJ7k2cUUbKYSNzHPoOa6m7ja4uFRiC465OM+1cXdWt9ayXMVkiiZiTFEx4685z7VnKDi9DWLVtTZ0q7k02F1t7zNvdKBcRYPQHoc+nXIrQtJUdJN8itEuVRi3PPf8K43R5tZuLl/tcUQY5jZhhT+P4V0GnzrbNIk4/dEBFZgCVI9KITtoEqaI9Qt2tbuGWKQSHOfl/nWBf7YpHk27lf5m4+YDvW3832udkVhGeMf3RnJxVTUbcOflJYNwzYwQDV3Rm46anDaogF/mJ1Kt90+2K1tDvcqYz83OPTNVNb02aC2mFs6PBC+9HA/Ss+xcpPHKjfIwBPoDQcs1yu56BCWxnsBUVxAXmhaJyT1ZW7fSm2MgktiSTuA/OrcSqJgyt15BNKxpFlmIsqkbt2fXtSxM8f3jjceo6im2d0skdwpjxJHL5YYdxjP9adIQFDNwScZoKuMeZ2naNoyF7GmytujKP95ejZpZLsKAhG6MnaDVaAeexwchTgkHv6UxXECuzgqSGxw3rQ8beXuZc44I96tuhjHyr04IqMSEHdKcRHgt2ppEyZmDf5mDwPWpHheCTc5Do3QipnmRJB92VVOfrTnnWYO0KhY3OCM/dNWkiGyldgIcjlG4BqtvLAgE5HSmajvgAlUs8QPKk8CootvmLJGw+bqoNMzcnsSR3Jdtp4YVK4GwFTnuai1CHEcc0YHBw1KrAsBg4PFSNPuL9xAV7+tU7uct1UqO+KuMQMqRnHai5jj2/IxIPUGmkJmTIySY2yY+tVZLYHLbx+dXZtPR1yvH0rDvo7iBiqOcVSRhNiyyF3CvgqO9RXIjRcxt17UxJvKT94gyeue9NS2ectKgOPQVaRk2V/NdfY1DdzmRSAPm71LPvwdy4YVmy3HlPnqe9BLYttIQ2G4A9e9FV7yZXVTH1oq0jO57/4T8A6bqN+9jqdjJHdk5WMTY3gjqp9OvNO8R+EtJOuWen+G5ryFstLLEtwcRhO+D39PWl1fxFf6xqO7Rk+wXNtndOzbBHnggZ6/Ss9tbjm1aK2sbeW81AxlJGX77ucAnK9h1qZTOuMYop65oEcGqNNo8t5d28QbzIZdrylf42Lj86xx5tlapBHO8Qu3LSLjO4DlPm7Ag8V10sGt+GNPisUWzijnc5M7fvHJPRwOhweOeRT9G0t9BtINQOoRSQRziS6mEW8wtghNqnqBkZHpTTu7NEuPWJq+GDHoevyv4zN7b3FxGiRm2YOsMKjIDBexGOaSe7gvfFNpLN9n1CyjZylqjZiRipKsSOrDjNYRuxarPNDcpO0+It5kzlv7xz/AAYPTtWTpeqPp2qTvb/YIpdPgK3zJIGF8C4IEfocDqPSp3fKi21FXZ7FPYvdahbCe/RYpoRLHb2oKNOB2bacZ64z6VyvjCwuPC7ve6lZLc3N1KW8hbkM0agjCsM5PBFZusa/r7XP9tHRsmQjHygryOGwpx0rk9H1a/tvEU+p6jJHHfoNqtcq0rKSv3x7gdKmS01WhanZ2izR0nU7bVLy0t5VTD3JzHdxExWzA4+fjdIP9kHit648N3OhXL/8JEonS5YXFssR2WqsRuYbAeRjBA6VnvO+qQaX/ZGnSL9hjFxeOxxv3PgSHPrkA4+td34s0Z9bjtbLXLtdGgj8tE82ILLsxy+5flx7dTkU29LLYiK15nuY7i+j8Pw65eGGOHUS5cxKqAkdFKjoAADVHw1plxe3MepPbS3NtAUmlLqQqOfuR59AOfqa3fEljf3lta6HJAstppki2bXluQfOjb5kJHTO0H3q9oesHwv4ZSaSS1uYb8u0EatnyWZtvI/vbR+FZ21u9jZN2S6ljW54be2+za15drHEwlR48ltjchQV5Y5I4NRaXHq11bx/2jdT3c8jtcixmjZN+TgYcYJbH+FaMVvpV0y3d3aKsAf7PbK0oKxyAcyPj/x31NLqPiHTJNOEU2o3MV5bsoW5dcjYv8II5HOarbW4PWySObv9T1TQfMhitWMEDm4E8T+YYMjld3qO4rzzX9dF7rduNEtbwyuQYLablzn78rYwOcnHpXd6x4qhj8PX1jqDfY9ORmnhg8vzHupGzhnycgDjjv3rn/AuhTXK3uo3bPBeGNWM8jrjaT0Cde/rUuCbsgc3sVR4ZtrO7uLuw0m4+yrL5ctzqLDdv6kBBnI/Ot2CCG21CPVdAgls7iNVia1T5VYn7zxtnhjxlTxzWvqt9faUkWkzfZZbaGQn7Tb8hmbpuBq1o86QaPd6dqGjxLei4aNJmk2OGIGN3qBQ9HqVypJFL7RceINSjs3mlsGHE01xEwbA6c9B9RmretxQadaxWttbIjQrlpd5cyk9D7fSr2ka5PZXEU84EyRw/Z8MgI2jPCnp1Nc94h1FIYkSKNTqTylYYwMBy3QH6Zz9KTdkVbW/YxWSQajcXdsscssahILdDndI3LE+gGACa6mzgZdJgW/LyaiSTJKq4jIJyAB14zisvRdHt9DE+y4knmkOZp5AMk9SF7BQenrWzHcSvIqJIdqNvD46HrwKlWiXrLUz5cwSMQGO44Ve/wCVZMt/aaxp05uH+z2xLRiRgRlh/d7k59Kv6u0l201vYky3khKySn7sWepJ9fYUlrpltpkUa/fkiiC+YwHA9h0H4VLRW+iOWmvtRn0aVMrbXKSJbMMZllZj1H90Y5z9a6EwQWcXlWqFVwPMbqXb1J71zU1y0usR600aixhf7MGP8RPHmfRScfjUmv8Aia0jgmWJGedlKpsb7h9T6000iepzmrR/2nql1GpHkQsGJx2zzW3bFJTbqjIgxwFA+9jv7etZ+l26/Y4pUklDzJ+8YgDLZycVs2WkzIglOAnXLDqPYVD3N4R0ubcUqt5KArGUYlpADvPrz3q9qNjJcW7XFu00nOEV1HI6fgaybZZGvVt5htYgFCF5rct5VCSxTSGPaemeQR/L6VcHoU007opsJ7KVEaNGkI+ZQ2dvsa0tNv5LdgZXaHeQMgcbM1QhjmnSS4iV53d8+YCBkeuaieGK5lIMZDsf3mOCPbFRrB3iacqludFd2lre2zvYXkMuD8oPDkHvjvWHqULw3YBZRLkFAR8wx1H0NVrdTpMpeN1+b7/mAgDPH449q2dKCyCdlkWRdvJbBJ74Gaanz6PcXJyrm3Ryd3ZBru4uEZkk5YCPjPsPWqFqURpI9Q3b5HB809F/+vW9fXNnHIjXDLHEZV8zaMuq98etYvivVbGXTMWmTIrZQ45KdwTWMpRTujohBydrCa9rCWMUXlwRyoSUDIfmOPUf1qgupwXjIIZSisvQ9VPeuImnInLqxePdkA5w2f5VvaREY9OinjGZBLhkY9ePSqV2VWoqmtTcjj85/skW07gV5OAfrXJzWiwSSWZZVkhJDEHj61fubi5SRtwRVYgkgnj6Vb8QWscllG08bRXKoNhC8FTzuJ75rWLTWp51WLRBoN8NyQuRnp9a6eFlIABAwMg151cD7NOHtScxYIAPX1FdZpt+Ly2RoMFmUEHHAqpHNB2dma9rhNRvDgAEJJgeuMH+VWXl884VCOcnjpWJZ3DHUd0/yOUIYdjtNaUlzGYfMRsq3IxUmifYWaENG4DAKvLk1FpAfy5JFTEbtuC9wOxqG7aCZorQyFYZPnlOcHHp+NLY3flXhtwjyBz+6YDHA+vpVxXUly11L1/c+VtcoxUcEjt9aWRoZrdldzzygHQ0twsoVSzxgN94AZ/nWXLE0TSMiGXDYIPp6D2p3E32KN2i2jM8cihSPmQuD+VVY7m3gBeG5BBOShatXSpoPtssckSFGyV4+6fSory1EIeQfKmeRjgUWXQjWxBc3cF7bF4ZFzjDJuGfyrG0+Xy7wpLkKhwTU2oxxX1ruCLv/wCemOh9Kz47SC3Zyw2SFd6PknkUzKTudDdMot3UEsD0qpIJYlWRW4AHBqNjugjweZApwKlvb0NAqouxl4we9MblYsx3AdMrjceuahuJREhaQgZ6Vn2fmTBmRguD07U2/kMkBWZScdxTWhMpaaEkl6DHlGG70qPbJLEZJUwD/erAWZoZ92CYh3NaWoap9pslVWxtHT1q0luzCU7leSJVkJlyy549qu2UR8ppIZVX2NUorxZItso5I61XL7H+Un8KE7C0DUWZn2sBu9u9YGpW8kDgspwe9aeoSK65JK89c1WN6LnZbTAEZwGrSPvbmUnZ6GOil2AHJPair15ZNZXKAsQp5DUVSj3Juj1zU2gmssxWMoki+ZpJWO1sdSCeufpU/g5IRc3l3eI0e+MSxRRT/IiHAIIHOciti+0ybVLyOzvo3WaBj9rZo8fMMYRMdh3NY3jTTxpXiC1utOgkfEBacOcADsx/wrKz3O2WlrnYpJp+ulyDtgjcHy1HmFlHX8T61zs7Rm31GPT9UV7Ka4cLBeKQy7RgHcO/tXJ2viNLS5uNQ02JrW7DAJAhLKRjBLD3602bxGsrKthY+WpAUvcJltx5KrjsSPrRo0Ln6nTWqN4kuxBq6f6SYVVWs03SRBc5AAwMkDqc9arW1naT/ZZdN0mOWIHJhmI6burOOp9c8CuYuvEDSwhH86yumba8sZKIEzyMDnFbUmrLpdlBbyazC1tJl1W2GQMjrjr+dHNZWSJUVN3bPYNTtdQ0vSZbrxDDp9tEAqwW2mYclS3Rjjg9BXG63eQ63cW+mTxokSzb7u7iwXZhwQrY7Lgema5ebXLPUPD8kFpcXK3IUL5cchkaZlIJbHYAZbNdp8L/AApNqml39zb6Zey21xsS2Z5EU4yCxKk5BPPNL3nZGicVuaWk+HtM0bXdKvtQDajY38LgRG4+ZUzgE4xgj06Vd+Kehw2Uqpp2uTSRh0igtp285PVgWzkbQBWH4/8AC+s+H9Q1C8tNESLS4Io4HZ5zOyljneOnXHbgV575l+7i4lnWErltrIcjtzzUy5lutyo8t7ps9N025S18W6IhkDS3NtIdlvKwRZSuFbPHTJ+nSrmlRX8eoX19ffYTCIBGsIAYRoSP3mP7305rznw5DealrNjLJfASodlo8gAjRW4BbnjnnFei6TpFpCsJvruSe8uS0aTuGC5zjOcYwuM8ZzmhJ8pSd3oa8sZ1G1ubWwsUWWKTzJdWnZljIzxhPToBSXvhpLrTZb+a6hljkiIeGFTB5DMNo55yA3J71Bo9vrNm51C5mFp4ct5PLguLhSXPPMgQ9FP+0Kg1Aam9teWccsNtZTgXB1C9lOfLB+UpGO5PtT26ahp30OA8Tags1va6TbW8ds6SLBesrZw5OMg9SDXdeCbxrO1tpZ/K8q5V7ZlmjYhwMjeMDoCAOO9cPqE+kXaadLY2M9lcQXQS7vriUNvwCA20jjBPT3oudRm1mS10zSxdXGpJMUZYGbasbc5C8Bec/nms7saaR6bPc2y6ZayalYS3UFuGkuoWhZJCjfxlhxt44rgPDWqhGujdRA2hZpIEnlPyISQFJJySPei5urvzptP1q0vFSD/j6meTMrIFwkWC2CvQ+tYmnLMIvKs7BYXSVyPtIVcjtgdzz3pSbZaet0d1qmuvpv8Ao+mTx6gjRBtlq/mBVIz8393ms/SEtb8W2q3EQj1IO0cUcLkpEo4LEn+Jufpisi71S6sbCGC00aS3mlXBlTBe4kJyCxz09uwrb0kfZ/C+n3FtYXEkk6YkBcMXlzlmOPuj60r63Q97Jm5qj2mmNc3AmWSzSNgsm3K5KngZ6nNM0/R72LT9KfVm8m0urdZmVG/fOCO/9wGse9hkNncTak4ecI5WNQfLh44wD/M1btbi8ksrSa4jaG3WCMW+88tHt4Jz0HXApJlO+heuVhhtSlvshjUZXsFH9a5to5dX3pOZbSxjzvZlKvP7L6KfU9a6G2R7h/tE/MfAhQgYX/aPvVPxDdNZWlxKQWkOSSx5NDSfvMvf3Uch4v1sXv2iwt4YY4CArmFAFQAYwoHSuQ0+0kf93tZXg4IJ5Y9j+IrbsrWWV3WYDe3zKysCMHnH+IrTXRpbicXW4RPH8hbHDD0IH6VKTkU0k7ol0eGXy4k2MgU9hkZNdFYaYsiE3AkIHyq27P4Uzw/DayxldjuZRlAjYww9a6Z3WzsVllRyF6L3q4wLctkinFpcChZHWWWdDhWjHU4wBTLCzkslnS5803QJLqFyzE9M+vFT6NqayljNE1vIxbahPy/U+9XiWSVZoIy0gGHdRnjPXnt2qlZq6GnJXTG6FYkKFTfFGpYug+8qj+Jh2Bpb+0s44o7m2/e7WAlaHBIJ5A+tQa7dqI4hFazrdqxPnRuVDLnlCueKw7/W/JQmHKm4wGhGCML90e2PzqJTS0SKjCUnzGne6O2ugM8iWcaKHlnnOETOcZb3x+dYOo29zp1u91Y3cdyiqELx8AcHPB6/WqF54jktopYp4Uu5JVKqkzkIGPQkA847VwD3OqRzE3BvmEgBGEJBHTOfSsXJSVoo7KcJJ+89DpbSyu9WVtjRkRkklh8zDGT+FNjmSG0ntHWM4JGT/EfY1zH29bK7cSpcyJ1KFvLYGl1HUbNnc6ereXKoyHOSpPUZPpWMoaeZ1wT5iWwso5ZXWVRJDGSSvoD2zXU6LaRhW+0qpncZiZuAB2rlvC86o14JZVAEXmKGJ+Yj+H61cg1P7JaQeUd1yGYsB3j4I/XIqoaGOJTbsyLU3Y6oYZIiDBJyD0JxWnf3kn9mzsqCUlAoU9Qo7A1halePNdT3bjy4nfeYhz0HrUFl4iNxaXFvOrxyqCyEDHHoa2h3PNqroc7Z3rrK8N0Cu99/zDoa6fQtRisJnRmTyXAccjgnrXOw7DfO1zCQ02Sgzuxx0zW1Bpwjt4iyI52huADtJ6gn1xW+jOCpFx1Og1S5i+1RXFs4mkjBJEY3Fge3FU9Lubi5jAhbyo1dl3tycfSmadd+RI1s7BMjaDgdvp7UzTrhreB0xlLp2EWB0ye9QwUrm7bWpjuLa63M7TEoTJyQP4eO1S3kUkt5OjOfMRFlj9iOtVra4HkQQM+JIZwo4zup8eqA+ImiUHBiMbZH48U0PYsX800UMFwh3xNjeO/NWIZQIHkJXaZAoXdzk1Q+0KtoIZ1yhdowR9azrCQIFhY5CzAjPegbfQv65CbG4trgjZubaQRjOehp7SxGKX7S5Mnp/eq1rZ32koky6KQSevGay7+W2e1CqcXSDBA5+hqiG2nY5/UJmhmieF8x5wVxxk1ZuZIn+0I5UNHCAccjNZN481teIkqGRVYMQp7+9aepmyGhQtCp+0SP+9YDjOelUlpcxcraIbYXSA20Tk7FAAJH3T71e1XEYNvKnBGUYd6q2MaKPKuFBEh+VvWrtxDKkYCnzNvOH9KaDc55Gmsld5ciJzwfWr/2mKeFYo5ACexpo/0uYxmP5VByueAaxdQVrKXYylVHK+1NGbdi9cWgkLAYyvWsKeN7V8qCUzyKvxXUjPuydwGG9xUqKHlJyrgnlTQQytFPG0Sq+MdieKSbMTKOCp5BBqDUdMbc7wh/Lz0B6VWtnkeNom++nQmtLWIbLN/PCISqj5yKy9PYRXIeQfLnvV2GGO6kWQ5Ld196nls1nQxACN15qkrK5F7sXUZ7W6tfnYb1HFFZV5YtbkbjkGirv3FY+mrrxhpei6bN/ZlgzzSIIhJPlME/xbjyST+leeNqmteK7u9toRBb6eWRbuccqxX1Y88+gpPGfiDUNT1e3tr+0js4flmEEP7zacY3Meoxnp2qTw5qVnp99d2do5kju4s+Yg5jkXrndxk1k3fU6+a75TW8L6PNfXNxcWs1qru/kKzW42qFHQDNaF14fkfWkWOSK4t4XXzmB2GZz6DoCOlX/B93b6fpENrHf2xmkmYByMHLfebPoK0vEl1babpDm22SKwI87fhmb146EnmhSsi1TRy8fhqS41qabSrSa4trYBxbugnVefuMT94d8Va8nTVunh1yFre28raL5rErFvxkIcj5efzq54Y1H+w797W+hnkgZknie2kyJCF+bB7sDjrVjxl4h1TUddfzYhBGsUbzLNypUDgsOnTtUymuo4Un0PNZfDdu/i/7Lot/aXAkHm+bHII44hnnJ6c+lel+HrXVPD+o3UMuv6fHqNtEZDFdSKzMu3AVcfe45Aryy602S6iuvENs9nFYx3Akkt0dVJBbGUTr0ya6nS9etbbWIXS3h1u+mYJGmMShMfKMjrxxipdmTB2uWdW1fxHqunzanejUbrTWItVmmfyouOxBOT69KzfDPgDxH4mguZYDFaWkKjdHKThs/dUHuW649K1b3W7S6kFrrtve3K2RK20EShVjlZvuvkZIrpbPxMuiaLeFGdrm/wA77ZYCSvcbGJ74wT2otFPQpqUlucbfaVqOjWqrfxywSBzFvtwAgCkcAEZBHOTmrupapDst9P1K5vLu2tJAy/vd0SRdSA3ue/tV3X9Tu9RhKtbzpGoF1LFdEsscp+8E74IxzWVb3dxCJhqLWcC29ssFtawxhjPnJR5OewOMmhxRV+U6q115tWvUuE1FTcRRboVuJ8pGBwAEOd5z096txW7yXqJdXA0h03faLudftE8xP8IA4A7YFcppWjkyS39rdabZyh8f2g0PGQMsqA8e3SrlvoviDxJqnl2N/CyHLNeSxeUqN1wgJwB7+tSlppqVfq9A8VeHNN027vNKuoXjvvMFyLz7+2NhkF1J+UgjIUdc81Q8KrbWN1ZalHcu0V2jwlIzsaZmyPnPXAbn6DirE/hYWshutdmuNXtwxSV4LgKWfHXceWP6VpWaT+EdasbhrVXspkMEMd3EIpIFbG/I6E4Jw1N3e4tFZkpiknt7ZZVjaa3DJJdbcyTHP3mY8kdAPYVra9HpNk1hbNaK16GM2YpN28bOmf1A4xWBqWoR3epXqtcxabY/aii+QS1wyBeFUHgZ45p2p2UNm2wI8NphH+yyyedLMxAyZH7fT04qH7uptH3rKKsR6XpN7rt1Hqsk62GnyRN9lWR9rsoOGYHt6cc10mhXFvoMjaRCiSWsTCbKgr9qXqGPclTxWfFqcEkMK+UkKgY5AAAxjavoAKxvFc8Z05ljfEvmiGKZH/1ZPcH6ZqOdJ6FuH8x0njq9t9VZVjISSeGRp5YFxvOMnr+C/hTla01LTNLt4bhfPWFJLkSn+EKAqg9gTx+FYN9/aNiIoL+NbpIoAImQBJQhGRuHQt3P1rN0jUHh0ie5EEkhykYwQNqKAOT+JpptsnsdzJduxPmIu4ADGMcDgVyvjQXeoqLTT4Zbi6njaU7F+6E5P5Ct+718XjBCtxKGYbHlj2syhcBSBVfTEaPUF1Z4t0IIhVW43gH94COuOcfhSv0LXdHFaOWOmwxpu8qM+YwIGd3c56nit7T4Z77YtpuEjknL8JhRnr/eOOKW8shHey29vMjIZmWJoR8uO3P6Vd0lLmBGjckJjgDjP/16EtbGvS5UhiuI757tW8tJpArlCFMT44OO2fX1rftvtqSF7vEkDN8rNzkf41BcxxizcOEYPjPHI/xxV20kaTTomxuhUblIznOMYz6VTjoJS6EPyzXWSqSrKMFW7HvWt9jRoVSBZ8AFTGX4TH8we1Z9vCRqhntmjmfABUjAPqcV3rWUMejCSWMS30si+XEpDFk9MDoKunEVSfLZHnPiqW/sbS10+3treXUriPznCoQkEYHViRy3oRXM+I7PWZNQikvrofZEYK08cS7QoXhwMgtgHBOPzr23Xba40qxU3yyY8xWS6jAJGeNpJyRxx6Vn+JtMs5pdOZLO3RxAsfn3MW8RkMCqgDqTTnCLWoUsQ1qeN3nhBrqSBrzXtJOmMG3ahFJlBxwmDyH749qy9d8GS6WWksNd+2aesW5RvI3AchQM49xXe6X4Vgu/G+qxa/JbosUb3C217HiPLHlsLjJA5z2rN8QW6NcRaN4Pm067tJXHlo5y+QDlQxwMnBPpzisYqKi7I7o125JOV9PkcBfeHzdW93e3V2zXZVBBAWMjvtAByePlx37YrAFhE2m2stsu6X955h39Qvcg9M5/SvR5RrPh/wAvWLt1uRbKti8UkH/HuM/cB6d+vevMtRRUkunhVmi83qR26nH59KJRujanVSlq9C/YQW0dj9oMitcZViBn5fYg1RnYzFX2lXZzECgPCnpnFXtBuIZr2f7fPtRoim4R5JI+7n0rWtLi0l1CKzsk/eGRQGA4yOeD71z2sy6lR62MfTYXlu7y1u1O+3woBGCR71uaxHFeSuygec6qu8qBnaMY/LFUtIcyXuo3t++2WYttwc5OcAe/SrQEv2cujEJt3OWqzz5avU5Mo9jqfk3loxkjf5Ceje35VsXyqsDNbEKivuCtlct3z69abFIb+8V3USbQWwT93Hek1B1eQwq2crwAeAa0jLW6OSpHTUq+KbaTThZzGJ4/PhDL824N2yDVlIJf7Dt5XfYvlCRNhBJxxz6CsnWNRS/0a2RHfdb/AHtwO1BnPB+tb+kpbS6ddreRPDK1uFtzE3HHJLe1bNI4VK10Q6bKH1dEkIB4lJ+gpFu9mpmVmAUyufcYWs5rWbEVxIzPuj/hz698VXn8giVkTaPMLDPb5elSlYtyZ0czmfTGkDkM77gTxg56067U2Wu2PmOjgR7mwc5zwKz5fk0yyhhLKx2CRSeG5Hr0ya0r945rCa9ChJFlHy/3VHAH070FXuSavdPbv50bN5JYCRTzjnqK529u1+3NPAQZJPliUdc+9WLyd2kCnAgCb92c5Hf8az7a2hhlN60LhJjhCDkx/WhK+5E5Ns19IQW8881wS8qgFgw+6TVfUHDs8QVViQGXA6ljUFzI73UkcpfziQqBW+8Peuj8YeHBotxC8l5DNcS2iSlYukRPRW96vfUzvpYpNtXTIEkGG2Aq/oadpN+13LuYKGjXafeo7FzJZC2chpQvfofes24RtMELZ/eAfNjoQelCKvYtmOVJbmaI/uwcFR61VupheWglMe5kyCcdq0o4pGsC0THzWBcoe9ZWm3B/epIgDHOFpkPsc/cXC2xBVfkz1raiS2vLVSmEkGM4NZmopHLIQvGeox0qLS2GGVCdynHPcVSMr2dmX9SMto3lq5KsO3ORWcXWAK7ncM9PStDP2mRI1zuHGCai1TTZPnk/i/ujpVxVyZFdFjuJ5HtDtOMgDsamjvVlARk2XC9SeKzbLFrcAjd5pO0DsTXYav4ftItSjgutRwYQPt0kEW4wMeSqj+LAxVeRO+qOT1uSVAYblHilGCA6kHHY8+tFafjDTL3+0ZVurn7ZJFGhW5JJ82IqChGeg244ooswuup13h7TEvbOXWJtQ2zoWa4jlbG1P4Y/XcTWv4oubHUNANra6WttqagNG0KttjTHRm4BJ7mrekeHIZ9Ag1zVZYLaS4kM0bRn5yM/KB2/DHFRXOvrczCGNprtGUxM8p+bjoABipvZ2OlR0u2R/D7UbO20lBeW4v0KESpGyrJAQeAM96XWUS/1f7RFpNw2mW8qkwfaAGmJIJB+ntS+Fvh/Nr+nG5s7yC2kjkcO3IfjnbiovE9lqGgwm23x+ZhVj2AtuJ59eD7VLi7XsVGViLxLLLd3dxZTwvayacFlhgE+8887Rt4+7ySfSrnhTQrXUdYa1u9Zu5LGSHfdIJNwuHP3UU5/U+lYcdvPBpfmDyJVjBMshyrSuckgk+npWl4VvXjs7aW00N2jVtpnGAQTySOecdvSpbsgiryO50/wT4I+ySROXmlJ2qPMLMzAY7ds/wAjXJ6NodvpmoSWemQ51pZvLjZ4yo8rdlZFbI2njGetd/DqhtnjSOBdOuGKt5UqbQh6hgR7e+c0zxHB/wAJZZiKzitlGnjaNQiJDOxbJjX+pPFDdzTlS2OVsrR77xULqwjhjkXzDe3Mk3mPFLyNpB4LAAkdRzWxpdtaadqjz69eK0cmTbzuctMecIx6KRwcflWdKv8AYuupqEDlILMJFdRQqI2kjxyw65b+dd/fRwXunW8Wh6Fa6no12xmL3jkfaSo4x/FkE4xxyMUrXGvdOe8XaxDrVxarPJNFYC1WP7QUVjGxByTgDdyOK4TRLK6vbye+udOSWWO4WBppyItjn7mc9Rxkj0robqwbTvKkviNSUlYGtJQ0JsyOV2jocds0yDxtH/wksUl55LxM/mzLdgKryCNlDMcc9fxpdXccrtaF/T7OHRnsV1zUYR5comHmpm3Uk8GNB97p37V0qi51UXguZrGFLeNriIJIsccqDqSOu454rk/Dek/2s8mravK8NgqmS3Xz1RY+wds87T2AqG/1Wxs7y1kLW91ZGRwGhgbfPgctz26DimtdQvYt6Nfx29xFLd21pIyTBVtbhyyM3Ox3PYjPAqK+bVbrWBFqFpPeXTQtIq3TnyWXsASQTg59uKNEutFspLjxDc2erPPODHaKy5+bHzS4boMkKBjpWWniK+1jW7+8vlvpipEMLNGTtwOU3Z4zxUNLZlJ38jVurN/DuuHUNUijjvNQtVCQQxg+S2cKSf4enb8avGxvo9Qgsr+/0iCEfPLIUY7Sw5B5+8Kv6boA8UrNaajBb6S1qmJo5pGEkzn7rFudoB6+tctoWoR3Lx2eoPF51uzLLdMN7P8ANtLN+VE1bVlQ1dkWria9uLmC1tLK1vbePcFmJdVC5yW5GcdzTvD/AIQ1nxDqF1c2q2UlnaEpayuzJGfWRQRlh2p6FdR8XWNtbl47FEaO9mWXyw0TnauO4yB3rsprg6ZZfY7G4MFudsO5D8ixD5QQByOnJHWoik9WXJyeiZxb6de2ccsl7IJsO486MFU4H3VzycVR0BriTwzqOkWiGQyp5knyg4XAYHPUAGuo1FUn0W5jd4pJIHkDouSXXacPnPSud1DUZY7q2udGmaWIWy2dxcbdscY7AY+8RnBqXHsUmupo2jzPBYLbk3Oo3UKtHF/cJ7n2GK1YrOKO0SIqQ0SkHjmQ9SxPrk1U8FWUllbX9xZ3DG40+4HnTOPm2scrj1HJ46CtyRxMyxMvlj+B9pywJ5J9RnmjYpO5yN3ELKGRXiLI53hgPu+9TaXqcEAK3JzExBz/ABAeg966e1mi07WTDPHFPEN0TjB2lWGMj+dcr460a2spBeaXPNPZOSuZE2tEw7MB2PY09tUUpJuzNezDR3LyTqkg25XcclQ33R9abp87LBIRIG2SnC9gSc4xXN6XqXyxW8jhQcbiTgnHQGt9ZBDbuVAbdISy5zxniq5rlKL5jdhh32sUUluVmjPmGQNg8itPS5LqO8hcOsUitvDu20EAZznt6YqnBFdXlsJFCsFAdiTyFHFbttdumnmGR7eZSQF3pgJkcZPpVxfUzm+4zWtS1PWdDJnIt7WRmUKoyFYc5z/drI1M6nNZobya3itbONB9pHy7j0Ue/sawvEd9PbCZElY2cXDlH+UM3Ix9ADVGDxHBJa6LPqFndKlvcYupJY96TKP9XGR0/lU3U3YpU+SKlFEHia11GPVLd9QkaRyPNc3DqyPGvRScg9Cfl6VgapqFjaR2zafbMZYiGRnI3ouSSgb0Pp+Fdr458TWmvu0F5o6wwRgBkU7SoBySD0NeTeJtWjv5pGhQRIhPlwR5woHAx6ZrKc4x0jud1BSqRXMi9rfiu/NveWmrFprK9ZWEUL7QhA+UbOhHr9K5SSH7XIV01ysRCl2nYLsOcbc1WgstQ1WOWaGCeaOBlErgcJuOBk9q0tS0XdBeT2xiwtyttFGmcOAuSwPseDTU3y6lOhC907Gdax4naNYd8pf7q/xgelbFrqVrpRm8lEDsgiyybvMycmQf3SBxVWCHUEktlmU272yEq27BYMf89OtPuo44Qryswd0+RCv31PAI/lWT02HLVWHXWo7Li2PlqbYHLRR8OwGMgNjg4qvf6ukwZFjdY2yQC/RewNc7cyTzXccA3ne+2NeeTnHFOu4JrXUnhvgYpYn2unoR2qlBmLs72Oo0rcbeSdVEgj+8egGfes9RthkmmAdmLBQvP1rQ8OIr2Nwu6URkZ44B9vpWHfSvpbCRERiSfkPQ5PNVA461yHXLe5tY7XT1a2mWY+YphIZlDcbWPrWnESNEgSJjGYneMk+vNcxbu76hAryxj5h8oOOprp3/AHWmThctvnbBC/LkccGup7XPL2kaOmzRf2NIJWBKIBgHHOK5uYxCVY5SQsrAxsvVcjv61o6aIYLC8d2H3APvdzmsZRNKLJ4wH2qyRDHoe/51NhvU17iO6uL63tVG1ppVXI6YA7e2K3PFFutrFG8ZwgxG69Rt9av+BtJS61J7TUJh9rt4vNhuDyI5G6xn2I6e9Ra4rXFveK5zFBJtYEYL/wD6qTNY9bnOWul3bQ28lxFJHBK+6GZgdsoBwcVqXtg9i8lvPcb4ZVJXavAar3hWK41W60XTftDGF5HESOxKJkHgDtnFTeNoBDbNFOpWRclD9ODTe1yEtDjdRV0RZsASpt/EetPF/NcwyJKzSSuB1OSfSpNQt2vNKeVCQ8PQ+vFVfD6f8TGOZvmVAGPvQ9UQtzqPDNusOpKl70dPmOOV9qxPGQ8m8MRDBY3+Rx/GueldJqpCajb3MI+Ur8/0rB8TTx3Xys2SACpHUmqT0sVLRDbK4aaIPG5EkYwQT2FR3cFyg+0LHuducqKzbVXj2I5K7zksD29K6W0uJlXABZIxg+4prci10cjcqJ7kTLlSOJEPT607TYUkfeD1bAxWnfwx/a/NjQCOY7WwaoQl7KeS2ZQVU5ytU11M92Mlsrj7bMYid49KdDeSoTHMce5rTFyRNBLAR5i/eH94U3xDbwXFuLqArk/eUetGjQmrbEb2FtPo0m8hLiM70deuK6uwsrrUZI77VvCF3JczqvmTQ3Qhjn4wHZDyM98da8/tLojypI3yykA7umM9/au88X6DBe6pPqS+J9OjFyFcJJI+EO0ZUEDpxxVyd1dERVjG+I9pf2ery3N5GsJnVV8hPuxKFAVR7YorntbuGQSWIv4r5YwpWeJiUOR0GeeOlFTe+yG4o6ZDqE1whvLiCO1hCq0ow6xZ6DHr9Oleg+GrPTbJFjkurDUGfD+TcfJ5nPABB6nPWueudI0vT47W5vbeIwLuhmh3bm3DpIw96i/se0vElvLLTCtsvzSXSjbGgz2J6/QVnJ6nXCLS1Lmo3FrpuuXsMWpy2MMh84pAfNWI9CvPJOcd6zfDMV7fTTahLezRmMsoDoGOP7xz0zWPrOmyx6jay3ELxabGxWNzG0fm9yx7gmuntdPlGlfaJZp4rJ22RwxyqzF+w6Z+lDi7jUu5L4o8PRLfWbubuQ3Ef2id2YYwP49o42npzXSWOn6voENvLCtneWVxEAISu2RFPUp2FN8L6PcKYLrWYZGvCSX3vkiIHCqO2Oelb2pyX8DWs9rGbWz3MR9pIMbhD9xQOVWh2erHFW1Me61dbC/TTrqaW2acg4uRjEY/2uQfSupeSwEKz2NsiwzKRFLbjehwMZODzz7VW1SeJtGfUtdaws728CBbCOMMAmfkQ56ZBzu9TXGXNwbiYR+GNJXyFbKXCO0UinoVD8bjz2pbaIttvU6nQJIH8QXkMzkwqsc/lQICZHQHDZbsp6irl5Z6jALm90y9NuFYy3lmZMmUsQS4U/dOccCuTu9Du7GaOedtYku5oTuVUWTDZ4UZ9+461eVPEujJdP8AaLG9higWeQvGUlIPVQT0Pb8KWvUNGT63NeXGo2t5rJci8eM7mIBxnBBHb6Yrh/GWm2q3V1cSxS3MV43+jqJAphZeMH+8ehwMda0dXubwW0c2siOSeRhNbQ7iS2Gzz656E1N4xvbfxGtjcEQvPeosdvDAhWO1IHzLt6kjH3j6U1buEry6HIPfSQadBNK4txbybBYThj5uPvMrY6Z7dqnt9WPiDVbSFXxY2gPl29zOFBYjJVT7nn14xW/eeC5baHSbfTLmeLWpy8TQTkSQIpBLOhHIAHWtU6Rp9u9rp8mmxtLZxKIBsXfKucs6tjnnPJ5pSS3IjGW2xzWs+II01C0caXIs1uSJ4Llj80nbcOy+wrZ0nWLO50CLS7W886SOVpp48lS8r8nah9Omc1vDwrpV1fLNP5nnzZuFtFLtM/O0bm6A+9aWp+D1h1kxf2LZ6bIyphLf96+7PBMrZ69xT5U1cpOfN3MW91b/AFZ1W4EBjl3l/MALLx8uBy3QcVy3iOO7fWZNViQW9tcYfz9uxUfuNv8AtAD2BrtNG8LSy75rqK1vIrQs8v2h0jeZc8LGf4T69qqXVhpWpyJp4s0tLyaXBhuflMYY8FgOwHeoaNYvmfYZ4CisrrS53sCZbtpAJFMZyqAZ3E9yWbFauuamlhbT6bZO66gyoJxLgxIAc7mb05GB1NcZDNJ4Y1F4dKlkt7sNjON0cJB5ZgfvbgOB3roNPtXGlWt68a3NwrtJNG3ykuTlZZCeGbsF4AqJKyKi29GQx2/m+G72K4d4QzqVfH764ZjglvRM9FH4102tahp3l2kEVtDZi3txbtGgxvIGCSPeuemn+13kForeXO8iqI2+XaqncTk9frXV6YlteXKrdF3nL7Ztw5EYA5z61MW7GnKlK5y9gz2N/dwoGexvIlulfG5olT5egOSP1rUt7u4vHiuo7hWjiX5NjYG0ceuR9Peql3a2uo/EK2/suKOKD7HKs+HwmAflO49c4rrNLs9OnieWfT9PmZYkjKlNhGCcf7xOckj0oau0KMmkypEGkt1ugvRgzktx7EA8mtqKO3n8i8urdpbS53CaA4PmRr0/L2rBTw/pTwaeEe6tJyxSSdZiyj5uNwPbHb3qURXkltcW1nPEIhINjupG0cjrngHqaa0G/eOc1fSoLbUDc2UZlQMQ8aDIVDyCCeuAcVqWU1nFHbvCUO1RtJ6fQ+9RanpYuIIYpLm5a5RGFyFIjiYA5AAHOMetZOhyi2kmiuYXfj92g6Lz97nrxVdS4u6OusZ2llY7CsQGfL7E1vth/Lkba9sigmPGAyjt7d65G31BXlKK+1YjwQD6Vo2100kLMZskjBQ8bqu62JlG7MT4iagb2+SW0jVJIUCQkHjr0cdG44rmrWPWb3yYdUhkMEMhmEMb4V2IwWJ6AAGta73wSTQwxeZG2cPuw2T2zUdpqF7LcouovCYgApCrghcY2jHAHfHrXLzu7bOvlSgopBa+F9N0+G6STVJ9Q3ARWwyVVXxktj+6Dxiqh0O2XTzaSoGNuo2/J87O33i7DnHoPeta/R/Llkt2CqgUxjODkH73TtVG71aS085fKkVZVUKynJPPRmxxknNXbXUItpWTK+qWstroF3psFmpiu5RcmIHyvujqcc8dQK4mzECTxxXN0gdX2JGpyqDby5x3JwP51o6rcXgBt3mMhjlyEWTe3P8AhnFZ+rWosbeCfckgMZjZQOBmolK+xrFcq16kFxK1vpd7MrOZfMAwpDEJnO4/jxxXN3F9JJKJ7lFmYkZJP3NpycDvx/OrU9x9kniK+TLHJhmiViAVH8J9BWbrt1b3l8JLWzt7aPYoZIslS3cjNXBK2plOck7RW5LY2txqmqtcrbl7YTqq7AUhRnPC5H3RRFbE6tJFcyb2WUqzZLZIOM56mnabq17p+n3NpaSlIbiRJTx0ZDkEelFvLcR3Ru8yeactv/iJJ5P86JSvoi6dHkTkzb1GWLSGihtpjMSMsU7Z7f4ViawsmomGCyhnkuOXmjKY8vjP8hmn30qwH92j7du9lYkE9ag0i8lOl3sWEiW5kVvOWRg6BeMADjnNaU43PPxM3EboGnfa7K7uUSUm3Cu0mwlQM8An39/StKygW5+1fabiKO3wSbjPOc8YH8X4Vl2r3Gm3UtqJ8RTQqSiyZSRQeN2P5Vbikm1PVIUghZp8gCNBgFs8Io9K12PPnNSaaRJqMltCjww25SJB0LbnkfHU+n07VJ4btlfTrDfIp/0mQlR97AAJz7UyVbmwmuU1GFft7MVeNv8AlmMd63dH0bUmi0i2hgS3lWCa8YupwExnc34AfnSs3cFKzRseE8Xcd9cyFkimud2U+8AOBiqHi1iUaWESeTP8jFupcHmtfwkC2luSFQ7ycAYXPfis/XVkl028to0DCO4WcyZ+4CMEY9DS8jb7NzO8PsLbXNE8wkIt6oZVYr8vfkdKv/EdvM1240+3x5f2htpzuwvoDXPwyFNRtUmYKgG4MD3JxWzrdtIjPdzkiVJQOOm096pp2M467GZp04hsri2c5IPGfyNZmnH7BqULEhoWfyyo681t6lprERvFtKTAvhDkqB6+lU4bMXN3aRAbZI2IP+1QttRPRpG1ps+2/SC4G6NWI47A+tYev2q/an8vDRh+xxxmtDSIns9WkhkJDOpKsTnmoNSt3N6zuCduSwUce5o6D3WpVsNFkvtQFrCynf8AdY8Cm20kum3c8FycgAxn8K6HRrOOR4lMm1peFIOOccVlXOlzTyTG7kVFU7S3Qtg9vWqtdEW5Wc45Z7/ehP2dTnBq7ZCK51ONpG/14Py+/ar93YJAipbxl0I59adFbQ/aoJZY2XYuAcYANO9tCeW70Kev6cmlzIIZC4YZB9DWXIHKkq4BbqDXT65aQ3EaFWbapBJ61XfSjLG3yZUjhx1NTK26K5HexkabK/hozedYWF/9pUEC5j3hPp9c1sp41kutL2/2BobPCCApgPT86xbfTrgzMrktt6AnNRS2b2TmSPjcMMDVqojJ02Z2shtTZ9QgtLe1LbQ0Fqu1FwMZA9+9FbJl0/RJA9reNfBipZGgKDkc4OTnB47UVSZFjsru/jtL6aPTjZXt9NCFaeZCVBAySCeAR04FTWt55ltbTxXF+LiEqYba2jAtxJ2cIeD7g1zoXVRZW8l1BIbCOTYDFjBORz64r0vQF1C98R3MNpcaUlxDAsl5qjSq8VrDx90gY39sdahXZ06dTkb6fWQkltqFlLc3tzJtQyKPNyf7gz8v5VoQ+E5bdVm8RausV7CMtZb8eWR6+pxXRW8Xh6y1O+1XT9Ru7yGP93E29dzerEk5GTmqsWvWUt3dWQtLeeGdhLK6qZWB28ZbrnPbNJqMepoot+8amsavoNtBBNaXlzqGVUxxBSoViPunjnFcZr/ie+vJDFaW2oC4lBUDYUR1zhhjGce9bseiNPMkt7dXIdyY7O3yqyyHH94cKB39u9ddoIj0uErI7z3cTLlk5DFew77R6DrWbtv0NEptWR51bW8N1IH1XUdN1IwECKzMhREbgYJ6sR05ro7m7RpLLbY2+nWcsqlBDPvKKAScdxzWjd61pVvqsn2mwtRJeRvKoNspVccYYEA5Oe1cLbR2ereJrJLnTbSKz84iRYw0byDHXHYGh2KUXZ9z0JtettMtWnn1FZ3TEphRleTb/DnOCO/Sudv7661nUoJ5ZFit5AJC2/cyRk8bgOmff8q6u2stL/s9tMutLihTTZuQsYM0sjD5WPsAQMUan4Y0280ibVrhfsggUDNuwQk9Fx2684PpVNdhRbW5dn0JP7NtbS10+CV4EExacriaRjnc7n+HaOi4I9K8z8VaVeWmu3mqaR5VrJChlmhT5YYw7BQ0RPDg88CoZ/ELPqqW2pwLctE4IcufLIHGGAOFJ9au2ttqfim/u7bT2lurA2gihdyVjtsEvsweo64/Opvd6IH8IukapNf6yWtorlrxEJZwjO4J6lSvAAHb3rs4fC8moaXeK9u1qzgfZp5stcnHXywOBz69s1X8MRx6dpFrqWlwCG0lf7NeW07FjC4ADSnHJB7+gxXT3upSxJ/aK2qTRQkiMbtnzZwCyjqPYU0kndgr2scbqbaxpYtGkUzWtji3laH+Ldyrbjye/HUV0F94p0twLiG7upJTZGOHf3m42BR2567qg+2ahJrtrJMiTQSoGERbAeVRlWIHfk4z6YrjdVgvp/ESzalEguJWaWS42YQAcYZBwGyaUrvYqKtubumXEmn28y6nAXmd1W4kmGfJk3ZO3H3lyKryXN54nuGDxwR3Mbul5fSnBjxySzfQDAHSrF6NWu7iKLV2s4orVlsTAuWlVOfnQdGP171hw3aR6zeaWnl29jKBLeRLk+ayEbY938LEdfXpUq6Wo3voQa1Cq6HHJaSulpNfLDb+bjc7H70j55PGMHtWjp1wZrUNI/z7ikkfOAyn0/WqnjG2sbq6sRG3kG4vVC2L5HlxbcgknqSaTQ5lTWPsyqEAjwWBz5jL/GR2O309KmTbRcFyyOnluRDqMSxqshWNnZig5zgAew6mppodukXl9BfXtraRILVY4SJCxbkLk88+tU7KOC40uS5ZXRp2ZpJJDhViHyx7fryfxqxoMYknZ3tXaGGJhbxMpyX6GVsfd46UnuNbeZnx6PbWPh8XmHvdckdZZpcE7UB+6v4dsdq30vwlqgVt0G7eh75I647VajuY7TVpktJXisXHmxZAYNKBtY5PYgn8qpX1jBaafs+0Ce9ZzgKxIC54BNKS0v2KilezLTMi20MnmLP5o3yRh+Qwz1HbirtxO0sBsTiARRAsjpncw6AAcjqetYzlIrS2S4cIZEdlU8Yx059z2q5BPcXsoaOMxyRxgqw++wAxyenqc1mpa2Lceo5rN7iZLVZ49pOS7kKikLknd1/CsTxFpyWlrbX9tDM1vJmBriRuHcc5QemOK0r+cWz2ilGaWYM2cfKuO3PeptS1ttStjZ6rHD5bYXftORt64A4yxP3q1Uk9GRaSs+hj6Rc2E9rNBJF5V05Dpchjgf7OPepIiLS4kebNxEF42N3rM8VWlro93DNpMkk1pIg3I3342xz9RWNcXqCzZxckSQkMQrY3An0qZO2j3NIe96HV3NzC9+l1b7FAxlAOw/rVqW48yESW8XkCWUyRW+3ccntu6muPsdTtp7QtM8jzEnbHCMnOP15qeHWooNi3askikbSxwcn1qFV7mjg0tDfutQuIw9tdxLaodwZpVwRnqD3FcszxpbTC7b9zJkAHOCB/L+lbNrc2Vzd7b6SWWSfaRJGwdlYnqwP3uO1cV4pv2tdaxazCJA5hQqTnB4bPb5h1HbNS5XNKdti/pVlasWkgusKVxv65U9QD/Wq80CvM8UrKsCchnOGPBxj2z1rYs4LO20aymhIS68xjKigGMEHjA64x60+6u9PeGZ71o5blxjJGMc/w46+lNaKwpS1PLru2keG+uIolbyhlnY9RnGB6/So9W+zs2k29lcm+t4LdWmDJsWN2OWQN1Kg1e8SanBay/Z7cbbJ8SNEy8lvT6VRg1V7bR3RCgM2RICAR0wMDrxnrWsNEZzlzPR7GdPBiJ3EqbUPyhc8jvVm3uo5dP2lC0wBjEikgZ989ePSsmzkkurqPTftMECO/+umO1V47n09vWp0zbECPLhjkuDgAZxkfWnyPqQ8Up3t0LupW8l4sKs8rELhmHJAxx+FSSWttp+iQxswec5YhT6+v0q3oyLJbTCWRQ8gLZfoFA/nUGnwPNZzzXKobGNCxYjl2XOFHt61rHRWPNrS5nc5wnF7EpG1FGSAeTzmvRfA+n2N7rK22pTC3hkhlkSUcnzVQlMd81xFrbWwl+26hHK1qDuMUDYb7vYnt0zXo0Fu1u+laheC3L3tqpVBjCMMgBgOnGKtPYxS1OdWz877Wm7/VRtK7vkljjqfqa6/W9Suns7mSF7qeUW8GnPdDhYVwCU9y2MV55rF3IGLnKrJ8jhTw2Dg/Wug8KXUl79o84gWsMouJCP4iAQv5UQlZNFON5JHWacudPhSEHziPm4wdx65qjpMok1TXbaWHzoobMGVOm3DrzmqkmsTrbMqWrLIWL+a3y8dqb4aDy23ie4vG8yaXT1j2JxjdIMD3JxULe5vJ2jZCeKtS03UPElhdWdnHFZrEIRGw4BXgE+uTzUPie4/0FGVgVceW5PRiOmKo2GnvLHF5MzCaT58OBhCDxWiulSLKYblvOu8EAsPlHuBVSbe5nBNaISylaFc+YVt2iKO5GC+ew/Go9P02awv3vZmzFGu0AcgE+la9vpXnpBHOkgcMC6sOrdse1aS2ThPsTbgFbc2e9S9FY1jFt6mctpBcXTzyRkKiADHGD61RsIHup5Zlb51+XHYittLaeaG5QvtDNwcdhUaWQtb5kJKxypkEeop82g+TqY17cSEiKFcHdxxVW6kkuLiKN35hUEA9K6DTtIVctMzvMzEg54Aon0WI3LTZJ+tJyYKnfco2Nvbz2/mhz5h4I9Kf/Z+YgGIOK2o4kjjxHEoB6ikRY3yMYPoajm1saezsYE6G2DhI92R0qpE9zGyF0wjDpXTyRqj7doOR19KawSRkWRBtHp2ob6Bya3MibTVVElBAZmGSPSuz1DRbWwW/u4tLiLRiO2sUkTzBM7DPmYP3jWFPgMI0GcnAFberW9tZ2Eoaa9kuNOliV3MuFG7lgg7Y9aFIU4I8z+JGiw2ustFaQLEGSN5IkHEchUFlHpz2orqfEGn29rqbxb2ljkVZo3cfMVYZG735oraFmtWcc6bT0KV/YzWdrJALWS/1BUWSJLSTdBCjH+LuD6Cuj0LRLKw8PxS317Fb3itvktJISoUjkr6PnuTV+28M6Tp0lv8A2dqUtndxKstwwbzEkf8Ah46E46j3qTVp9WtoFkTUNMnidiFCoQx9QR0FF1HY25HJ3l0OY1CC3vJ5g2n2U7zqHJs4iY4ojnOVHKtXN6TpyRxzXam5s7QuWQW7bgFA7g16bf6nZpaQ26ERnJN1tlCnb3G71xxXE67caY8cc1heym6MoRbRMvmEc8nH0GamVnpcLNO7R0Hhz+1ohG8kdtcRNBsf7RxKM8hlH8PA7V191pkN1ZyXN9cz2t6qkRrar5SoMZ5Yda4S58SLB5CXEcS3bH94s0hVQuOimq+seP72LV9Pgsbe3YRyg+Uo3RP2znPzDpnOKNt0UpRtozqvCkUotbvWL9RPdS3Cx2luVzIUQH7oOSMnJNRm2trDVLHVNevvNu52ZJI4XX9wCMqRj+tQSTaneIsvky7og0sj3sojUSk8hFU5xz9K5iTT59SjIe2lliS7iMsn+rVFY8AL6E9z2qG22Wmox3PTtD8VWmsXOoSQObu7uZsRtLB5a7FAUMWHVjjPFZ2vRxDQ7GC3e+ubmWVnSzTPlqNx5JPT8c12Qs7S4itYLaK3DJHtSOJwptmB4APUkdeawpZYtLiXVdWm/exShBO7nO8cEKB1OK0eqFF2ehx0Pw0lguDd6o/nW90vnzxkkIWzwqgckg8c9q1rbQtQ8Mx61Bo0zXcjRKrxCT5reADLsi/xfKceuAa7O21m2xLq1isl3DC5nhjlypTcMbiOp9Kx9YupIBY6pNLE0gQLezRA7x5hxhSeu0Y4p2TWpPK76EWlpp5ijvzctawG3WK4iVsPKCPlmwfyIHai1vNO1SG6nt45DZxP5dtG7AK5X7z7u44+lR6m2i29rNvtSsUZ8yOS4cM/TBDY7d8Vz+lXk0/haKG0sneRozEzuMRxqDnMePvN69hUpmlu52lsI4oZhaG2DRFpljkI3J8uCQRyevA7VzNstre6vqseoXNxDJLabEmDcEsfm3Z68Vs+GtFurmG81KDUEtgoFtDvK8k8vnPQEjrXNfa5LrVrnS5bjdHHKhkXgopIwcEfQVb6DUU7oz5NIEDzXBWK4izshnjDZZMcEpngZGa1LKwtP+Edjs0cTwTYldwozHJySQT1bitmZfs7CFiiukgTzFPAHr+tcx4001IHhTSXE5DPKVizgsRy4U9/bpUuNgt2OLuZLmfxPYsVF6kCOdyHDMM4yc9Dz2relgkk1rTrW3h+xNOuye43eYY1JIDADpwcVh6Rq7XOsfZoEjF4ym1WQZ2DuWI/p7V2tvHa2lvftaK63iCHdMSWLPv+Zt3YEduwrG3VofxfC9DrtAsRHOLOAPdDywGWYqhdFOQB2B78c1bDXHkT3jyR+VEnlOquFbBJwvqaZpYY6lbxvCWmmRgzSgtxt4Yfh0rPvngtUmMsYKxMZF35y47DH50nexaWpHq11LcSactrDJNhDbx+an+qyCSR9B3PrWld6ZbQX+QiW8YCOI/M3qqkZOW7t7Vzvh641VbvWNak06aW22eSv2dwywgsPuLnJ9MjrWi+t6fKsaRziS7GRIZcoSc5B2kDHWp23CLu9Cz4hubme9k0y3UmyhlDgFBvf5Rjkdcc8VLbO0MAuEZoY5P3W1STle+T6ZptrNG0kTecT83zhG+ZfU5+lF2Y4bmZYDKIN48tGwDgevuahJXuavZRtsTQeXrGswfaxILJcQ/eG7nkkE9Mn8q53UJo3iYWsB2I7AIG6gH8ya0Z1kguGLRjYQSEOG6+p9aoyxm1uyImE2E8zdEcqn1ofYFa9ygLd5AGnZXZVJbzD0GKw7XRftWnwOpzcyZYcfeyTgVsapf29nbzpMiO8sTBOzBuucfgarDWodFitLqSMzLEifulOGfpgAjoSfSqjbqQ207oyo4dTsIC506ORI2K+ahAYAd8dePWsrXbnUNScC3tInAQr++wccc9e9WLCGXVGvLtpZBK7sFUSNtUk5K57gdKiF5c2kkkUrK2MHYMEx/7QoslqgVVy+IzTFe6c8cs6SrbyKvRMAMP4R7e5q3eLcauluWkhCwlQEA2jaOvbrT7q+FxcwxLLjcc7m+UVft7B76bFqVVVG4SEds81Cjd6G/tLLU14zYy2iQ2oTzz8vJxs+prC8QXFmIpR5KQTKnyMr5yfUVZvNOWO+uoJmdZUAwwYbTlflrzzVLTN48szOxDfdQ7s/T2qnFvchTW6LH2cQA3N6S1w5CqrkHg+1O1uA22yOIAE8qVIyM8/wCRUV+Y0gLNhMEZdzlj7e1QPcJeuY5S6KTgyZxkY7VcY3MalZR2LllpOi3k8+xibnYWO5ztDYz1qpOqpZzx264eQKJCQCUXHJ59zXS6nY6Tomki2hiu4pBEsh87G7zGHJOO2Olc9phWLTZJLm2f7a8ieW8oIGAR271ujhntYnuIk2QySG8VU+SUkqPNUMANvHTHeq9xBZuQluZfK3MyQyPu78K39TUV6JrrUJPKDrbqMSu5zsz3+me3atKOWSKSC6nFu8iFT5RXHmRqPvHHY9CabdzNIqLbC4HkHgJCJH25GVHLc/pW5q73H/COaZBPELdrUBzjG+SGQ53t/Lmp/D+ofZ9bgl1OEJp2qIRJapjb5ZztIJ9zmsqG8afUb1Z/3ekE/ZvMLbTkHCkDqwXuOlNLSwN21RjXkqrDceVlY5XHkb1+YqOprpPBtqj2D+ZMI4pGLuP7xHQVjwQXOo+JlimnSRFk8tZUGUCjgYB7EV6HcSwJH9n0q3SS5C4CooA9z7VM2tjSjG+pzc0wubu3gjglZwGXa+cMwP3vpVm5afwzaSSwzA3rlJHcgMVI6Y/E11VhZx6dayXl9hrvaGz6AdvasPULN9UvNPPlsGuJvMlLjgAdBj8qlbm7i7Eml20gEd9Oo+c7QrfeOed34muk0jThJftdxMJJI0wqnoG6/jU1zp0W+aI/KTgKe3FWTAIFAj+UkYIU9Kd7O5UYaWK9ria/lmmzIC29ieOalubdZ5RKincmfunirdqUhkWTG6MAqPyqNmZH7BD0qG+holYpLbjHmKTjGQO1J9nidgW5OM4ParQUK5Ebg5HT1qNn8hSRGpJ4Oe1A2VyoZwYyAQMYFQzRskRXJ3k55p1w0SHfuAfuKpT6hvYliMdqm4JDHbygd2S3XAqs8in5wcHvUEt3l2bIx6GqtzcjYM4z7VO5Wi3NczRui7Tz3qs10ACoPSsU3TYwpAqI3BUHcfxqieY2IpWlcsDkDv6GuukOrTxtFfaBa3Mk2xmkN0F80r90lQefw615ml/JEhUAMCc49fatvVVsNZ1J9Rg8QWlrDJtJinZlkgwANoUdcY4xVJGM5XZP4pg1UXTX2p22wSME3RkFVI4C8HjjsaKTUtZsLi01yaG4Li8EVvFCQQzlMZmYdBmimkZ3uaMNy8Gk2ltqks+mXodt7YAW5LHhw2MYwOlbdto2mDRn1B7/AFEyx/NGqOu33JJH14q/LFYaxoFtauInjt0MbiTpIc44J/ixXlHiTT203xHDpVu94bHeFKeYVJBPAGTjA4wa080JvlVmdF4k8P24eKKRzezBfNFu0+PKXk5dxwTUmg6Tp9laLeajavazORI0EY2YjPIy/YkHoPSkm8P6ytpdWVwSFYjbEcMT6eY44963vDenG6USy6obq5kj27HQHYRwRzx+NGt77By9Cp4li0p7hlTT2+wy/Nbq43yy8Y/i7f7X5VlJodp4PmW8mNvc2d/C0clqzElGPQRjqSOldzNptvpc9otvZ+Zqao0ardEusygZZmJOAo7Ac1B4k8PaRZeHrqa/ji1DWp5gIFSRozbnrlV5wCTjFNJ6uTHJLZI45bS9k1FW8P8AmXGnCLzfJn5kjUfeyOisP7pq/bzKdPnminL25YIHIO5sHPOO4rCsIxo2tSJemS1t2kMcsJJaZXPQlc8c8ZPatrVvAloZbieW/NmgiklHkEuGOMg4zzk8ZFKyewRlJb6ncXOo2DR2/wBl2mP78zRk4LEdOfWoNI1nT9Tt75VjaTToEPlFo8qTjnr1bPSvKbe/1bTdJtZ5NMgu7S642q5IkULz8o5GPX1rQt/Gi2oOlWtpNZadIkZlinBbABJBA6gY470m2PnjdI9SgvftVxYW9ptciJp5tzAfID8gZvqCcHrUWtarps1x9h8uGd7lMu6SA+WSOQueOmfauQvNYs7rSLy7iniF/egeSiZACrgKMfTJqyl/ZTKkdhAYZWj2NLeHBfJA3lzwT229qL9ilZsypXkudTW110y/ZHXECAjFyozsBb+904HHHSpdNv4tB0hXedBq8EzJbw7jiDHRnHTacn8qlj1SbVNJltrqFNRuIZWghEWDGgXjnHIOBwRXCeKrtNN1CQRM0xcxzxSiQMYWOQUY9x14NJeW5TnZa7Hf+P7qOwj0m1izcXN1bRS4jYne7E5YL0yeRWOL+K48VX11Zadc6VboiGRJ2BAVV2nK+pYfhmuBK6hr9xLeWcV5LPGcuUO/af4cd1HTmt/wnp80GvWkWuW1407gypEP+Woz79fmHepae5rTqKSSW56hpuqW11oivJIUZzndsDMFxgAevPWuP2a1LP5bQC4mfeYo2kVIwgHLuo+bbz681fudRTR1upLyFRcM7IluzAGMknj6DiotD+2XEVy058u1vmSK5uWYIHTIPlx+g96q90FSy2ZxF8mpWP2fU9PjiQadhBNADtDHjk/xHOa62bTL+y0izk+0Xbz3ixyzbSkis5YcYGDjHarPiaCPydStbJnj0+3w0UTDaW2ngkfnxW/4IFve2mjG8RnijzKQxClivCjceic9fas+bm0I5OVssPdkW9szLfyah5bb444mjSLHATJPfrVyfRLjVV8jU2SCHYHaLePMbaA20t/CPYcmt2ytEvddNo8sf2fzGYlWyMDng+hpbpFuPNuQhWIusSLGNqBs4wO7Yzmpsty2+hDZwtc20Frb2wVgCyOfkVY1HTHp7+tQ3lrZyQOtzFC7Rhe4JJP8X0GKCEt4bsxpNvhnIRmkGdh9V/yKbHkqisNsedrsFDFVJyT70X6DSMK90VDKTbGW0uMY3Rt8pz03L0IpsF+Y76Oz1RWiuUGTtO4SDuynv9O1b9u8EV1uuy+xwQrMh6Y+Ukd6zY7azu7uGDUiDalzuKg7x9Mcg/SkNu2w3zknlWDzvJjmb78nC498VnX/AJQTBlcB0JWTaVXcOox35xXKX2s/2NrEtlFMZ7QPhJW5dB1Ab2x3rK8S+Nbb+0LeZmkmMZcyDGFOR2/GhLWzJc7LmF1qdp9WtYpjIiksWPXJxgZH502ItPezwzbXGzyoWcZ8scZk9M9hWbFfNrl7K1pDLOmFL7eNq9cAnpz19q1dPC7rpHd4nfa3yEYxjBwe3NLla1B1FK6JLO6a2u7qw01HVI1QFpOREO7k+vtWnpCW1vc2jRRR3TeaJWecD9+wPO7PbtioPD01paWGsxG2jaa6l8mCV3wYio5YL/ETz1rLv7+O3m2Bx5ccTAt7Ejt+FDumSrNXZL4lSXTfFN1BrFj9lkfMi20LAgFzlQpGeMVDo4vXuriKRxbyQna21sjn09ux96oeEIRqU1xcSSGJ0VnSWduY0HHy/wB5z0HoK6DV3FrYR3VvCf8ARFyCOhjz8wb1+vrV7GabauUbqwv3F2ltdAytsAjKkmRjxhT7CuWezlsbK5keTzQq7lkQkBWzzkHr6YrUbWoLrVEMkzG3OGKQnlsA457Y4rLuLyW7gW1QOUDZaNF+XYD/ABMfer36GblvqZEkbTLH5xO8ne2TkHP/ANarwtEk8y0aMpFuylwT/q8f09RVeYeZqMUeFjBK8ryNvoK37YpBDclPL27SGkl5xnNPZma97VkV/p8zXkaXU0k48vgqc7mwAAPw9atX8dxrXipYXxaiNVBEjhliRQBnjgnAqNJRb2kkkXyP5S5GckHoMn1rRms7az0OXULtkhuGMafupQTtK/3frVJ3JcUYTu8t9PaWQMgmOxd2MFfr71H4rshZa7cae024WcKQnEgY8ruK5HBwTineG7SA+INPuLoMbJLgPJE5IBUc84/Cquu2ovtTv5och3nLOTwBk5CgVSVtWRKV9EPt4bdoDNcXU0l6u0R28IzsHH3m7fQVYgtp9Vlnd3OIyVC9ARnhVHb61Y0TTi81v9ktfNm3GIPv/wBYw6nHoK7K48PT2tounwXUL/apB5six7cjqxB647Ur21NFBtHDWaXTXMbNuSKOYLII+GccnOfQc816noVmkGnE6bF5u4M3nMcbsc4BPf2rIvbD+zLrTZAA6DNu7FeAjDjP4/zrotHRIbe7tYkZ1ibcgLYVQ3r9KzbR0Qg0rFU6fPf3tvHMzOm7dKsfTPUKfqa1WTOqmWYbnRCCOBg/0q1BMLONY4v3bMc7h3PrmqF7LFazMZHDs5yWz1JpOyNkgDh79yXJ+TnPrToplZmWRsqo49SawZ7wJdOU5Q/xUhvySWJGAOlTzF2NqO6HyxxYG0c/WlmvERFG4Mw4Jrk5r8iVtmRnrz1pjX+QfmIx6VN2M6Ga9RAz55rFutW3cA81lz3cso2oTzUCAhgH61ViHMuLdMzlpGP509plZfr3zVB88AdRUsgBRcnnPQdqEhXuMlkHmd8VXkZmz1xVqVVUhU5Pc0zaM4xinYnUrKhPJ/CiZf3XTnOatFQRhTTJ1AjANILGUELSDecKSNx9BXoN9eTWUmtW9ppVljT0iltUNsGMsJIDHP8AFnOcjpXCpGzNgcZIGT0rotQn0rQtW8iTUNba+s1EPnQuqgDGdq5/h5rSKOeZleON48QyswCebDFIIwoXygyA7MD06UVRvZLa91Ka4hkupIZMHfdMDIW7kkcUVViDvNU8BvpsF0dQu76O32SSRQByQZVH3fl6E8VT1zQ7j7Jo8/2uTzVTYQwDnfsye2T1xXT/ABA8QRXmnWo0OKdJoyrlsknduGOvXpWBH4ntNa8WWLeTN5NqhFw+7JuZursMdO1HMuho49zptC8NLFYwRytJcXBUeYsk7OBjk4Uda6rRraHR7yV7eCJoJWLtCik7Exzj69a5+78TmyleSN/strldkkxAIyMBQByQawNY8ST2otheXsKNO3lrDBLiYoTznHTj+dLmTV0Xy8qPQIR/bFhqV0iqLiX7pcLEYUB+QD8OSB1rin1G61e6kkRR5lqTBDBjiV8fM+/ptHqararrch0wyQw2yTzN5avc3fmSbj/FtXgYHrS6JZaXpssEzSz3yRDOUdmHqSABjPrmk25aMEktjSvrIaJ4efUl00Xl9eI6XkqHcbiHjOwnONvT1NclZeIHv7RrGJJTbwkojONriM8gn14r0CbxLp8cUv8AY2mXF8mQI57nKRwjHIx0xmvP/F/h5xJbalbXLW7XrCK5hEhYKhHL4HRc8fjVNcysmL4W3bQ1fhpJb/2bFeXM0f2mPdbW6sNwSNSTkf7THt7Vu63o/h3WbeQ39hM14wx56N5ZyRyeB644rltH0XUtKyltPZOsf+sTHzAdsMBzxzXd22leIb2OCa21HTUgVBu+zr87cHqX43AegoTktEFo2uzkvDPh6MQ3E1nb25ntpRDI1+7K6kDHyleMHA6jPNS6qsGkajYySW1zexozNLYXefJkJHMiP90kH8DXa6fZQWV08cSu0vEl49wxdt2Mbs+4xVLxFDqmq+ILK2OroYYrcNzgjaxxjA+mcU3ZCUbnkuuXVlf3F5qeg+REpO6WEv5cgc8YTHX3FYWoeG45Ukht491wpG52OyTJwSWU5+X0xXtLeCIdTu5LtY7W907TwYYJPLAE7buWwozyTgZ96peL7XSotME7wpY6jGgg2RRkEMDyUIPHGBilsrtjUebS2h5TpFpe6JbTf8TEQTsRs8qXG7HQsD1GfWtC3jlmmS6uNXu5JSpjJjcs3JyV+XoCeavx21yb0WMdqk+oSwmUFgu8KOTleecdB39K6HSPDd/dpEk08OhpI4VlkGZ3XaSXI6KOnHXnioUerRtzpLliYtrpL3SKqIyRAHMsy5kI9EXJwPc1v2em2lrDDFZxszAYzIxbafX0Ga2o9FlhWIWxcmSNhA5kXMhXruz0z6Vd0V7W5tBMy7I0y4KZLSt0Ax04P8qGUrbmRrGl262TpGzSM6lJJWX5AccgHvipPh9aqPD5W63QsUWKJVBbciE4z6Ek5xWnPefZNNndYnn8uPy0QnoSfm2+mavaJJJplrdWKxRiaXEqfxtFEDyg9wepNSkrEzbuaNlA+npckGSNo4gsmz+A55XP07is29tnkk3GQxsCDHHuySzcjp6+ta91aoun3cizyjy1R2LjaCp/xJrK05zJrlrDp5FtaeaGMk/OPr/SlKKtZjUt5Iu2enNbux1ERRtEHEiTZ49Bx97mqv2S3GnXABme+U8ImQsSjqzevatDWRbG+jP2mSa2MjCe5YHc5zyFzxke1VjMv2JraEyiWds8jAKAfL+NO1nYm7auc/4ku9XubmJbaC2NlHGsUTu5BKgcnb2Oc1XtE1g289u1jayKy/aDIJRvCr1xnH5dTWjqM9ms4W0uxdQsgZpVGBkjJH4dKparcolm6WbmEEb/ADCAXR8EZU+nNTZXKbfLoea61LDJqAlh2LHNiOV3G3bz1OemK5LWFhMhAiE6Id7Sx/8ALNc4Oc9fauk1K4kWN/tscX24bYfKbuSeJAe5PWqV3p8ekaZqEc08b7sEumR3A2n2HNNK2pM3zRsdD4M8geG7VI9iI7MflUZxuIyfwqn4glj85oY4kZrRPMIB6g9QT9KueHNMRdLht45LW2MwB+0+ZtBz/eP90Vz/AIghtjK8rSMlqWEDshIB5+9n06/nTk7kJ8q1IJ7aZLPSpER4zOjXIkLlhg8E+3PaqthC2p6i8JulMZTbLKFB2r2Vfcmkdrm51VG08SLaqfLWNs5xjP3T04GelXT9ksdNiu9NMkEzA73k6SEc7WHrz1FPpczWrsy1Np7zyvOl5JDbWxCQsQFIYDsMfpVBSGtJ31qWd32/KjSEKy9iB3z6UxJtURPNurTMbfvFYNlVz3NVr7Vpbywit5rpxZQEPEXXbukJ+8TjtSRTfYNLEcLlyscSCMtJIFwc9WGPyFN0xpJNPd1IT7U2TuByIx2z79arSf6fCLW1AkcNseYE4kJ6kV0Gk2kN3aW9sb2O3eaTyXEoI8qJcbmY9gegxWkVfcwbMKZRAkZVd07fMSOVVMcc+tOivwsSRoqhVwcSAgMT3PrV3xGyW9vei3CoWlyFiGVx0XH4VhljIN8szKdmF9Qe3HpTaTYlJxLmng3FrKGlQxRkuWZwNzA8Y9hWrcQyP/Z2nWpae6dA0pKBo13HIP0xVSDQ5rm2WcRx2WnRjm4nO1T7L3Yk9hXS6M48QX9v4T0aKSK0nlSW7uWX99IqfM8jeiqoOF7VpGyM5NlS9vbe1057PSoAqy43XUwBlYL1PsM5AHpWfbQ7rSC3kVVQyZkcthmPXAHWtHxLdW+q63eXekWaRafI/kW6Iu1QijAI98DJPvSxxW1lY2RhMk2ryhixkTAjUngj145z61Lb3ZcVrZGtoFrBb3baiYjDJJmOKItxGo4P4nrW4bwSS+Y2FVRtFYkLIscakg+WMAHufWp1u4/LVZMFvT3rBts7opJGxqAW9sJouOU4z2PasfRNbCRSiUM0xUI4/wBoVDNqLqxCH5T3rFf91fNcR5KynL47MO9LlY3NLU6W41FnQbmII6HPSqM98zEEsTiqDSO3TNNEUrZyDzT5A9quhO85b7zGm7mIAXpnmnx2TscsDV5LBlwCDVcoudlEQ+aR8wwasJp7MuI06da1LSzEPJRc+ppftMsDSDAVPUdTRZD1ZlSWvkRFdvz+vpVcQqSSSfxrSdvMJPXPeonQqDxihlWRS8tVcsTTGDM3yDk8/SrLr8/q1TRRiMHd940gsV4rdQpLf6yopY8sK0FTcTjvSra7TuPLehNTcaRliEhuOlMmXcQtaUyGMHHU/pVFyIxubvQDVinNtU4YHb0OOuK6fxFJq8N95Vj4ct7iySNVt5JbNpXZMDGWznPXg1zlsljdyTf2jqP2FVAKERGTcfw6VaI08kn/AITS9H/bKT/GtInHVkYmtm4e9lN5aR2M5Vd0EcRiVRjg7e2etFU/EMyC/lFvfvfx7VxcOCC3HTB546UVaRg2dhrsFra+G7eWLWb2fVpGzII8FYl7Nx+VNuPDtz4ee1nisnidoAZFuJgXd2AJKqvQnPTrW/qUWn2WiyRwSovmkLK8SZdySOEHepNElSLW7e71OQGVd4jt2OfKwvEhz1Y45PbpSudHJd3b1J9K8HyX0sNx4vila4b96IEBWKNQOOmeak1aKx0jW7JbbRwcSEY8j725cDqMda6Gz8Qab/Z897FqgXfmNY8EZHc5PA/rWBqfimO/s5bBftBt5tqm4kjbamOhzjPHtRJrYpQtqdDp8EV5dWc8+kQWy243qCwYljkHcqjgVZn1eHT7aUxpIsyMZJNh2qid8nsPrXnp8dhZFiuGnW/iBTytPX55T2fd2Bqnpmi6zfXaz3iAWsjb44ZXLoD6sB94ipcm+g/dR28c2q61b3d/ps3kaSVw9zOpZcHtGvVj78Ck0DwlH9ha91J5bi7YkLuk58k/8syo49zStDrT6fLYxX1lJNCiOYVU4QA/cb374FaGm3VxFbsZ7mJTK2JR5RXdx93uQPyqrW1sF+Ypf8IuqRQrHeTwJuyqJhiFzgEGn6HaXEerGzuYTqF95ZMMs0hChPVR2I9K17nU4oiwtZG8xVBJHCL/ALP+1z+Vcxa65qeq6ldXNp5YWQsjXKx8YAwSMfkAPrSuitTq9CubSKxvrrURc+XPdMBGsgAcgbcleuARXPCfStTiuEvYuEkaHNuzCZeM7lPTuK1WghstHgtd0KQmMNNI3Mm3OSM+564rzvU9WivNd1EW0N3I1w6vZJG207CApPHAGVHJ7Cjnsrgo/idnHq+m+H9MlttJMttHncyeaSgx90sT/EOtcRqdzd6nZtqFu10LeOQSXN/nJ2Z52A8d/rVnS9DlbVkub5l1f7OweS3BPkI+cKhx99geTXd6N4elSS01TWJLe4vEkPk6auPJhBGd2zofxpWb1e4rpK0TmdOktTFaHw1pO4v+7lv7mQhZy38eepPsOK6TTbKaJ7q11OWAvpzBy7As8obGxfU4z09qijt9R0HULeW2KW+k3krG0mlGfLkOSQq9dpOdvHBpNJlubnWL+7R2aSOKNppZpAvzEkD9aT7McdjW2PbW0dw9vF5lwX+8vJ7fKB93/wCtWEsx02+trS1dxHMGlWQDaFk/jQe2MH86ljur69kl2SRJaxHaHAG937nPfuKuatZSLDagoBcwhZIF3EnOec+xGRipeqNFpuRzRJcxWFm8skKT3BnZNuQY4+c59c1tvpwa3S+gLBhKYY037C8AHzAn1aoNGtC8t1qWrkWaSrst4UGSEU5IXsAWPP0rSywuoNsKTXzDcsf39p7bh0wBTViW7mNq0MWsWxk+13sRGFt5o5go2DG4OvQ44wKwxdvpOrNY60yXKOSsN5AcJI5HyqSehH5HtWvqRNjft9njCwFw0gK7tjd2wP4SewqprV1pVnY6jZ6ofNa4iCxcKQwIBz6g+mORUSauUotaouSyM9vHal5XeEkbFYbASew/nRPt1H7UqblENqxQvLtKlRjOfx4FcLpur3Nk0NrPaXDMqloZ9u03EY43nPfsa0Jr283bJ7O5RT90KVxjvyPrSUnsU0hllOsXhKxNrBvuI0IYu2PM5IAx2PBrn7/X7YMv20PaSJklJB/I9D7VLbal9g0xra9ju1Ed20fl8dScqAM5Jwaxls5by4ubtLC9S4EhxJJhYIEHBJ3feJHWi19yXPlWhk+KJpp0F80+Z3PlJEhB2oe2R371FrMkd3p0atOoiklVAR9ec1rW/hue6WXUXjt4opEYQRNHk7ezHtk/yrLurIp4z0qJrVBLPKkksMjfMGUc54wAfT2q0r2MJSavpudTa6ppnh4Jc6dZ/wBpS2+SgmTMG7GMnPBweayLiGCKxju9Vne4nMuWgWHEKoBksRnk7jirvime6vNTtNP+zwKhYyuFfIwnPJA4H0qpDpH2+F5pLtIY0bfLGmSUHXac8Y6e/NNK+iCT111K0QvLa+sr/TESO/mZ7hRG2SgZSAq9gNueDWNd2pN8LcSMwLfLbwjzFHH3iP0rR/s63vJ7yVg0Pl4xJu2Nk/dQKvfHJ+tVrSyvYLK5uYLqK2tidqO7+WcjqemfaqtdGbfyIb+8uhcwW2o25bA3fY4ydxPYn2qxeQSX9mH1FobdFPEYHAHbP+ApNOlkjEkkXkoPKKl4g0sj9+SenNC2QuH3XEjzTKu7acBUH4UWsF776kOo2cVr9jksbmOfzISwjRsnOcBWGOD3xVm8e6jW4kn8qa8lUea/9zgcD0NPnkDtGRtt7eIqsZC5Yn1z65zS6t5s6vfXN0LmeeVI0LAAjA9B6AVo1YzSuRobZ9BuJZ3zekhUizgAdMk9/Ws7TL6zsp9sOnCW4Rtxlmbcc9uDxjNW0sXv7zyYoGmnbP3VJqxcWlr4dCSRBbrVWHyoBmOEereppRlbUJU31GeJ7i+5tNTf7bq8zKXOQRboBlVTHAJ71u+EpbfStM1a4+z3MN7exrawSk7toIzKS3bjgD3ri/L+xA3M8rPcSsS7E54J6D1NdFFqN35cdldfNaxqWRd2CHbkn+VPm6iULkZY2+n+TbrJNsYrFGw5UE8E+5rUsNJkjhke4naW76OzdcdgPQe1VkvlnuElWNUtYThcDh3/AL3vjpWvDdkbJ0GV6P7ik5I3hTvqQrYSYHbjOajjsHMoUEkZzz2rakvIR1O6nWcaSFnJwD0qbo1UO5mvpxCqDjjrTra0Qtho+npWq0fIII2+9RxnZPtUjDe1NSQ1BDGSKIfLCCfpVWS6EBy8K4+lbRtmfJDjFZWoWzFCrAU7lKCEXUkI/wBWNopf7SGPlj/Osh7Z1OQDVadpoumaNCuWx0CXzyDnCioJbkCXGwu36Vi2d3++/fEha0ILqNrjEbDHvScbrRgnFbmor/JuEWM0yWBpcYOF7mpoJv3ZUgEHvT2j44YAHrQ42KtcrmFIk+Xk+tQrGZJOBWjBaI2TI5J7c1OoiiyFx061D1QFFYxFx1NPYKq5J5qC7nAY9sVnT3uFIBBqLDH30yjO3HWsG7nLMQOlWbh2cks3Ss6UlifSqSMakiTT9LvtXeVdPhEpjALZcLjP1NWZfB+uqmPsafXz0/xrFbG4LkBmIA9OTXS6rbeF7KPVkmstQuG0pokuHW52l95ALKOwBNapHFUlbc4bXoZ9Ku5LW+j8u4QAldwbAPI5HHSiq/ja2t7PX5IrGExWRijkgy5cujICHJPOTnkdqK6YwVjjlNtno8fie2t7uK8dWubtZV2t5WEjAB4QevvWrrGoTeII7aZdNY28QAjkmcQKzE4OR1xzz61z0Vvb6ZfRXmprqM91A/yRSr8qP67hxnNb8kem3tvIt7YxQuwJaV3dsbuue2c1y2tueinzHRWWn3EcqRzyaTNfTAIjkiTZjsq8Kv5GrWpabHKyWdqr6hqoUmS4ncGGHjn5BwcelZPhYaAlsk928NklqMCWKLMjuOoyc1rafdaXa2N5N+/uJpMykR5CBB0z0GapKw730ILfQtKhYRWyXMFynzNfBk+TK/MSTxgnt6VP4bjub25kgm1WGTRrEefPfQ7lUD+6oI+ZzjAAqrLbf2hZTTahZ2Nqk0Aa0DTt0GCWKjq/14xVq78UfbNPtYoR/Z2kWYVFCW4HmPjJlLHoW7DsKm19ZAnraKKsPjm2g1S9nkhlsInk2kSW/wBxRgKOf4u+TVdNft9aurhrOxuGkbINys3lndjAyO/PtTLi30/WZmvNI0+5nulILXFwWaORQOQM/wAXoQMCpp4NL12ZJdOaa0Kj/Sr8AqwI6x+57e1J33uOOqtYs30NjcRRhZr65tIiiXN3IdgZsAeTGo68/eNdHJqSWQP2Sa2s4/8AUqpAKxDvj3PoK4OTVLi1mttN+S8063YFPJ+UDnC7/wC6T1PrXd6JoK3Nzb3cqJf3sS5jELbI4UHdQeh9+tLV7FKyKaTpNLA1xcmxt/Ics0se6eROmAvRAffnFcT4mtIJNLNx4Xje2tLP5kabmSZiMMoP8QJ6eldLug8TeKL+6zjTLPFsIHb/AFrnkkv3UHr61f1y3W5urG0kktyTOsXliTbGFUbioA7dBmn0Ho9RngCWwbSrV7hpmwGMiRgeYXxjHGOR39a1LjUWtn06ys3FpLdT485gT8qjLM3fAHb3rBbTms/st1YXYjvJDtltkHySIrEby56Ec4Perem6hHd+L7/VEnGnpZJHbxCdQxHGWJzxknk0nIElY1r2GO/wut3UwgCZUNGWd1B6oO344rmommuPEdysUEcSTbVRYwAqhVJPH97Hatm+u7/VtYuBb3EkMEgKyXkqEGVSOiKegOOCaw/EE9jZWcsdkJi9rcQNEqY2+fyTvY8nC8E96Teth7JNHax2gMW1jjaEd/LwqxLgDH1Ip7paW6yOgZlJIjjXnOP4i3fnsKrXU6317Nd3j48xQVMIyp9APYVcltNsaLdLLM6AYhB4Axxubt9B+NTd9ClotSKJGubbNxPGHDs7fISQewJ6YPpT0u0hVxCzRlIWUvkcseuSPWrMLJFpwgliZl2EhQPvPk8E9l/nTokMEUYlMUchYyNlMrGAMfMMdT2o2He5yl5cXjXqQ2KBbuRNwbGRCvA3H1PoKqpoek2FrNP580d2wyZJSGWR88k56celdDDDJBJJNbNDBNOxLyyAnbjvj6cYrNs/D51LUhGu+d2y4knbJIHoOgqGrLQvqYd5I94pk2rctG4aNoQUI9cE8AGqNv8A2o2jSaqvlQRKxg6/vGl6GJQe/viuq1HULCxkcRQ+ddAgLbQjzZWI9h2+tc1e6brpvnvDbJa3EsYNxHPtzjrmNeisB3PXvTsyW1fQ57w9PYWGrX8+vRyLqrFBFG+XfBGPkyeckDmuma1lvSH1lfLswQ0VipByR3kPf/dFZVj/AGWl5fLPw8iKsn9oKNzcn14HboaqXz22n/LaeIBA4+YQsfPQD+YFLXoJaG7q8my3aWeQogHyrjBPp+NebDUTNrz3JDy3qSq3mSAv7cn05A/Ctae71e+c+baSSJGoEEiI2wsf4znHauOurvULe6UxGWAhtuWB2u45xj684rSKfUxqzXQ6NXlvLieVbm2hiuCbfzMNv2Dlyo9CcLmoNcluYbaOy02SRolcFbWCL7vH3nYd/rVrQbCRtMjuftNvKVKyMg+YYXna2enJJNdlbwx/ZXezjG0kFmAxuz6/hTt0Cze557BaalBpUVzDdLEsrARAqGmlZj3PrWrJoVha3dla4e4MeZJHmbdzjpj0zSLc2drKGkbi2d/s0e0gFf4nGeozwPpWfe31xJZXeoWx80lxC8iH5YwRkAZ68VViNFuXfEF4n2Z7O3EcYb5WKjAH1rL0eCSaDEMrta8eYcYYnvg+lV9AtDqtxJNcb5bZOFDHG5veuhSQJA9paqm4ZJKjAUegqdikufyRSnnkvJo3cMttZjyo0jAYDPoO/ufWrNnFZ3i2/lI0n2fcjRlgmGP8RPpWxBpxsrO0l3Ixkj3BeuznnHvVm+0aCVY5U8uKR2+fa2Mjrz+NO/ctQe6OfuN1lHLFayFJXOxmUnbz29TWZNa3ERMdtA0t065YycHb/ex2FeizaUpiD2loJGcb429WX171lJprwxEo4lnmOZXbgsfT6VLdivZ33OO07Rw9/A1yytIXUsxHyqM9h2o1ktdatd84V5GaR1HAHYD3NdZax29pdRG8Rgxfacc4HtWXPZAyypbKTHuLrkckZ4qea43StsZMXyW+xRtUDCr6CpIrlgpQnilaI8DbjnpSvbPt8wjan944/lT3J5bE0MpwijORV5dRaJvLx9OaySxCgg8g4oRlbIkyrDo3XNCGpWN86hIECv07VPaTjeCSMmuejlLA7m5XpVq3uMEMGHuMUMtO51y3gKgA5I9Kq6hMqwkk8msqO68tmIPB4HHeoZZWk3ZOTT5mNI0Ih56Y6n1qpcxbCdw61Lp5IXaXOc1ZuIkmTBzupNto1TszBmto5M7TVZrKRSWhPT0rpBZxhMAnIFZsnmW8zBR8p70K63B2ZkR6pcWrBZAce9XYtbEuAXwT1pl8kU3+sABrJuNPIUvAelVz3M2mjp4b2Qp8j8fWkFzM5I3En2rkYJp4iQWO0djW5YarGoxIMHHUiqSTJ5i3K8pbgE54qB45CMkYq6L+FvugY9RQZFYZByKTjYV7mbJGSCO5qnMmfuiteTYQd3ArJ1K/t7aNvmG6hIwm0tTB1SXywRk8+laOoanqNl4ntodYn0kzXVqlverMpMYXOV8/bzvHynIrlNRu57oyS26SNHEVLOqkhDnjPpzXU31ppmt3bajqWmeJLS8lAa4gt7Xekj45KseVz7g10Qjbc4Jz5noc74xbUG8RXI1dYVuVCqBB/qxHtGzZ/s7cYopni28kvtaklltJLJUjSKG3kB3RxKoCg56nA60VsjFrU94fXPtV39lFm9pAqDfLd/dbA+8QMgVDPi4/0pr+ysYG+dLbeGWVR/Ft9/SuQ8SyapcWEwjGoPtK+eJXVAQT93aOaZo9vr8twraf4cScsRtVG37R2B/H1rju92elzrZM1LjxLqCXuowFwthMVwyw5+bAySg5GR61eg0v+3Fjntlml53Ts7iMYXtjjHasjVG1uPWiNV0c2Usw2b7ZcMXHPOOvFa3h/wDs67jWDW/tt/Ip3Kdrxgt2RsDj602tRRkx9/FaTSRf2pqOpRWPlny5ZI/vnptA6hcjn1qvP4givp7fT9Xgijs7dSttHDhRM/ZnB9PeuivYLSa0tX0rQZpZ5ptvnrcEkKM/Jz07EntitBPCAXRpIbgQ2ysuWgtY/Mkdu+ZX+vYUlFLUttvQydRutQm0me91W6jW0iVYY44X8rJ7AKPmI+lZt/f6hdCPU72Fo9NiQRtBGBFuONqMqdfY9z1q1aaZoWny3K6pHJD9lYGMShpHbPQc89eKs3yy6zexm0ZoJBHhhNy6jpgdk4/ED3qd1qU9DMsr+BXa2t1dYjmW4wQBLKemO+wD8zW5NO+naWLYJdrJfJ5NnuAGxz6tnlSM9aW08PjS72VgpvwSFMwjwyZ4IA7oB071L4i0izubmxg0mFh5jtJIJznAx2xzgZB4pRtuN3t2HaCPsFhfRreaXbG0mMckUjgysAoOfRvwrLvT/ajz309tqUy+SVBitiqqzHnaRx0xV7R726xZ2NgkItL6V0kkKKP9ITjGSO4HFdRoep/8SsXconnmE7osTO20gZUNgdDxT0YveOC8LeIVsFGmzpF9pV8LLMcrJ1KnHqOpWllZ5vFwa/ljdbudXW5lTYzlRln2dM5+X6VqeLVhhvYrjUNPssSKY2gEXmSgHpIccgg55964q/t3GvXM/n3yPbxxlY2jMxBLZwTn5eMd6V30G11Z7FLebUkvHtS8CKo2KfMJboBn1J6CuX161lj0fS/tOY7i51AXMzKnIBO1iR0wAQKnj8OeJLmCK6vtStLW2hPmraWY8wK5yFJJPLAflmtltLuI1ubWRGv5lAaQltwULz9AOfzo1tqNO+xrQ2wF7HPJGWjifDRO/JwMDj0zg/hUxG5pozcrNKzMuMfIucZIPY4HFYtjdtNo8WpF5i02R5hHTqMDPfjFaWmwTxLK98YpvJHMZOEDEcAEdSKkvzNKzuleKOFFRjGxCO4yAByAFHUn1qrdOXt2mkdkeVs4wfm9/rntUsBdrOYrcRxJuGVUAYBxxv7fT61QaZrh1wh+XOwI27AHv7UbglqSzFYo/LiLFZMbiyBR7Nn65zVHVIblCttbqoSQEST5I2juq45J/QVaMbiJhCWeE5DPjgY5/nSOZk2PtKNjauSTz3xUjtczrDSv7Ey2lWFsqjBcmbbK7Dnc3Bzx2qtr9xqV8VmhsbWIygu7m5LEDp8wA4PGfxrWvLpBAJHZg7NjIGBjuT7k1Qv5TFIfKf5XA6DHb/Gm3oOMdbnLJo9zd6tdxT3cYYRxJtgj3cHJxz3xSXsVlHcNHZ2wTTVIS5lBBeTGBgH+7nqRTpNRaTUNRs4ZfIjSVfNkHG0hOcH+8cke1TXzW9rpJaeNLazjibcw6sCOMA9/SjZWQrJ7kOu3ywWbxoxSKTGTnOCPT1rzHSo/7V1+SdZnSOGfdbxjnBGCz+3QfnW9qXmSafHHLOpZbdTKU+7boRnBJ/jIxxVSwt/sk815BauLkxJIiE4DQYwRjs2QCKa01M5PmsuhpXt3PpcFzdyW8U0UiNGLqGMElWP3XX1z3pbbWrGz01baGZDJEmzYW5J/H+dXbGO1vdKE03mto1modyCFaR2zsQ+5bt7VzV3v1qVbi6tQEhHyRBVJcjrz/dHvVJXV7kuVnYY1zCNZgnFyLmaG3kZgpD4PoB+NK95DL5qXh2wAGVEA4ZiMDj1rHe6catErpFbOCYz5YACqRz0710kWnQRr9tv2KKpzHE3JOOhPqcdqdyYrdB4YtzZtsKlWaJWZcdWOe3rWutgpQKTjnbuUfdqtJ5tvaTalucTB1lXauQmOin8K6CIsqwT2pJn2ecVK9+c8emKmWhvFaWRX0JRPbNFMZJlgMi7lGO/BP1rU0+zjkkhe7MbR4wwA5J9Kg0SyeRGhiAQXbb956Y7n2rYs4irLHEV+0wFpAQMhvcUdS1oRxxNE7CxD7QpO3J455AoRYvtIlgEQ3qy7ZRwDjn8a07WSYxwOsf7wAtGVP3vUGo7nSUk8ieEAxzAyhVOWBHUYpNXHfuc29grGK6uEYBsgccD/APXVTU7MeZvSIwfLwPUV0l1C7wQ27q6ycup3cEH196hgtHvHj/fBpVBG2T9Khp7IqNtzjWtI/LDYJZepxWXJCGdgORnr6V6Fp1gt1OwgXF7v4Q/dx3rKm0jzDcqke54wzyKB0OaaTE7HISQIEYYfdx16VTeB9xwcH1FdKlqGBIXoO/amXFivk70Uhj2HIoTJcDnPLcbevPrUXmGP5DwTWtJCWADYVTkc+tUbiBhj5cmmiHGxYt7kAJuAO0fnTopHZmwOM54qiykBOMYFSW0oDckr2J9qrcadjWUl41dDjB61bE4cAZBYdT61kRSFVYKxK5z+FTQNtcEc7qWxaZqLcYBA+9SKBK2ZAM1TSQeeVNWhjbxyaRRXv9MV4XaP71YqK9s5EmMdCDXWQSgqAwqjqVgty4cYHFJrrEV+jMW5hiktzLGoyBWWbdZ1+U4bHatC4R4Cyc7SeKz5A8J3qDVKXcmSKNzcXFiTuBIFVYvEuHHzDit4eTexFJB81cpr2hNbZkiGQOTW8bM4K3OtUSX/AIlkfIQj8K5+6vZbgnexx6Zqu4xnjFNrdQSORyctyxb3M8cUsEU0qRTbRIiMcPg5GR3weRXpOoTW+m3y2V7461yOcBd6iFiIiR0b5+orzBCVYFTgg5B9K9OTTTryx6rqfha4e+nUMfLv0gW6OPveW3zDOO3WmxGV4w8P7Tf3kWsz6ldWfl/aRcx7XMbABJFbJ3LyPzoqrrPiKZ49ZtrrT/s2o3jpDLkkCCGPG2JVP0GSaKauSz6Kt7qG61iA3cQlji3XcyRxhSjNwASB0AFH22J9SdfDoXy3yXtmY4XHJcP0Ga4e21Utrt25jeR5UC/ZLYnZx2c/xV01pceIdWmS2WPTdNt1QrmQnCjHoP51x8zZ62m6HeJ9XksDA2o2kiTswlRmjy3PGcjIrIF3I2pTTadNcStIBuiSMxrv6D5jWVcWOsatexwPfW0li0/kmaMGNZ1xk8nkAYxn8q65U07STBZWmnNNesS8cActlR355xnuaXmxXb0RBDPBbObiRriDUR+6Z4ZvLCHHI24x7E9aqXuuI+9Y9UmEqY+9OGz64wKjvdGuv7S/tDWrOzubWaQKI1uWVbUHuTjGCeD7mtaJNLae3sLaztbKRCbiaD7OFdgvChX6Pk+lU+wlfocBYeI7Q+Jop764eNyrRBs7nDdizNkDPr2r2bw7Z2cGiC4JtpZbkcGFwWI9hycD9a47xBZQahJplnJZrHNNcN5oiRcgbDx6cYBqlp9pIlyU0yWTTdZVzG2P+Pd/fHoR/dqW+wJP7R6zYXdpbJcNFG4VoGUYThSR0HvnqTXOahdRAwTOsKTljAGD7Qm8AbuPfFZVrfyzJJZao62lxy3nxR+ZFKoHJyTwevBFQywRajYtFaTXV05AjyXEUUeT1JHX1wKHew7o5bx5aSWeoPpucw3c/mxXEEvCTKMELj8Oe9dDpeqEGLTEgih1CKLyZVidmSzIADS+5J6DuTXJ3+kmfVpLSXUXllsSGhnJzG0o6gHoOwwf6VHplzcG/v8AUbW9eG4DxwS27pkFevO3kkGk9BLdnoNx/Zun2G2xlmDOSJZrp9zyEg5HqSfyFc3ojw2llfSXWM3Rk8uWdSVKIpAU++elN1K61JdPm1aCGKa2tMxcN5nlSHgsQRgnpgDOM881DBrxk0KHS7W1UPNGtqXllUHnl+G5Hfmk731LvFaI7q51+S2t9LtnjVhOVjiS1wfmC5JYdxxWhp7IZy9zcTQWs6NuQ5+Zh0DdiM158t+bjxJZxxMYUigcQwznGCMKAHHXjNamo67dj7LpiGS6uAC8UUMwdU9ye340OWmo0lsaXhQxQwOrBZkgupXXLDYwDE5I6EZPH0roLdIryISyyfKwLlc85zkBVHrWR5K6T4dtLYWqNc3gECmTGEDtyw+vzc10LvcKzoG8sKCFcHaABwMccjHbrRYdyJbbbZNPOkhbOEjH3dxOADWebmSBjJIWeWVhE4Q43ZPQAdB3NXLhVR1iQnyzhg753e+B6nPSqeoSWq+Irc5/cgvFGpTaDiPrjsetBSNRrrzFn2QulspEaoo2x5z371A8ql5DcBkjjjCkZ3szHtnsKiuPLdEljmkcKuSCAV9l9zVCe9g2KYZA0oPzRKDhcdNx6UgSEc4kGSvzgsADjaOwOe/fFc1f60sW+4IWVYcbYf756AE+h4rSmGy4Mt5G1w7EuQjBUx9f0z1rmbzTJdX1GSPMRjgCvJCCVAY/cUN6gdc1m03oXdJaE82mXK2MH2NDJcI32hmLAIzdWUk9euPwrG1sT6ndTvrV5bxWq7QBBJlVI/gTjk+p/Cuij0W/RTE95AsRXGzmXaPQDgZ/Cqci2VhqE1qln9svWRTBcTNuIbOCAvQev4VpYzaObu44neAwWbrpschjlUglpQerEdz7mr2q6bdXL6e1lG8QkjLE5A3W6kZ59ciuj1aCW00TzIVG3BxI44d+5B71y2kwanZ6dcTxlgs4UTQyNgkdcLnpgnpTSJkyhr2nWmmxedYanbvclPNktcMURj/FzxuAqhHZ39rZQ2KXCtdXOWMEYPmLu5H4HrWXcaoS9yGUrmU+bvHvgLnpwKm0m7mllk8oTFkj25hUszDPO5vyrRbWZz/a0IbuOTT7qOxMsrSmQM4ZVJ39+nPFbtncw2V7BNeBJSX4lLs+z6gjAFc1oujahqGuYIuElTEjMIyCiZ5PPXivRIfDkz2U9pDLFJF0JYE8euPXNTJdzSmt2hNQ1ddVtBYWkiyiY/Osa8IAeQfWtl7G70y7NzIzLZxqEcI+Wwwx19OeRVfQ9MhtLKKSKEJeISJ3xlnYdvQD2rdt4Ib21lS4dkV0eR1UHg9uPepubpP4noWJLLyLyCDzStuEyrIOTuHA+lDTXssqRwB0lMflkqoBGByKpeGfts05F3KMwPsjUn5sAZVjWnNMY7iO4YMzybi4D5+Y/wAqT2uXck021+yTws8wYRkfMxO3Hp9alvWl0+QiKMrJJIZY3U8Ef3ahhjMs8SOZFjZsyKOh9MU4XEkc3lEZuFf5M9VHp6UXsK1wgmiZDFLxHKTnP3gR0/CluIvMjZiiJMm1UCcZHqajuSsEMSPEC5yzyt1wewpbY7knBYiJkDZYZzjoM01q7AUJZvKuiyAJdLKB8nSmamFbWTFATCHwsoJxknrmtJ4Fup55wsMUbhcbOxqG8hhubyWCH5iSNsgHUgU7aDuZbwiC5MTIrsq4AA6n1qld2rwI0bqyMfmx61ry2/2m781EdSnyHBzkipdQtWvLuFlyUI8vLHv6VMloO9jj57FNwIY8jv2qjNaM2M8YySp6D6V1IsSMqRuKsd2O9QXFnskiDqQWORn0pJAzkHtsDewBQD8qzXQ+ZnjFdZrFqVlZY8bW5OOlYj24ALdKb7ESj2KKOVc7e4wRVmEg5XJDDkUxo8c+tNjyJ85IFK4JWNC2UOdwPzD72auQA5ZRzxkVlWjBZnJbCjt61esHLXOwNsQ5wTTtoUmW45VwOzE81ZUgAlhWecBzwOCcH1q4GBhVicnvS2KMzUY0eRWC/UVnXVqGTco5HStidVkfI/GntEpiOOtG4mtDjGjaElssMHpUsrJcWrLJg8Y561p3dqGLH161kT27RLuXH0ppNaIymk0cLq1qbe6bAwpNZ9dVrVus0Bc/e6/jXLEYJB6iuylLmR5dWHLKw6MhXViAwBB2nv7V3fiDSk8R6xJrFhremraT7W/0m58uS2wANpU88Y4xXF2VheXxcWVrcXJTBYQxl9v1wOKtHQNYx/yCNRz/ANez/wCFaMzL/jXULfUvEEstnKZ4kijh+0EYM7IgUvg+pFFT+P4RB4iWIRiLbZ22UC7cHyVzkeuaKaIZ6l9og8KarBd6NdfbIo4jDeMGwqbzghCemPT9a6BddsdTtijT29pGHIMMrDe64zlj6D071lwWsN3ayaORbjT4F8uaeKP94ynlI1f1J6ntVOz0+zW5DTxKdTs322TOm4XYB+YN2wo/xrjv2PUSa9DWtNRXUtXtf+Eeh8q5JAjM4yjAcNM4PTgcAe1dTa2Fxp0k9xcSJc3Ux/eT8s8h79Og9qu6K9pJp3mIRNcXX7xpNoUAdlHoKnklCQpI2xAGORuwAKTsWk9zOutTsVt5o5Hi5+UxPIFHPYg1xUFwJirzTRlIFAXawLl9xCbTnrWr4h1ZL2eO0so0Yod9xPIoaNR2yx6E/wBKveDtH8vSkaaFd8gkkVxDucq3PTH8XH0qbX2Kb6FI6jLrMdqt5c2ccljJ81vEAAx6Es+cksD26V011Yw6vYbbjdFbBgQyyBtresZ/hxXMXSRNqv2yHSbdQ0K293ZyQBXTByHUf3vWt3U4/D1nDHNJYRRxLj5I2I8xj0wPU+lVZrchvyMe+0gwONt/HfwB22x3SbSq+pYcH8RWHfeLL2xkFrbrbfaW+SNon3hM8buBwuKbruoTatdpp2l20bzMBmBCfLhOf+WjdyOuKtjTE8NXdrp2nt9s1a7l3XMhAOUUZO0DoB0GKnTcd2tEULCxWzsI7e91VMSyie5aKB5ST2+XvnPHpWXrekW41DdYTahbu2TdmaPaBHj5flHfoTjoDXZwE6t5n2W5kjuQ5T7QoG0AdVwep61PceHSybGu7S3hth5wYq2SwHOWzzkdc9qd+xKijn7nUb1tDj04wW09rbypDHNHNtWV+q8HnAH8q27HRbu7RGvbKzbZHhBcyb2JbkucDqewHQCsjwXo8lzqV1qEBieO1IktrS5B2AkEbsdsgce2K9JsrtrmEvd28dqSi7uTgsep+nShK2492eXa14JjGqRxPNuj89J4IIcorI3Eigk8MDzj05rp9D0XRbHypXguPPhkLRuj7RPFnG1u5YGut1SOC8jCbM2xbctwY9rIR3XHQ/nXnBt9Q0jV5rVd18bfde28pcIXiJxJHjufpSdug4pJ3PRQY5tUtrkWSxpbNuMKydGIwq8+gyfxprasl9cTIhnJhlKMXPIbPQdunesKw1KFi7vlJ53MnkO2wgnoACOcCl0m8m0rWJLeYny73M8JODscDD5HqRik2Wo9TelYO8sjIoGcIQxOzjA59apeI5Wm0yHyhHG8MqTwoTkhwec+uRnj3qWO8VvllkUxoNqLkICc8HP9a5i4uJtW1KWDT5wvkEmWfBKQ9cAHvIe3p1qW+xS8ybUtTkv7xILSOSONBgLAB5jH+Q92NaaQCCdDLGkEEQx5Mblgzepb+Lnmq2mxWtrYqlvldzkMWJaRv9pj3/lVs6jZJd+XNJESwZUjduWOOn4Ulba43fsO1JWks2aHapYfLvG75v7xH9Kj0ixgtLby4pGGV3ySuMvI56k+5/lVi5VBDGWcHeflbJJUgEkAfSqVxcRWkEZu5RAAgVN2fmz0z9aqzQk09CRx8rE7UC9SvfFcnZoJ/EzT7d8cELkNkgliQCPyrrpJLb7BcHLqPLyd689M7QPr3rkvC1xvuJY/nSbyEbjryzH/ACaTS0KuReI766NjcWyMdqxl3yeLdc5AU9mP8qxLvWrqxtpTbWhazvEDW8Mr72V2ADEDvzzXXmxt9QU3MdtiwSRjGCdxmlH3pG9QO3auGgIXV0nlIl/s8OdpOD5ZONwPY+n0qloZS1d0R6RoDXExhnE9rbbg0qkZkY9yQei9a7Pw3p9vaLdrbIGjilJ/edduOCfrmt4WmLPzZfL8gRCXLHHynofxFcxY2mqzT3D6a4nsMjYJRtZgP4gQOVHvTuNQS3N2KRrXUJ5ZgPMuQI0k27hgDoB6GtG3tVe1ihgWR5ZpDwMcj69qpWmlmOzS/uZGN47GNYBysS+ufU1bhheNi6HeE+8qt696TkzVRXQraeHi1u5R1M0k8JcL/dI4NXQBECoxmaMIX6bR34q5ptoZWW5KDy4sxmYnBBINMEIlWJo4QQRlgz8/L1P0NK2lwe9jMjWWPWGuY4yI2gCElflJHf8AKr11GjStKANpX5QTgsMU5oxcMqIoTzNxHzY2j057U3ajzKYlO0gBxnqfUe1DBDnjXIkSR923G30qHeyuQseMHcJM88jpVm2mBaFJUULuYt6nHbNV2uwp2PG5DNnIHIPYZ9KTAlvIo3WJmYkom2RWONtDL5cDoFb7M5yhXnn0qC4hxcJuBkwMsD2qOa4nEaR2YyEXDZ5wTTuFhu6Py4SUCsgKON3JJ6U60t5PJSXkKJfLPPOD6VHG5NvIJ41MkRDsh/jqHS7prtzn5GjYt+fb6U01cGjU86JftPkqsZYhQT/Co71VS3UTRRShwCuQc43Z71m3KnzGkQO3mNnA/hA7VpRyE2qXNyxV8kAN29sUXTFawl7JHPG7RxFJVOzC9DVZjJeY+b51G0HGcVes5UneNSoSBCdzAdahjEKTNskMa8kEjrQNGNd2xjkaOYDn26H1rIurLCOEXK54+tdJdeZJaysybiSMO1QwoJyqsgUjjIpW1KOOubQhVwvNVXgIDEA4FdrqmnxhIGTHmYwRWFf2jIhOOOgb1pPQRzzBkCkct2q3pqtLMqDHPPPrVmW0OxD0OKZZLsZVc4JOM+lC3BKw5wu91kOCMgU6KQ+QxA4HBOai1HMd0UOMHnNMtGYpJGpBU8mhjJoHySOf8alWQ/NVOEnz0HbpUrfLcle2aAfYVCHypHOc1QvoBhhge1WSxWYkdBSTsHIFUmZyWhxF9CBO0Z6nmuT1GIRTtgcGu/1iELMH689K5fWYA4Le1a03Y8+uupl6bql/phkOnXlxamQAOYXK7sdM4q+PFGv/APQZ1D/v+3+NTeFbSx+yatqepWzXkdhGjLbBiodnbaCxHO0VbuNO0/X9Lnv/AA9bm0v7ZS91pwcuGT/npETyQO69q6bnKc/eXdxe3DT3k8s87AAySNuY46c0VseObO2sdf8AJsoVhhNtA+1emWjUk/iTRVIg9YsklsdSksdGt7i4kuog4mnyEhRs5cg9Ce2a6E6dJpSJIk1mSV8lZSjSH3C+30rBWJLWEr4X1K4R3cs4nxIG7cnqBxW3pTXS7PtEaXE7MDJN5q53enTgD0riZ6sb9TPbTdYvmRhezWkESeXGscYhVwOnHJp0mm6pmKzuIohM+SZpLhm8sf3yAOntXaR2skuHu72KNFG0tGcbD7t9PSsppbabVE0bw/LJcqq5ubpiWROcldx6mi1th+pztzo11HbWumwajEwdsmNVCrjGSzE8mupTVbzRrKDCM7K237VbybwAOBx1A9zWh/ZFnpMcH2mOCFeJxLI4YuPTPr7Vh6z4ohYyQaZFsuM7R5ce4svbdjhR7mpl2KXdbEHivUbm9MF1eWs8kEZIlmGIyGPIcODyR/I1zOnahFqt00t5eX1y9tIY7a1tk3Zz1d5MDj0xzUeq2OnnS7q41S9lkuJWDJborJCrc5XHftzVnQZ7fTrK0tYxftIVQmIwlWjznIHqO4JoS6md9bbHQ2E9/BaS22iaLFCSNxk3hdmOTk+p981SsLLUtSms7yJks/te+0SKFsySqGzJLv7Dg9McYqC58Q2d+gsbS6uLWwbmV5ImHmtnGwHHA9TXQ6L5WsymeyeFjbf6NbNG2VAABbGPU8fhTWrKe1kzahtPsTJbSxKlvENxhVto+pP071nXV/Hq1vAMY0UTeVDCAA96V5YE9REPXueOlQazq+myQiPUWdpUlGYTIVDgdAw7jPNUjdW48y8tpoZtSm4Xaf3NpEOmT0/4CO/Wl1DsjZ066X+37u7a1je3kjEQibOEKjOOMZwCK2riTyTGCQZyo/dspOAecf4Vwmm2l/q1qstuWhsLdi8PmPs+0PnmVz1IPYDita3iW5HmTajM85fDrGSnlnpt9SabvYuNrnXzuNyJJDdNHtH7onHzAenoa5fV7f7Xq2mx7AWtpPmIJDKGByp9c4FWnaPTrWeeGSdrdRl3LEscdxnkin6GWuZ/7U1OIw2ZD+VGzYlkYrjew/hAHCj6mjcG9C7JaC6jaN7e2lTYXZpBnaPQe9ec+Obg6bJFb6Wbkzwss7wN8wjQfxA/wjGeO9dE3iG9JudKjiSO/STKvnAEJHDn1H9ax9Zs7bT5bW9RxcSglbp5ny84Pcj0B7elDC5qCAyWaSy3kkrIgcLbgBCpGcZPPpToLCLTEt7GdS7XbM0hSZh+8Azk4Ppxn2rC0PUfs2ji1v8AykUMJQ08hUrDnKoqjk5yPwFVr69udSuLAXLDTbRS7i5OEd15+6OuOcZNJO2iE5J6s6xtK0j7MGkE5lJIAjmZVb9e1Os7PSLMy3kdtCZkG3fvO78ySefauN1PW49OhtbbTbNrxxJsje5YhWPfC9TjqTWbG+rhJzDPLKiFndordcJx0z0/WjXoN2W52seog397PKIxbWcIiAboGPJP1xgVJokTalMNR1MsAvNtCwz5Y/vf7x/QVyfh7Q9bnQxy3qKcrN5RUNvYkn5vbpXTaVeanbNeW19awXMrD93KrFV5PUf7XsaVnuxqSexuaq6SQyIoY7k2nc3zMfWvMt+I7S68w29ysZtorkMR5bbuPrxniu71DV1WLZcRfZ5EXy03LwxPfd3ritK0+PVtTt4JJJntI7l2iA/dkLtJD4/3u5pPVlXsjQuo/ELaOFtBFBbRxkCZ/ldkXvtPQk1jw6beQWcL/wBmQm5UAl5GDCQkdMetegx6jLHHPZ6i8C3SwmNS65WVT0Ke57jtUWjIt1bRyeVsaBDHJk8IQcHHvTdugKN2U/Dgiv7eSbWro3DxIFW2VCFVwABuHfFbkepQ6bbSy+Q8ZZlEMhHGB1AHcnpil1HTbW6EcpiMd0q7vMVtm1ew4+9+NSQ6ZHaiA7S1wi71eSTftB9M9KNS0kaVj/xMLdt8YW6ZjIWYjC/7NZ7J5Jl3uQ+NuV5BrSnt522IroqwxbnxzjPX8az+LW/VEKTMEIBxkbv60PbQaJ7Ys1hsVX8oTDqdu/I5xUcsDw5jLFSz7QjHLBam1JTHZQW5yrRHe4Xnk9ST/Sq8Q+1MrIB5m7DEnqPYUn2FHuV3faqoI5E54IGR9KuwWsTzQwpPHGhhMzscnkdvrUF3IHlkDuTEp+XI69qii2syOuQCNjBep9KRT2FTeLeSUrEVVhgk/Mc0sLwve3IlDBdu5e2D2qG+cRRRogKTg5JxkY/xpsTySPw2wSEhmfqB/SlzWYrX1FufMikMs0jGRgCcHqDS+dG+UYE/IApXgfjTYxG0hV5NzYwGzT7mON41AbDyHAbONoHtRux7bjGJt5m8hg29NrdyvrVKZlfeVZVO0jKjqR0qWRWsLfbFuZpRgs3bmqsCyLI5fkk8KKdwEM0rwQROGQRjO5e5rRAQxH5i0+M7TyDUcJkW2kj8pmmU9SO1RW3mR28kjgIxGRn0oWgblywgxETd70j6jbyTVSZ0WTaxPz9AeqimR3Mn2UyOz7jkDPcUyUh5oTnBKkMD1am2IvWqqUbz3aRUHAXnNRQmINJ5gba33B0wfeoYbgxzssQ2IFwSOlMmi8zyju+TO5mXnFCb6C6kl4Sw/hUMOD1xVS9X7TZjzCoji6DuTVxykyMIsFgMDAxn8KZhJYseWqBVwV7k0x3sYN1DI0cZUFiOvsKz/JMkiqTgjOR6V1NoVWcGRN0Y4VRWfqiKbqa5UKmfl2AVL01GtTmtRQJLwCfWoLTaZ8n5QRj61piJpp87CT0qOSxeK4GVBAG4imtdR7FNWAuV7fNge9Sy5TUAXP3qpXLZmO0EYPFOLsJlckkj1oRDLV4NsrAVVlIQg9qmvH3ENVa5GUH0pdQexj6o+WrD1GLfCSK1tR+VM1mTSB4WB4xW8Dz6+5meFn1u2v5p9At5rh1XZMiQ+ajIf4XXGCDjvU1lofimxv0vLPStUguUberpbsMH8untVTQ9UvNH1yO50/c8m7a0IziZT1Qgdc1dvrfxIJJriK11u3tGYsiMZG2LngE98etdJxlXxTdane6zLNrkBt78ogdDF5ZwFAB29sjFFZc8ss8pkuJJJJDwWkYsePc0VSIZ61/aV5ot0/lWr3Mbuy7XUL5cgOGJPToOO1dBo+s3F3KtuImQAN8sbpv6Z5wOvvWRpmm21/YSJJBfAdE2yHBz3OeOf61HZaNquj3wmi0qeW2ZTEXchPMI5wecBgO9cWstj0leNux6fYQW80by66Z54mjJWMHCqexOMbqNR1aHQtKZY44IbVhtQpgEnOTwOv1rltP1GORJ18iTMaEiC4lCOP8AgJPPtis2REvLq1k1QRC0mjFwyI4y0W7G3J4Xpz3o1a7GjlH1ZetxrfiZzPHavb2ceQN6847E+v0rc07QNX07Tki0/V009SfMk2xglyT09/xNR22uS3VpEmmWqWtoA203EuM4PACrz09a0LqGO7iW11HUrWS2YCXy4RggkdM5z7UlZbDs5blHW9KjhVrvUNUF7eTDLtcJuI452Acdu1Q3EFlqD2sGoWZGnRRL5LpHvkuF7b2T7v0qxqGiaYNKkeye5hkRMs8cpx0+7gk0mkG70rQLGXT9StrtZrdHeF0CshI6bvUe9Ny63FyLqh2o6dZ2mltcafbzQwxZVDGpCZAzgq3X8K5bSNBv454zpjrY3JiWWaRztjYMCdpC/wARzx6V1reJY1l+wTSWUNxKvDzSAhcjB+v4VJpVwllYiHT4Y2lt8xz+Y2S7kY3An+9xine4OOpzjWGgPpySX0dy+pwki4mL5kR+dqhTwR/MVnINSkntkGmebahsh4wfIcgcBlxnHqPWrWs2klzrAmaRIbto8syY8qOIHB46k9geuea6fSNW1C7sgmiQpY2VvtUSzNgO3qqdW+ppXvpISi09Ctqo1+5tzNc/Z7YFFUAx4Vhn6jA9qyry/wDFl7rMF1b29tJNHtheUL5Ucvop9T9K7G1tktrdb3UT9peR2WOWaTA3j0UUalewSqkUUjtwWBAO1GHTH40nGPVD12ucuTe2csWoeI7PUTeDiMRoHiiGecAf1q7qHiS2uLVl0yRXnk+6rnaSxPV/QD0ouPFAljO4SPNG371FX7h9fpWRfa5ZuWurmSxtFZTGQwXJHfjGeaXMr2RXK1qzMmsriB1uby+tYr3JxcebuL8/dK/3fpWNcjWZbee4kJ+z7mjCQrt8wEYzlucV0pvP3Ym0nR5JETb5YFuEU5/iy3OO9VDYeI9V1aWCa8sobcIGdixxEvXbnHBJHNO3kZt9LjLBz4a0GZZYIptZQiAlj5jEH7hB7L2HSpJLXTtNtt11MZ9RkTdJI3RW6lVz90A8ZrL0+eVtbV4re0lgXMSSgt5ckg/5aEHlscgVeutPn1K/tbW0EV9K7CW5djkKAeFbHQZ7Ci/Qpaasv+F9Dml26trsXySgNFbr2T0Le/oK0o3e5F/blZYoWuUhgt1GFXGNwI/OkvbXUyYrK31jN0jFmWNB5NuB3PoeMAdakuVWC2iDSnIkBaRyTIzngt7nrQtNEUtdS94fc3N5qsgZFYTLEBzzx+gGa22Eb2ZIZ2kVvmYH5QBwPxrjNJP2me+jExS2huTI+0YMhwNqk+/Wule/RbISPGI4lGFyeXb2XqTSKRLfqjWe0x7o9wXcf7xHp6CsHQbaKa606SRmT7NExKxrkNuYqAfwGatJa3Wo3sMuoiW3soTlYUX52A/ikx/Kk8Nx3semtshAE8jMGc4wikqpP154pajbVzRuIY9S1q2VipjgzLGD/DjoSfSra2xtfMleQBLg8emR1wPes6JHs9RdnnSaSeEqUQ46HpxWlJvlMaqN4UhWbHC98UvItFpSsSFAYZJZSARtyUA569M0eW7Mj3EgULlioXLAZ4B9KSWZAHHkqXJwHA/OiJVNo7tOsYbjb/FJ60ykWzOrm4kaM/vAECKSSfX+VVTNFG8AVCfLBbZ3HPeiSOJGjMOYX27sF92c+1QhDDayXCMu4t5fXk/hSvcEuxJKYpJ/3iAOXJPpg+1JEqQENgrCSULL98g+1OgMKwzyOEkZkIBY42n29agguFSKVurFdo55Ge9IdugiM1rMyxxKWZ8oHGSB2x26VXIG5wGIyeAOOadaScxvHyynk56c9frTJ0/07gfLvyv41I7CXEgJYLF+8Xb9aJVEcSykhyQSQeo+oqG7kK3hW3DyOT19DVm1tmngkdpEV1BzuPX6UIeyKTQK0STKzBgTgY4apIbnZAgRCZwc7sdPamTO25S5OAe1IFcyKxQorDdz0Io9A9Rbm4e7VTIWCjkj1NCxq86vbhtmMZfjJ70sReNWX5Tv46fyqR0Of9Zjyx06U/NiCYXH29vKcJvH8JzkYqCRHuIm3Z3RjABpxklJ8oxsq4zvpbd/MJBDAgEZoJIWfFltuTiTovoKq3hjW1BBJlXHJqeVyAw2sR/FkdKpXZ3XkQA2g8NmncGV57qXy/LzlWHynpVuG7kWDywBsAwQvUmsu6aH+01glcCMAlT70sM4jYycKC23NNEXNfSr1FEwxtk7EinpIxnDYyT196yoZT9q3Jyg5z6mrkLLLfsSrKoXnBpLcdy68ixSlmxz0UCsu5tnlJkZsKWzS3900QUBd5c4FSQFWIVt2F5IPeh6lJo0bSygSwypBY8kd6ydQCxwyueTjAq0t47rLsXYnoOtZN2DLGWkb7owBVOVxowZ4x54AJJPX2qN0KyZP3QcVfS1Zg0h4A6Z71TuI3Vgv97n6VImNu2BddvTFVrk5AGe1OlY7yCOlVbkncCadjNsytRAKkE1iSvhW/Ktu927W+lc9cH92+a2gcFYv+B5ykmrxWV1BaaxNCq2c8zBQPm+dVY8KxHQ1dt9H8dR3IkF1dwsDnzpNQUIPcktgisTwzZWEtvqupatHLcWthGjfZ4n2GV3bauW7L61avtKsNX0ibUvDazRPajN3p0knmNGv/PRD1ZfXPIroRykHjq4tbnxLPJZvFKNkYmlhGEkmCgSMvsWzRTfG1ja6brvkWMflwfZoJNobPzNGrE/mTRVLYln0Ja6NoDvJJBGlvhVKojMMH05PX8Ki1zRbtrR7SwvLiVWwxt53G3B6HcOQfwrIg0i0ljkKLLCrY2TLctke4Gau2sM1o8s9vfXb2rqVAmCsXYHGMnkDjmuNO+h6jSXQ5bVYdQM0VjqriNHIRLoqreVt/hLjv2z3qtpWkajDr0CWhttTiiL/uLkFI3IG4rx1x/OvRNRuvNsZ7q/gtmssnzbcDaHJHBKjtkVwWofafDTaYj6gj20n7yKFGEjRFl5BA5A54NU0umpDjbc6dL/AFm7d5T4dsHQoNqR3ezyfrkc+lMhj11XMiaFaw9cmW7yB+QrLh8RytCTaxyRCMA3E875Csf9lefzq3pvlaqyKbmbU2Oc5lMcIHoAKzdm7NfizZN20Zp2Wl655wN/qOnWdsxODFC0xx7A8Ve0jwvbw20Uc1xd3sKuFRJDsRufRf8AGs/V5dXXUrPS1ureCKcBmkg5aGEeme9atxDbWqrN9tubuaEY3SvhBnp04qlZbIXm3ctXuj6baxTgWNnCo+WRWTP4Z9K8s1ee9t57jUNMEv2a02rKsrfKCeAEPUn0+tdJ4gvr/VIzY2h8vKFvMPCAA8sc8n24qr4ft/7Z8PhtVLRaNbSt9nMWfMndeS577c0fFvsTKy0juZng1ItdjvDrckrSPhlt1BCxhegYjnpXVXtmqSQjR/7RhlVQGY/KNx+uQVwaqXWmadDaxvpkn2O8i2+S0MZaWViOQ3bb7GqUmq6jfzvFcTBJwFZxGpaMEnkFu2PSjyWoLT4txDrN9pWoTnVd2oSRDMc8R4VfQL/AfU1WPiXXNXs5Ro0PlQn5N4wFHPdv61qap4fspo2F7qshWIgyyRDYoP8AcCjq56d61f8AhHvDU8b2trbpaJJGN6yTldhx156mhQVrNi5pdDiYPD5kkH23W4LeIndcNEDtbvs35y5PoBVu10Ka3mN5b6Zpt3E7HyWd2ikVPZTn8zWzby29pfm20ez+2NBEv+kKNpVj/D82e3pUOoa9FCqrrMy2ojJZo1TEj+3v+FF+lhKKerYsN9qSxSK1hNZxbdxuWbzF47DHHTuagkt7nUdMthaM1vp07bpJLk7TOfYDqPetVXj8RRRmeUWuk2+HWz4LufVvr6c1uWS29lFHf3GwxxqTGJRvEY7DngUKCRer32POdZtI7K1QR31xc3Of3McKCONVHVhxjA6YrqPCfhu5slFw15LaNOS7xwv8zE9Nxx2HGBWU16dR1eK6u4/3TymRRkt5nl/cRVH8IJyfU1vtr2rQ6x+7sZZHeIsrMAgVu4wT70ttkGjd5HQm0jsLIQ2yIUYjdJngE+/c+tcj4ia4j+0TRmL7Ha7Wz2ZhkkfjVyO91e7aKG8tYbe2UHB84NznnpXO+KNbt57aTSIoR9oW4LOyHJnOMKoHYDqTRa+43KyH+G9QeHRbi4mED3M00jmEnKxDplz24FdR4asZUhsbi+dp7yUZOTwgJyFX0rzrSrG/tZP7NlUraHbNO8Sl/LX0bvyRW7NqLSWo8zUxGQ3yqgzgdgB6+1Tqug4u9rnoGrXVtYWkrGQ7pCQjLyWJ42geuaZoMBtNNRCqJ8gTDZ+Vjyf/AK9cHoZ1ye7N9cWjy2sR/dLKNkjepAPG7Fdva6nb6hLKRDMijCiOVCCPY9s1Sb6lKz2INT22ktlLA4KrN5bS7ODuGPx5rSuI5GTfDKyArucNjl8fyqDULf7TAYXj8tAMDnIU9mqGz1KKaG3SQOLkEh1J4+U8/nU2NEyyq3hbE97CcjAwh4q6BHFDEu4yS45+uagkcTzuTGsUf3sDk0GPe4WIN5g5zkcUloPoaC7VuWdEVJlwck5C/T3qlcI00pbcNxbLZ9fWrI8uFnUR+bJnAbOQPXIqpc3jgzRpGrbsEOB0oeiH10HygSuxWMEIMbh3NJeQ2z2yMjN5x48pV4HPc02ZjEoDSNuZf4R3qKMHaWlG44AAztwSf1qRq4+BfKBJIVgecelRSeWspEZZt3RjRdF7aSRSihuAFDAjJpORjaxY9yB0NBSCRl3wfL5bAfeB5qAl45QUGxWHJPU0HBkBdvmUHO7qaXyn2B23kdEOO9IZCcsfkQ5U9+eKUs4PznCqMYNTR+ZCfmA3HrnvULq5kcMQDnJ9KPMRZtSFnaQLvO3gHoKq3Uwji3ZzIzFWLDgVPG5V0LnbFjrTJy0ihcho1PeqJZBDdrNBtV9xX7x/wqSOZfJbACv1DGmyJHzggLjkAVVkEbQ/u1Zmz1J6UgGNcNLKVP3Qfmcd6kmEbRq7/eHA96gQ5jLSfI/QKBWNdzyyazCgfCKCeD2pp9yJEOtwgYfJ5cDd7UaksUSwRxPgHG8k9afqd3bvHJEfn2859K5aSeW6vIYUZhk4Jx29av0MZPl3OnvbgGaG2sANzD5mz90VfmmMUCxq37zG0mqFnDDaRvsI5HzOTyapzzpiQxu3mnheOlFuwJ9WWrmbzJ0VD90+vU1tWUmLYu4+b1rl432R72O4jgfWtJLjybeOMvln61HLYtTNGOV0DED5TzSNGZDu3ZHpVe4mKbEBypHWpBMIEAzkd/rSaLuMcbiAy8L2Hes3UQTIzbcDoBWhucq8gHXoPaqNxuk+Zvypg2YTg785qtctlTWjdINxAwKybw7B17VUUYydjMvn+Vq568fER+ta18+Rx1rA1KTAAH41vTWp59Vi6FrN1o1zJLaiJ1lXy5YZkDxyr6Mp6+tRabqVzpuoJe2EvkXCkldvTB6qR3HtWn4S02G8lmubmH7RHE8cUVvu2iaaQ4RSey8En2FbNrePeapfadImi3cECsUgjtREs4XllikADK2AcEnnHetzI5vxDq0+uam19dRwxysiIVhXavyqAMDt0opdfsorDU2jtXaS0lRJ4Hb7xjdQy59xnB9xRVIk9c8PxRaZM0WsWU8oePERCMsa8/xk85HrwKvzeKLK9Se1sTLG5dVjMmW3HPbtz6mtC8kee11ZZnaRfMxhzkYweKx/AQH9mRjAx5rj8ATiuVndBXdkZF/Yy3Us6Xk94J+FFs77d43AdeAw+ldTqHhaG10dpbS3tbe4ORHFE/mScD+JieKpeOvm8PXEjcyRlSjHqvPY9q4Rru48uQfaJsMDu+c8/WovZ6Glls9T2M6BbLZrFPYQugj+Zg4Abjue+KzI/AkFpcLPZXoEEkTF4VmOVJ75A4IqHwfPLNOqSyu6h8AMxIAxXocqKt8oVQAYTnAqlPmLUFpY868MeGb+41HU2h1xlnhCRxy3KK6gHnBz+FdG1gYNMaa9uHmu+fNdQNgPTK/Wq9nxrl8o+6SpI7dKh11j/Z8oycbPX3qbpaJBa+5X1W1+yaSpklL6lIS7h5dwxjIB9gP1rn9T1wWNjBZQo1rdNEBJEx8tskZ69FU+g5NQeK3YzzgsxAj4BPTityeNJ/H2rPMiyMsMG0uMkful6ZoWtyZO1rEGgNdXmmrc/abe3iKhPK3jzZUPB2j+Efqa0b66isgGEFjHcyMI7aDzQoRsfeIHYDua24YImsLQtEhK2hZcqOD6iuI1CNCNZcopdTbANjkDNVYV/dLh8251TTdItme4SNzdSlF2CQqMs+W6nOKzPE9/qFmhEc17EJ9xEatGwbHXIwSD0q1K7NqMLMxLATAEnnqtcZ4tmlW5tysjg+eeQx96h7lSvy3R00UYttOln1bV5izEO8UMm1C5AyxYAdBwFo02HSfJ8+Zo0ErFdzoW8uI8ljn+Nug9KzdcVXj0YOoYNIu4EZz8veluVU6FrLFRujKFDjleD09KINtimkjodVv9Fv32wwXEkqHaJF+RtuOOn9aLSzn1vRI7ewnur1Z5DFHFGPN8sDl2OcDPYfjWC0jx+GbFo3ZGd23FTjd9fWvQNOZrWztltmMK+UDiM7RnaPStXDqZqd3ZKxi2mj31hNbJaEafAcwGaVhJMwI56cDkVev4Ugt7JrEyXElqS8hYnLZ+9k/Tn8Ksai7DQoyGIPmpzmtQqBpcBAALbs8dfrWUbSZstjiPF2uw2NrG9q5mu5lHloB8qZ/ix3/Gl0XQY9H0oahcfv8AVLw/Ksgy2W6AHsPWuTux/wAViF/h+1SjHbhDXexEtqNjuOcWhIz24FUkiVq9RUmbTtYewtJYzLIg+1TkYyQMtj1wSAKnkkWyjSWVPNvN4FtCACMnjcfVvfsK57JbxCu4k/M3X/erR0V2k8UJ5jF9tu5G45xz2ot1GuqOxLO/lwRkOB3Hdj71aMvlruKK0m485zyKjgA/sKU991YUjsG4ZvunvSkbeRZvtXhhv4bUAu7IZGwep9MVQ0d4rjXL+5DKfLVQIx0BPUD16VymvMy6gGDEN5R5B966HweB/YsBwMlGyf8AgRrNO49jrEkBfDEghc4A5NWUCsRkgKxBJC8io4wPIjOBnb1p9p0P+7SW5Q2N5Y/tBt5GVGypPsahtgpDrKCqjAJB61a/5d5h22is1ed2fUUdhot3ADNsfHmKOzdqrnbEEVQzMeoPAFOuQA82B6UISYXyc9KC47DGUgtM5+6OFxnmlt53lkL5KnOdwGMCpG+6v+9TW4i4/v0gImAWUEKGzzkn9afNK74dicDgKOF+tRADbL9aW4PzgdtopLcEK+T/ABAsvO6klgZxvJHzc4pAB5LU2P7i/jTKGh9hVic54x2ps4IjcqykDpgYyab3FJN9wUIlleA7LMJI+ZGJJNMeVYk+cFVx2qFv+PlfpTn5DZ54pLUXSxn3F65YGNWcYOeKxlNzNqhKrjCcbj0rebiJsf3azoP+QvL/ALgqktTNgmjo88jXk3zdh2rElby9WeWPBjgG0EDANdFc8iXPvXM3HB49RVmMtUS3FwPspZX75PvVG2vhcXWT8kSjDH1pl9/yD5vrWbD/AMen4U0jGcnexvG8hmvEVGIhU5x60+S9SfVFijJCKeT6Vz2ndGPfBqTSD+8nPfNO2pMajbO1u7iNLQEuc5+SoJrppFQHism+J8uCmzE7hye1JpGymzf+0Y2qGHShieSCOazU/gpzkgjBNTaxrF3C8VUQsxGTXM38gLNzitzU/uCucu+rVUTGq7GTdvjJJ7d6527ffLW3qn3G+lc9/Ea6IHBLVm/4U1KG0ee2u5mt4pmSSO4Vd3kTRnKOR3HJB9jXSBbWCWa8CaJYPKrK97BeGfaGGGMMIOQxBOM9M9q89FKoFa2JuamvX0eoak0tvG0VrGiwwIxyVjQBVz74GT7mis70+lFUSf/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large nodule is present on the face of this patient with molluscum contagiosum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_45_5848=[""].join("\n");
var outline_f5_45_5848=null;
var title_f5_45_5849="Post-polio syndrome";
var content_f5_45_5849=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Post-polio syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/45/5849/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/45/5849/contributors\">",
"     Laura Simionescu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/45/5849/contributors\">",
"     Burk Jubelt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/45/5849/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/45/5849/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/45/5849/contributors\">",
"     Ira N Targoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/45/5849/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/45/5849/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/45/5849/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 9, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paralytic poliomyelitis was a major cause of morbidity and death throughout the world during the first half of the 20th century. In 1952, shortly before the introduction of the polio vaccine, more than 20,000 cases were reported in the US. Introduction of the inactivated polio vaccine in 1954 resulted in a dramatic decline of new polio cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36553?source=see_link&amp;anchor=H3#H3\">",
"     \"Polio and infectious diseases of the anterior horn\", section on 'Poliovirus and poliomyelitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although polio no longer poses a major public health threat in developed nations, a 1987 survey estimated that there were 640,000 Americans living with the sequelae of paralytic polio [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/1\">",
"     1",
"    </a>",
"    ]. These sequelae are static for many and reflect the state of recovery reached after the initial disease. Although not well studied, most polio survivors experience a modest decline in function and muscle strength over many years that may reflect the natural history of old polio [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other patients, however, experience a syndrome of new or progressive disability, usually occurring decades after the disease itself. These new symptoms are quite variable, and include increased muscle weakness, focal or generalized muscle atrophy, fatigue, pain, and decreased ambulatory abilities. It has become clear that this condition, called post-polio syndrome (PPS), has both neurologic and non-neurologic components.",
"   </p>",
"   <p>",
"    The clinical findings, etiology, and treatment of PPS will be reviewed here. Issues regarding polio vaccination are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17223?source=see_link\">",
"     \"Poliovirus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of progressive neurologic deterioration in PPS is unknown. The main theories of pathogenesis involve progressive degeneration of reinnervated motor units, persistence of poliovirus in neural tissue, and induction of autoimmunity with consequent destruction of neural structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Motor unit degeneration",
"    </span>",
"    &nbsp;&mdash;&nbsp;In poliomyelitis, there is progressive loss of motor neurons with subsequent denervation. This phenomenon is partially compensated by reinnervation of the muscle fibers through collateral sprouting, which results in motor unit enlargement. It is postulated that the symptoms of PPS (eg, increased weakness) result when this compensatory mechanism is overwhelmed.",
"   </p>",
"   <p>",
"    One possibility is that the expanded architecture of reinnervated motor units creates a greater metabolic demand, which over time leads to instability of reinnervated neuromuscular junctions, ultimately followed by failure of neuromuscular transmission. This hypothesis is supported by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Electrophysiologic studies suggesting that the most extensively reinnervated motor units are more likely to become unstable later in life, with failure of neuromuscular transmission ultimately occurring [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Evidence that excessive exercise or overuse predisposes to new weakness [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Muscle biopsy studies showing that pathologic angulated fibers become more frequent as a function of the time elapsed since the acute episode of polio [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/7\">",
"       7",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"local\" href=\"#H14\">",
"       'Muscle biopsy'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another possibility is that the normal aging process contributes to further loss of motor units [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/8\">",
"     8",
"    </a>",
"    ]. Motor neuron degeneration itself may underlie the motor unit loss. In support of this notion, a small case-control study found that patients with PPS had significantly increased cerebrospinal fluid expression of five proteins (gelsolin, hemopexin, peptidylglycine alpha-amidating monooxygenase, glutathione synthetase and kallikrein 6) that are known to be involved in different pathways mediating neurodegeneration, such as apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Persistence of poliovirus in the nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence and reactivation of persistent poliovirus has been invoked to explain the progression of motor neuron degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/10\">",
"     10",
"    </a>",
"    ]. Poliovirus and other enteroviruses can persist in the central nervous system as well as systemically in immunodeficient children [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41383?source=see_link\">",
"     \"Epidemiology, pathogenesis, treatment, and prevention of enterovirus and parechovirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies in tissue culture have shown that poliovirus mutants can persist in neurons in a latent state [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/12\">",
"     12",
"    </a>",
"    ]. Support for the persistent poliovirus hypothesis was provided by a 1991 study demonstrating poliovirus antibodies and poliovirus-sensitized cells in the cerebrospinal fluid of patients with PPS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/13\">",
"     13",
"    </a>",
"    ]. However, other studies have failed to demonstrate poliovirus antibodies in the cerebrospinal fluid of patients with PPS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/10,14,15\">",
"     10,14,15",
"    </a>",
"    ], and most studies that have sought poliovirus RNA in the cerebrospinal fluid of patients with PPS by polymerase chain reaction have been negative or inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Inflammation and induction of autoimmunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The strongest support for an inflammatory or immune-mediated mechanism for PPS comes from an autopsy study demonstrating inflammation in the spinal cord of seven patients with PPS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/18\">",
"     18",
"    </a>",
"    ]. Perivascular and parenchymal lymphocytic infiltrates as well as neuronal degeneration with active gliosis were noted, and all of these changes were more prominent in the three patients with clearly progressive weakness.",
"   </p>",
"   <p>",
"    Further evidence comes from the observations that expression of certain proinflammatory cytokines is increased in cerebrospinal fluid (tumor necrosis factor alpha and interferon gamma) and serum (tumor necrosis factor alpha, interleukin 6 and leptin) of patients with PPS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The finding of oligoclonal bands in the cerebrospinal fluid also has been interpreted to support the immune hypothesis, although the presence of inflammation does not indicate whether the immune response is a primary cause of disease or merely a reaction to persistent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, a study of the presence of GM1 antibodies in sera of patients with prior polio showed no increased incidence as compared with age-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the incidence and prevalence of PPS vary greatly according to the criteria used for establishing the diagnosis. If patients are simply asked whether they have experienced new symptoms related to prior polio, about one-half respond affirmatively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/22\">",
"     22",
"    </a>",
"    ]. These symptoms include weakness, pain, fatigability, and concentration difficulty. However, if new, progressive weakness is a criterion, the frequency drops to approximately 20 to 30 percent of polio survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On average, the onset of new symptoms occurs approximately 35 years after the initial polio episode, but the delay can range between 8 and 71 years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/11,23-25\">",
"     11,23-25",
"    </a>",
"    ]. PPS occurs sooner in patients with more severe original disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/24,26\">",
"     24,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the severity of the original paralysis, two other risk factors influence the likelihood of developing PPS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/5,11,26\">",
"     5,11,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The age at which acute polio occurred (when acute poliomyelitis occurs in adolescents and adults, the disease is generally more severe than in infants and small children, and these older patients are more likely to subsequently develop PPS).",
"     </li>",
"     <li>",
"      The extent to which patients recover from the initial disease (the greater the recovery, the more likely PPS will occur).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relationship between the degree of recovery and the likelihood of developing PPS suggests that new symptoms may be due to failure of the compensatory processes that facilitated the initial recovery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;PPS is a disorder with both neurologic and musculoskeletal components. Most commonly, symptoms include progressive weakness, fatigue, and pain in the muscles or joints. Muscle atrophy, breathing and swallowing difficulties, sleep disorders, and cold intolerance occur less frequently.",
"   </p>",
"   <p>",
"    Progressive weakness and muscle atrophy are a direct consequence of ongoing damage to the motor unit, which is defined as the spinal motor neuron, its axon, the neuromuscular junction, and all of the muscle fibers innervated by that motor axon. Breathing and swallowing difficulties are also probably due to motor unit dysfunction, while fatigue, joint and muscle pains, and worsening bony deformities usually reflect involvement of the bony skeleton, ligaments, and joints. As many of these symptoms are nonspecific (especially fatigue), PPS can be difficult to diagnose unless multiple musculoskeletal or neurologic findings are present. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Progressive muscle weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive muscle weakness occurs in the majority of patients with PPS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. The new weakness always occurs in muscles previously affected by the original disease, although the previous involvement may have been subclinical and only detectable electrophysiologically [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/7\">",
"     7",
"    </a>",
"    ]. The distribution of the new weakness is often asymmetric, and usually correlates with the severity of paralysis at the time of the acute poliomyelitis and with the amount of recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/5\">",
"     5",
"    </a>",
"    ]. As with the original disease, the new weakness can be proximal or distal and is often quite patchy. Focal atrophy occasionally accompanies the weakness, but occurs less than one-half of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    New muscle weakness may produce respiratory insufficiency, bulbar muscle weakness, and sleep apnea. Respiratory insufficiency primarily occurs in patients with severe residual respiratory impairment and with minimal reserve [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Similar to extremity weakness, respiratory failure is more likely to occur in patients who required respiratory support during the acute illness and who contracted polio when over 10 years of age. PPS patients with chronic respiratory failure lose an average of 1.9 percent of vital capacity per year [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Respiratory insufficiency usually is due to respiratory muscle weakness but occasionally is related to central hypoventilation because of residual damage from bulbar poliomyelitis. Respiratory failure may begin with nocturnal alveolar hypoventilation, and patients may require only nighttime respiratory support; however, more severely affected patients may ultimately require total ventilatory support. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Respiratory dysfunction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    New focal weakness of the bulbar musculature also occurs in PPS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/34-38\">",
"     34-38",
"    </a>",
"    ]. Residual dysphagia occurs commonly in polio survivors as a result of weakness in pharyngeal and laryngeal muscles. This may worsen in PPS, with patients complaining of choking and coughing. Dysarthria may also occur as a result of facial weakness or vocal cord paralysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12569?source=see_link\">",
"     \"Evaluation of dysphagia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatigue is the most common symptom of PPS and occurs in approximately 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/27,39\">",
"     27,39",
"    </a>",
"    ]. It is often described as a disabling, generalized exhaustion occurring suddenly after minimal exertion. Some patients experience generalized weakness, while others report focal loss of strength with exertion, generally in already weak or weakening muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/26\">",
"     26",
"    </a>",
"    ]. Symptoms may be so severe as to impair concentration and mental functioning. With rest, symptoms abate, although sleep is often more effective than simple cessation of fatiguing activities.",
"   </p>",
"   <p>",
"    The pathophysiology of this excessive fatigue is unclear. Studies investigating exercise-related failure of motor unit function in PPS patients show abnormalities similar to those seen in myasthenia gravis in 10 to 20 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to generalized fatigue, muscle fatigue is characterized by loss of strength and decreased endurance during exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain can develop for many reasons in PPS, including the development of spinal deformities such as kyphoscoliosis, degenerative joint disease, and joint instability, all of which can develop without new weakness. If polio occurred in childhood, uneven limb size can contribute to long-term musculoskeletal degeneration, as can failing surgical interventions such as tendon transfers and joint fusions. Progression of these symptoms can further stress an asymmetric skeleton and may require the reinstitution of ambulatory assistive devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination is notable for generally asymmetric weakness with lower motor neuron findings (eg, atrophy, fasciculations), with or without the superimposed musculoskeletal findings described above. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Progressive muscle weakness'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LABORATORY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine blood tests, including the erythrocyte sedimentation rate, are normal in PPS. Nevertheless, blood tests are useful to help exclude systemic disease as the cause of the late weakness and other symptoms.",
"   </p>",
"   <p>",
"    Exercise may result in dramatic elevations of creatine kinase in patients with polio-related weakness, but it is not clear that such increases distinguish between those with and without PPS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/11,41,42\">",
"     11,41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cerebrospinal fluid parameters have been normal in most studies, although mild protein elevations or oligoclonal bands are sometimes observed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/11,15\">",
"     11,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Electromyography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electromyographic (EMG) studies of patients with prior polio have provided insight into the pathophysiology of poliomyelitis, but cannot clearly distinguish between patients with a history of polio and those with PPS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. EMG is useful to confirm previous poliomyelitis, including its extent and severity, and to exclude other neuromuscular conditions such as amyotrophic lateral sclerosis, radiculopathy, neuropathy, and myopathy.",
"   </p>",
"   <p>",
"    EMG studies show that patients with a history of polio frequently have signs of chronic motor neuron loss in areas that are clinically normal. These abnormalities include the presence of motor units that are increased in size and prolonged in duration as compared to normal. Increased motor unit size occurs as a compensatory change in response to ongoing loss of motor neurons or their axons. Since both patients with remote polio and those with PPS have had a loss of motor neurons, it is not surprising that motor unit changes seen on EMG do not distinguish between these two processes.",
"   </p>",
"   <p>",
"    In addition, motor unit number estimation, which measures the number of function motor units innervating individual muscles, is abnormal in patients with a history of prior polio and in those with PPS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Thus, there is no clear distinction between patients with prior polio or PPS with respect to either the number of motor units measured or the rate of decline of motor units.",
"   </p>",
"   <p>",
"    Fibrillation potentials, which imply the presence of ongoing motor axon loss, theoretically should help distinguish patients undergoing new motor unit degeneration from stable patients with remote polio. However, these potentials are seen in the minority of patients with prior polio, whether or not they note new weakness. Other measures that indicate instability of the motor unit are frequently abnormal in all patients with prior polio. While weak muscles show more frequent and more severe abnormalities than strong muscles, muscles with progressive weakness cannot clearly be distinguished from those with static abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Muscle biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As is the case with EMG studies, all of the abnormalities on muscle biopsy are nonspecific and can be seen in patients with a history of polio, with or without new progressive weakness. Biopsy findings in patients with old poliomyelitis reveal evidence of chronic denervation and reinnervation as well as active denervation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/11\">",
"     11",
"    </a>",
"    ]. Chronic changes are manifested by fiber type grouping, in which the normal mosaic of fiber types is replaced by a pattern where fibers of a single type are clumped together. This is the morphological equivalent of the prolonged duration, increased amplitude motor units seen on EMG study.",
"   </p>",
"   <p>",
"    One sign of active denervation is the presence of small angulated fibers, which suggests degeneration of terminal motor axon sprouts. Another finding that supports active denervation is the expression of neural-cell adhesion molecules on the surface of muscle fibers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. Group atrophy, which suggests acute axonal destruction or motor neuron death, is seen less frequently in PPS than in amyotrophic lateral sclerosis, but this is not an absolute finding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no pathognomonic findings that distinguish PPS from remote polio. The diagnosis of PPS is made on clinical grounds in the presence of consistent laboratory, electrophysiologic, and biopsy data. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Criteria for diagnosis of PPS syndrome were first described in 1972 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/28\">",
"     28",
"    </a>",
"    ], and subsequently revised in the 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/48\">",
"     48",
"    </a>",
"    ] and the 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/1\">",
"     1",
"    </a>",
"    ]. The criteria are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A prior episode of poliomyelitis with evidence of residual motor neuron loss",
"     </li>",
"     <li>",
"      A period of at least 15 years after the acute onset of polio with neurologic and functional stability",
"     </li>",
"     <li>",
"      A gradual (or rarely abrupt) onset of new weakness and abnormal muscle fatigability that persists for at least one year",
"     </li>",
"     <li>",
"      Exclusion of other medical conditions that cause similar symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/28,49,50\">",
"       28,49,50",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of PPS is primarily symptomatic and supportive, addressing new muscle weakness, decreased endurance (muscle fatigue), musculoskeletal pain and joint instability, fatigue, respiratory dysfunction, dysphagia, dysphonia, and sleep disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonfatiguing muscle strengthening exercise programs can improve strength in patients with PPS, as discussed in the next section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     New muscle weakness and muscle fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle weakness and muscle fatigue can be treated with nonfatiguing exercise programs that use low intensity sessions with short repetitions lasting several seconds, alternating with intervals of rest [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/51\">",
"     51",
"    </a>",
"    ]. Overexertion or overuse should be avoided during these sessions.",
"   </p>",
"   <p>",
"    Evidence of benefit comes from the following reports:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 12 week randomized controlled trial of 10 patients with PPS found that those assigned to moderate intensity strength training showed significantly greater improvements in muscle strength than controls assigned to no training [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several small uncontrolled studies [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/54-59\">",
"       54-59",
"      </a>",
"      ] have also reported that nonfatiguing exercise programs improve strength in patients with PPS [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these data, we suggest treatment with nonfatiguing exercise programs for patients with PPS who are able to participate.",
"   </p>",
"   <p>",
"    Another strategy employs pacing of physical activities with work-rest programs (eg, inserting two minute rest periods after perceived exertion is deemed excessive or after six minutes of continuous work is performed) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/51,60\">",
"     51,60",
"    </a>",
"    ]. In a small uncontrolled study of patients with PPS, work-rest interval programs were associated with decreased local muscle fatigue, increased work capacity, and increased recovery of strength [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Controlled trials evaluating the impact of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/55/27509?source=see_link\">",
"     pyridostigmine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    on muscle strength failed to show any benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/61-63\">",
"     61-63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Generalized fatigue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized fatigue is described as exhaustion with minimal exertion. This is distinct from muscle fatigue, which is characterized by loss of strength and decreased endurance during exercise. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The approach toward fatigue consists of energy conservation measures combined with an individualized, regular nonfatiguing exercise program [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/64\">",
"     64",
"    </a>",
"    ]. Measures to prevent or treat obesity and the use of assistive devices are beneficial in conservation of energy. As previously mentioned, pacing of physical activities with work-rest programs can decrease local muscle fatigue [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacologic therapy also has been employed to treat fatigue, although data for the efficacy of any single agent are minimal.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/46/13031?source=see_link\">",
"     Amantadine",
"    </a>",
"    was not effective in one small controlled trial of very low methodologic quality [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/65,66\">",
"     65,66",
"    </a>",
"    ] but still is considered helpful in selected cases.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     Amitriptyline",
"    </a>",
"    has not been studied in a controlled trial but may help fatigue in a small percentage of cases, possibly by controlling pain.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     Modafinil",
"    </a>",
"    was not beneficial in two randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/66-68\">",
"     66-68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Musculoskeletal pain and joint instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Musculoskeletal pain and joint instability can be treated by decreasing mechanical stress on joints and muscles through pacing of physical activities, treatment of obesity, use of appropriate assistive devices (eg, orthoses, canes, walkers, and wheelchairs) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/69\">",
"     69",
"    </a>",
"    ], and judicious employment of nonsteroidal anti-inflammatory drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exercise studies evaluating patients with PPS generally have been performed under supervision with submaximal workloads and intermittent rest periods between sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/50\">",
"     50",
"    </a>",
"    ]. Using these principles, patients with PPS can obtain positive cardiorespiratory training without untoward effects on extremity function [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/50,70,71\">",
"     50,70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Respiratory dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory muscle weakness due to neuromuscular disease can cause insufficient ventilation, nocturnal hypoventilation, or ineffective cough. It can also be associated with bulbar dysfunction. Each of these abnormalities has its own related symptoms and signs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link&amp;anchor=H2#H2\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subjective clinical findings and objective pulmonary function tests are used together to determine when mechanical ventilation is indicated, as described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=see_link&amp;anchor=H10#H10\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\", section on 'Assess need for ventilatory support'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several reports suggest that the early introduction of noninvasive respiratory support is beneficial for patients with PPS who have respiratory dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/33,50,72,73\">",
"     33,50,72,73",
"    </a>",
"    ]. By using this approach, invasive ventilation (tracheostomy and permanent positive pressure ventilation) may be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3528?source=see_link\">",
"     \"Respiratory muscle weakness due to neuromuscular disease: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27095?source=see_link\">",
"     \"Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33896?source=see_link\">",
"     \"Continuous noninvasive ventilatory support for patients with neuromuscular or chest wall disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current guidelines recommend pneumococcal vaccination for adults with chronic pulmonary disease and influenza vaccination for adults with neurologic conditions that can compromise handling of respiratory secretions. These issues are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Smoking cessation is recommended for all patients, including those with PPS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Bulbar symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for dysphagia and dysphonia in PPS has been evaluated only in small uncontrolled studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dysphagia may be improved by a program that teaches swallowing techniques [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/74\">",
"       74",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17000?source=see_link\">",
"       \"Diagnosis and treatment of oropharyngeal dysphagia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dysphonia may be managed by instruction on voice strengthening techniques and by using amplification devices [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Sleep disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for sleep disorders associated with PPS include use of continuous and bilevel positive airway pressure ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1382?source=see_link\">",
"     \"Evaluation of sleep-disordered breathing in patients with neuromuscular and chest wall disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11301?source=see_link\">",
"     \"Classification of sleep disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given evidence suggesting a role for inflammation in the etiology of the disorder, the use of intravenous immune globulin (IVIG) for PPS has been tested in preliminary trials [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Inflammation and induction of autoimmunity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The larger randomized trial included 142 adults with PPS who were randomly assigned to two infusions separated by three months of either IVIG or placebo for three consecutive days. At three months after the second infusion, there was a statistically significant improvement favoring IVIG for one of two primary outcomes (median strength in a selected study muscle), but no difference between groups in the other primary outcome (quality of life) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another randomized trial of 20 patients with PPS, treatment with IVIG for two to four days led to statistically significant improvement in pain at three months compared with placebo, but no effect on strength and fatigue [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, further trials are needed to determine whether IVIG is beneficial for PPS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Anesthetic considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although data are scant, there is concern that patients with PPS may have increased sensitivity to local anesthetics and to nondepolarizing muscle blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. These issues, and the potential for impaired baseline respiratory function in PPS, have led to recommendations to use shorter-acting anesthetic agents for patients with PPS who are undergoing surgery or other procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19817?source=see_link\">",
"     \"Overview of anesthesia and anesthetic choices\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another oft-stated concern is that patients with neuromuscular disease may be susceptible to hyperkalemia when treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=see_link\">",
"     \"Causes and evaluation of hyperkalemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these concerns, there are no reports of hyperkalemia associated with anesthesia in patients with PPS. In one case report of cesarean delivery in a woman with PPS,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    was used without complication [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5849/abstract/80\">",
"     80",
"    </a>",
"    ]. Nevertheless, it is reasonable to avoid long-acting agents that affect the neuromuscular junction for patients with PPS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/57/8082?source=see_link\">",
"       \"Patient information: Poliomyelitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Post-polio syndrome (PPS) is characterized by new or progressive muscle weakness and disability, usually occurring decades after the onset of acute poliomyelitis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cause of progressive neurologic deterioration in PPS is unknown. The main theories of pathogenesis involve progressive degeneration of reinnervated motor units, persistence of poliovirus in neural tissue, and induction of autoimmunity with consequent destruction of neural structures. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of PPS include progressive weakness, fatigue, and pain in the muscles or joints. Muscle atrophy, breathing and swallowing difficulties, sleep disorders, and cold intolerance occur less frequently. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no pathognomonic findings that distinguish PPS from remote polio. The diagnosis of PPS is made on clinical grounds. Diagnostic criteria are as follows (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnostic criteria'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A prior episode of poliomyelitis with evidence of residual motor neuron loss",
"     </li>",
"     <li>",
"      A period of at least 15 years with neurologic and functional stability after the acute onset of polio",
"     </li>",
"     <li>",
"      A gradual (or rarely abrupt) onset of new weakness and abnormal muscle fatigability that persists for at least one year",
"     </li>",
"     <li>",
"      Exclusion of other medical conditions that cause similar symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The management of PPS is primarily symptomatic and supportive (see",
"      <a class=\"local\" href=\"#H17\">",
"       'Management'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with PPS who are able to participate, we suggest treatment with a nonfatiguing exercise program (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Energy conservation techniques may be useful in treating generalized fatigue. Measures include pacing of physical activities, avoiding and treating obesity, and the use of assistive devices.",
"     </li>",
"     <li>",
"      Noninvasive respiratory support appears to be beneficial for patients with PPS who have respiratory dysfunction",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Jubelt B, Drucker J. Poliomyelitis and the Post-Polio Syndrome in Motor Disorders, Younger D (Ed), Lippincott Williams and Wilkins, Philadelphia 1999. p.381.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/2\">",
"      Sorenson EJ, Daube JR, Windebank AJ. A 15-year follow-up of neuromuscular function in patients with prior poliomyelitis. Neurology 2005; 64:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/3\">",
"      Cashman NR, Maselli R, Wollmann RL, et al. Late denervation in patients with antecedent paralytic poliomyelitis. N Engl J Med 1987; 317:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/4\">",
"      Emeryk B, Rowiska-Marciska K, Ryniewicz B, Hausmanowa-Petrusewicz I. Disintegration of the motor unit in post-polio syndrome. Part II. Electrophysiological findings in patients with post-polio syndrome. Electromyogr Clin Neurophysiol 1990; 30:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/5\">",
"      Klingman J, Chui H, Corgiat M, Perry J. Functional recovery. A major risk factor for the development of postpoliomyelitis muscular atrophy. Arch Neurol 1988; 45:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/6\">",
"      Trojan DA, Cashman NR, Shapiro S, et al. Predictive factors for post-poliomyelitis syndrome. Arch Phys Med Rehabil 1994; 75:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/7\">",
"      Dalakas M, Illa I. Post-polio syndrome: concepts in clinical diagnosis, pathogenesis, and etiology. Adv Neurol 1991; 56:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/8\">",
"      Gordon T, Hegedus J, Tam SL. Adaptive and maladaptive motor axonal sprouting in aging and motoneuron disease. Neurol Res 2004; 26:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/9\">",
"      Gonzalez H, Ottervald J, Nilsson KC, et al. Identification of novel candidate protein biomarkers for the post-polio syndrome - implications for diagnosis, neurodegeneration and neuroinflammation. J Proteomics 2009; 71:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/10\">",
"      Jubelt B, Salazar-Grueso EF, Roos RP, Cashman NR. Antibody titer to the poliovirus in blood and cerebrospinal fluid of patients with post-polio syndrome. Ann N Y Acad Sci 1995; 753:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/11\">",
"      Jubelt B, Cashman NR. Neurological manifestations of the post-polio syndrome. Crit Rev Neurobiol 1987; 3:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/12\">",
"      Colb&eacute;re-Garapin F, Duncan G, Pavio N, et al. An approach to understanding the mechanisms of poliovirus persistence in infected cells of neural or non-neural origin. Clin Diagn Virol 1998; 9:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/13\">",
"      Sharief MK, Hentges R, Ciardi M. Intrathecal immune response in patients with the post-polio syndrome. N Engl J Med 1991; 325:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/14\">",
"      Salazar-Grueso EF, Grimaldi LM, Roos RP, et al. Isoelectric focusing studies of serum and cerebrospinal fluid in patients with antecedent poliomyelitis. Ann Neurol 1989; 26:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/15\">",
"      Dalakas MC, Elder G, Hallett M, et al. A long-term follow-up study of patients with post-poliomyelitis neuromuscular symptoms. N Engl J Med 1986; 314:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/16\">",
"      Leon-Monzon ME, Dalakas MC. Detection of poliovirus antibodies and poliovirus genome in patients with the post-polio syndrome. Ann N Y Acad Sci 1995; 753:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/17\">",
"      Muir P, Nicholson F, Spencer GT, et al. Enterovirus infection of the central nervous system of humans: lack of association with chronic neurological disease. J Gen Virol 1996; 77 ( Pt 7):1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/18\">",
"      Pezeshkpour GH, Dalakas MC. Long-term changes in the spinal cords of patients with old poliomyelitis. Signs of continuous disease activity. Arch Neurol 1988; 45:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/19\">",
"      Gonzalez H, Khademi M, Andersson M, et al. Prior poliomyelitis-evidence of cytokine production in the central nervous system. J Neurol Sci 2002; 205:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/20\">",
"      Fordyce CB, Gagne D, Jalili F, et al. Elevated serum inflammatory markers in post-poliomyelitis syndrome. J Neurol Sci 2008; 271:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/21\">",
"      Farbu E, Rekand T, Tysnes OB, et al. GM1 antibodies in post-polio syndrome and previous paralytic polio. J Neuroimmunol 2003; 139:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/22\">",
"      Bruno RL. Post-polio sequelae: research and treatment in the second decade. Orthopedics 1991; 14:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/23\">",
"      Kidd D, Howard RS, Williams AJ, et al. Late functional deterioration following paralytic poliomyelitis. QJM 1997; 90:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/24\">",
"      Ramlow J, Alexander M, LaPorte R, et al. Epidemiology of the post-polio syndrome. Am J Epidemiol 1992; 136:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/25\">",
"      Miranda-Pfeilsticker B, Figarella-Branger D, Pellissier JF, Serratrice G. [Post-poliomyelitis syndrome: 29 cases]. Rev Neurol (Paris) 1992; 148:355.",
"     </a>",
"    </li>",
"    <li>",
"     Halstead L, Wiechers D, Rossi D. Late effects of poliomyelitis: a national survey. In: Late Effects of Poliomyelitis, Halstead L, Wiechers D (Eds), Symposia Foundati, Miami 1985. p.11.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/27\">",
"      Jubelt B, Drucker J. Post-polio syndrome: an update. Semin Neurol 1993; 13:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/28\">",
"      Mulder DW, Rosenbaum RA, Layton DD Jr. Late progression of poliomyelitis or forme fruste amyotrophic lateral sclerosis? Mayo Clin Proc 1972; 47:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/29\">",
"      Halstead LS, Rossi CD. Post-polio syndrome: clinical experience with 132 consecutive outpatients. Birth Defects Orig Artic Ser 1987; 23:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/30\">",
"      Dean E, Ross J, Road JD, et al. Pulmonary function in individuals with a history of poliomyelitis. Chest 1991; 100:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/31\">",
"      Blomstrand A, Bake B. Post-polio lung function. Scand J Rehabil Med 1992; 24:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/32\">",
"      Bach JR, Alba AS. Pulmonary dysfunction and sleep disordered breathing as post-polio sequelae: evaluation and management. Orthopedics 1991; 14:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/33\">",
"      Bach JR. Management of post-polio respiratory sequelae. Ann N Y Acad Sci 1995; 753:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/34\">",
"      Sonies BC, Dalakas MC. Dysphagia in patients with the post-polio syndrome. N Engl J Med 1991; 324:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/35\">",
"      Sonies BC, Dalakas MC. Progression of oral-motor and swallowing symptoms in the post-polio syndrome. Ann N Y Acad Sci 1995; 753:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/36\">",
"      Sonies BC. Dysphagia and post-polio syndrome: past, present, and future. Semin Neurol 1996; 16:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/37\">",
"      Buchholz DW, Jones B. Post-polio dysphagia: alarm or caution? Orthopedics 1991; 14:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/38\">",
"      Cannon S, Ritter FN. Vocal cord paralysis in postpoliomyelitis syndrome. Laryngoscope 1987; 97:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/39\">",
"      Agre JC, Grimby G, Rodriquez AA, et al. A comparison of symptoms between Swedish and American post-polio individuals and assessment of lower limb strength--a four-year cohort study. Scand J Rehabil Med 1995; 27:183.",
"     </a>",
"    </li>",
"    <li>",
"     Norris F, Denys E. UK: Differential diagnosis of adult motor neuron disease. In: The Diagnosis and Treatment of Amyotrophic Lateral Sclerosis, Mulder D (Ed), Houghton Mifflin, Boston 1980. p.53.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/41\">",
"      Windebank AJ, Litchy WJ, Daube JR, et al. Late effects of paralytic poliomyelitis in Olmsted County, Minnesota. Neurology 1991; 41:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/42\">",
"      Peach PE. Overwork weakness with evidence of muscle damage in a patient with residual paralysis from polio. Arch Phys Med Rehabil 1990; 71:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/43\">",
"      Feldman RM. The use of EMG in the differential diagnosis of muscle weakness in post-polio syndrome. Electromyogr Clin Neurophysiol 1988; 28:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/44\">",
"      Trojan DA, Gendron D, Cashman NR. Electrophysiology and electrodiagnosis of the post-polio motor unit. Orthopedics 1991; 14:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/45\">",
"      Rodriquez AA, Agre JC, Harmon RL, et al. Electromyographic and neuromuscular variables in post-polio subjects. Arch Phys Med Rehabil 1995; 76:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/46\">",
"      Daube JR, Windebank AJ, Litchy WJ. Electrophysiologic changes in neuromuscular function over five years in polio survivors. Ann N Y Acad Sci 1995; 753:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/47\">",
"      McComas AJ, Quartly C, Griggs RC. Early and late losses of motor units after poliomyelitis. Brain 1997; 120 ( Pt 8):1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/48\">",
"      Halstead LS, Rossi CD. New problems in old polio patients: results of a survey of 539 polio survivors. Orthopedics 1985; 8:845.",
"     </a>",
"    </li>",
"    <li>",
"     Halstead LS. Diagnosing postpolio syndrome: inclusion and exclusion criteria. In: Postpolio Syndrome, Silver JK, Gawne AC (Eds), Hanley &amp; Belfus, Philadelphia 2004. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/50\">",
"      Farbu E, Gilhus NE, Barnes MP, et al. EFNS guideline on diagnosis and management of post-polio syndrome. Report of an EFNS task force. Eur J Neurol 2006; 13:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/51\">",
"      Jubelt B. Post-Polio Syndrome. Curr Treat Options Neurol 2004; 6:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/52\">",
"      Gonzalez H, Olsson T, Borg K. Management of postpolio syndrome. Lancet Neurol 2010; 9:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/53\">",
"      Chan KM, Amirjani N, Sumrain M, et al. Randomized controlled trial of strength training in post-polio patients. Muscle Nerve 2003; 27:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/54\">",
"      Feldman RM, Soskolne CL. The use of nonfatiguing strengthening exercises in post-polio syndrome. Birth Defects Orig Artic Ser 1987; 23:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/55\">",
"      Fillyaw MJ, Badger GJ, Goodwin GD, et al. The effects of long-term non-fatiguing resistance exercise in subjects with post-polio syndrome. Orthopedics 1991; 14:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/56\">",
"      Agre JC, Rodriquez AA, Franke TM, et al. Low-intensity, alternate-day exercise improves muscle performance without apparent adverse effect in postpolio patients. Am J Phys Med Rehabil 1996; 75:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/57\">",
"      Ernstoff B, Wetterqvist H, Kvist H, Grimby G. Endurance training effect on individuals with postpoliomyelitis. Arch Phys Med Rehabil 1996; 77:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/58\">",
"      Spector SA, Gordon PL, Feuerstein IM, et al. Strength gains without muscle injury after strength training in patients with postpolio muscular atrophy. Muscle Nerve 1996; 19:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/59\">",
"      Agre JC, Rodriquez AA, Franke TM. Strength, endurance, and work capacity after muscle strengthening exercise in postpolio subjects. Arch Phys Med Rehabil 1997; 78:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/60\">",
"      Agre JC, Rodriquez AA. Intermittent isometric activity: its effect on muscle fatigue in postpolio subjects. Arch Phys Med Rehabil 1991; 72:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/61\">",
"      Trojan DA, Collet JP, Shapiro S, et al. A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome. Neurology 1999; 53:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/62\">",
"      Dalakas MC. Why drugs fail in postpolio syndrome: lessons from another clinical trial. Neurology 1999; 53:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/63\">",
"      Horemans HL, Nollet F, Beelen A, et al. Pyridostigmine in postpolio syndrome: no decline in fatigue and limited functional improvement. J Neurol Neurosurg Psychiatry 2003; 74:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/64\">",
"      Oncu J, Durmaz B, Karapolat H. Short-term effects of aerobic exercise on functional capacity, fatigue, and quality of life in patients with post-polio syndrome. Clin Rehabil 2009; 23:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/65\">",
"      Stein DP, Dambrosia JM, Dalakas MC. A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome. Ann N Y Acad Sci 1995; 753:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/66\">",
"      Koopman FS, Uegaki K, Gilhus NE, et al. Treatment for postpolio syndrome. Cochrane Database Syst Rev 2011; :CD007818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/67\">",
"      Vasconcelos OM, Prokhorenko OA, Salajegheh MK, et al. Modafinil for treatment of fatigue in post-polio syndrome: a randomized controlled trial. Neurology 2007; 68:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/68\">",
"      Chan KM, Strohschein FJ, Rydz D, et al. Randomized controlled trial of modafinil for the treatment of fatigue in postpolio patients. Muscle Nerve 2006; 33:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/69\">",
"      Waring WP, Maynard F, Grady W, et al. Influence of appropriate lower extremity orthotic management on ambulation, pain, and fatigue in a postpolio population. Arch Phys Med Rehabil 1989; 70:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/70\">",
"      Jones DR, Speier J, Canine K, et al. Cardiorespiratory responses to aerobic training by patients with postpoliomyelitis sequelae. JAMA 1989; 261:3255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/71\">",
"      Will&eacute;n C, Sunnerhagen KS, Grimby G. Dynamic water exercise in individuals with late poliomyelitis. Arch Phys Med Rehabil 2001; 82:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/72\">",
"      Gillis-Haegerstrand C, Markstr&ouml;m A, Barle H. Bi-level positive airway pressure ventilation maintains adequate ventilation in post-polio patients with respiratory failure. Acta Anaesthesiol Scand 2006; 50:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/73\">",
"      Steljes DG, Kryger MH, Kirk BW, Millar TW. Sleep in postpolio syndrome. Chest 1990; 98:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/74\">",
"      Silbergleit AK, Waring WP, Sullivan MJ, Maynard FM. Evaluation, treatment, and follow-up results of post polio patients with dysphagia. Otolaryngol Head Neck Surg 1991; 104:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/75\">",
"      Abaza MM, Sataloff RT, Hawkshaw MJ, Mandel S. Laryngeal manifestations of postpoliomyelitis syndrome. J Voice 2001; 15:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/76\">",
"      Gonzalez H, Sunnerhagen KS, Sj&ouml;berg I, et al. Intravenous immunoglobulin for post-polio syndrome: a randomised controlled trial. Lancet Neurol 2006; 5:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/77\">",
"      Farbu E, Rekand T, Vik-Mo E, et al. Post-polio syndrome patients treated with intravenous immunoglobulin: a double-blinded randomized controlled pilot study. Eur J Neurol 2007; 14:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/78\">",
"      Gyermek L. Increased potency of nondepolarizing relaxants after poliomyelitis. J Clin Pharmacol 1990; 30:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/79\">",
"      Lambert DA, Giannouli E, Schmidt BJ. Postpolio syndrome and anesthesia. Anesthesiology 2005; 103:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5849/abstract/80\">",
"      Wernet A, Bougeois B, Merckx P, et al. Successful use of succinylcholine for cesarean delivery in a patient with postpolio syndrome. Anesthesiology 2007; 107:680.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5167 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_45_5849=[""].join("\n");
var outline_f5_45_5849=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Motor unit degeneration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Persistence of poliovirus in the nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Inflammation and induction of autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Progressive muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LABORATORY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Electromyography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Muscle biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      New muscle weakness and muscle fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Generalized fatigue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Musculoskeletal pain and joint instability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Respiratory dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Bulbar symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Anesthetic considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11301?source=related_link\">",
"      Classification of sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33896?source=related_link\">",
"      Continuous noninvasive ventilatory support for patients with neuromuscular or chest wall disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/17000?source=related_link\">",
"      Diagnosis and treatment of oropharyngeal dysphagia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41383?source=related_link\">",
"      Epidemiology, pathogenesis, treatment, and prevention of enterovirus and parechovirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12569?source=related_link\">",
"      Evaluation of dysphagia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/22/1382?source=related_link\">",
"      Evaluation of sleep-disordered breathing in patients with neuromuscular and chest wall disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/57/8082?source=related_link\">",
"      Patient information: Poliomyelitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/44/36553?source=related_link\">",
"      Polio and infectious diseases of the anterior horn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/52/17223?source=related_link\">",
"      Poliovirus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35142?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/28/3528?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27095?source=related_link\">",
"      Types of noninvasive nocturnal ventilatory support in neuromuscular and chest wall disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_45_5850="Buprenorphine substitution therapy in pregnancy";
var content_f5_45_5850=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Buprenorphine substitution therapy in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/45/5850/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/45/5850/contributors\">",
"     Vincenzo Berghella, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/45/5850/contributors\">",
"     Neil S Seligman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/45/5850/contributors\">",
"     Brian J Cleary, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/45/5850/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/45/5850/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/45/5850/contributors\">",
"     Andrew J Saxon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/45/5850/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/45/5850/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/45/5850/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H16284319\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Illicit opioid use during pregnancy is associated with substantial maternal, fetal, and neonatal risks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of illicit drug use in pregnant women\", section on 'Opiates'",
"    </a>",
"    .) Some of these risks are related to repeated opioid exposure and withdrawal, while others are related to factors associated with substance abuse (eg, smoking, poor nutrition, needle sharing). The rationale for opioid-substitution therapy during pregnancy is to reduce these risks by preventing complications associated with illicit opioid use and narcotic withdrawal, facilitating prenatal care and drug treatment, reducing drug-related criminal activity, and helping the patient avoid the myriad of other risks associated with the drug culture [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comprehensive opioid-substitution therapy that includes prenatal care reduces the risk of obstetric and neonatal complications [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. While",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    remains the standard choice for opioid agonist therapy during pregnancy, there is increasing interest in the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    because neonatal withdrawal appears to be less frequent and less severe.",
"   </p>",
"   <p>",
"    This topic will discuss the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    for opioid substitution during pregnancy. General issues related to prevalence, screening, complications, and care of the pregnant opioid user and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    maintenance therapy in pregnancy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of illicit drug use in pregnant women\", section on 'Opiates'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/29/4570?source=see_link\">",
"     \"Methadone maintenance therapy during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16284333\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR OPIOID-SUBSTITUTION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women with substance dependence (",
"    <a class=\"graphic graphic_table graphicRef50295 \" href=\"UTD.htm?11/26/11692\">",
"     table 1",
"    </a>",
"    ) are candidates for opioid-substitution therapy, regardless of the duration of dependence if a return to dependence is likely during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link\">",
"     \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link\">",
"     \"Treatment of opioid abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Candidates for treatment should be referred to a local physician",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    substance use disorders treatment program that specializes in opioid substitution therapy. Treatment programs that are oriented to abstinence only and do not utilize or understand opioid substitution therapy should be avoided. In addition, prenatal care should be arranged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1519984\">",
"    <span class=\"h1\">",
"     BUPRENORPHINE OR METHADONE?",
"    </span>",
"    &nbsp;&mdash;&nbsp;For several decades,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    was the standard treatment for opioid dependence during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/2\">",
"     2",
"    </a>",
"    ]. In 2008, a consensus panel from the United States Substance Abuse and Mental Health Services Administration (SAMHSA) concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    may be a good option for women who cannot tolerate methadone, women whose compliance with methadone has been difficult, and women who are adamant about avoiding methadone [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/2\">",
"     2",
"    </a>",
"    ]. Additional studies have been published since this statement and, based on these additional data, in 2012, the American College of Obstetricians and Gynecologists (ACOG) concluded that the available evidence &ldquo;supports the use of buprenorphine as a potential first-line medication for pregnant opioid-dependent women who are new to treatment&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/1\">",
"     1",
"    </a>",
"    ]. Currently, programs treating opioid-dependent pregnant women in the United States use either methadone or buprenorphine as first-line therapy.",
"   </p>",
"   <p>",
"    For pregnant women who are identified as appropriate candidates for opioid substitution therapy, our preference is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    therapy because more data are available supporting its safety and efficacy than for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    . However, we consider the following factors (in order of priority) when counseling women about their options:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Program availability",
"      </strong>",
"      . A list of local treatment programs can be found online",
"      <span class=\"nowrap\">",
"       (file://findtreatment.samhsa.gov/TreatmentLocator/faces/quickSearch.jspx)",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       Availability of comprehensive treatment",
"      </strong>",
"      . For most women, we prefer substance use disorders treatment programs that offer all of the following at a single site: opioid-substitution therapy, psychiatry and social worker services, individual and group counseling, and case management. Clinicians prescribing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      in office-based settings are required to have the capacity to refer the patient for counseling, but not required to provide counseling on-site.",
"     </li>",
"     <li>",
"      <strong>",
"       Patient preference",
"      </strong>",
"      .",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       Buprenorphine",
"      </a>",
"      provided in an office-based setting allows some privacy since patients do not have to attend a clinic daily for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      treatment. The patient receives a prescription for buprenorphine for up to 30 days at a time, fills the prescription at a pharmacy, and takes the medication as prescribed on her own. However, lack of frequent clinical contact may make office-based treatments less suitable for some opioid-dependent women. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    may pose a lower risk of overdose mortality than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    because of the &ldquo;ceiling effect&rdquo; (see",
"    <a class=\"local\" href=\"#H16284340\">",
"     'Pharmacology'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The overall pros and cons of buprenorphine substitution therapy are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef87713 \" href=\"UTD.htm?3/20/3405\">",
"     table 2",
"    </a>",
"    ). Ultimately, the best treatment option is the one which maximizes retention in treatment and prenatal care, and minimizes recidivism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1520638\">",
"    <span class=\"h2\">",
"     Comparative outcome data",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1519999\">",
"    <span class=\"h3\">",
"     Neonatal abstinence syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interest in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    as an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    stems from observational data showing a lower rate of neonatal withdrawal (neonatal abstinence syndrome [NAS]), which has been confirmed in over 15 cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/5\">",
"     5",
"    </a>",
"    ]. This has been attributed to its lower bioavailability, lower transplacental passage, and greater affinity to binding to the mu-opioid receptor but with less intrinsic activity than methadone [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a 2008 Cochrane systematic review including two randomized trials with a total of 34 women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/8,9\">",
"     8,9",
"    </a>",
"    ] did not find significant differences in neonatal outcomes between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    substitution, the small sample size prevented a definitive conclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequently, a randomized trial including 175 pregnant women with opioid dependency compared treatment with",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/methadone-drug-information?source=see_link\">",
"    </a>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    at eight international sites [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/11\">",
"     11",
"    </a>",
"    ]. Compared with methadone, buprenorphine therapy resulted in significantly lower doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    for treatment of NAS (mean total 1.1 versus 10.4 mg), shorter duration of treatment for NAS (4.1 versus 9.9 days), and shorter neonatal hospital stay (10.0 versus 17.5 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/11\">",
"     11",
"    </a>",
"    ]. However, there were several limitations to this trial [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/12\">",
"     12",
"    </a>",
"    ], including a statistically non-significant but markedly higher attrition rate from the buprenorphine treatment arm than from the methadone arm (33 versus 18 percent), which may have been due to the buprenorphine dosing protocol. The usual maximum dose of sublingual buprenorphine (32 mg daily) may not have been sufficient to prevent symptoms of withdrawal in some pregnant women (usually those requiring &gt;140 mg methadone daily). A subsequent analysis of data from neonates in this study showed that infants exposed to buprenorphine in-utero showed fewer stress abstinence signs, were less excitable and less over-aroused, exhibited less hypertonia, and had better self-regulation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk of NAS should not be the sole factor considered in choosing an appropriate opioid substitution therapy in pregnant women. NAS, when properly identified and managed, has not been associated with long-term harm. All of the pros and cons of each opioid substitution option should be considered. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/57/39833?source=see_link\">",
"     \"Neonatal opioid withdrawal (Neonatal abstinence syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1520507\">",
"    <span class=\"h3\">",
"     Other neonatal outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantification of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    in meconium samples of 10 infants born to buprenorphine-treated women demonstrated that neither cumulative nor total third trimester buprenorphine exposure predicted meconium concentrations or infant outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/14\">",
"     14",
"    </a>",
"    ]. However, there was a possible relationship between meconium buprenorphine concentrations and the onset of NAS.",
"   </p>",
"   <p>",
"    Compared with infants born to non-opioid dependent women, neonates exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    exhibit lower birthweight and smaller head circumference [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Several observational and randomized studies have demonstrated longer gestation, increased birthweight, and larger head circumference in buprenorphine-exposed versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    -exposed pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/5,11\">",
"     5,11",
"    </a>",
"    ]. These are interrelated variables (ie, larger head circumference is the result of later gestational age at birth) and most studies were limited in their ability to control for confounding factors (eg, prior obstetric history, smoking, etc). Other large studies have not consistently confirmed a difference in these outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few long-term neurodevelopmental studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    -exposed fetuses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. The lack of such studies documenting absence of adverse long-term effects should be discussed with women contemplating buprenorphine maintenance therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/1\">",
"     1",
"    </a>",
"    ]. Most of the available data come from small retrospective series lacking comparisons to existing treatments, untreated opioid-dependent women, or normal controls; therefore, the ability to address confounding factors is limited.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study (n = 21 children) reported lower scores on cognitive and language scales at three years of age in children exposed prenatally to maternal illicit",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      use compared with non-exposed controls [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A large longitudinal study, which included 73 children evaluated at 24 months (n = 24",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      exposed, n = 19",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      exposed, n = 30 non-exposed controls) found no differences between groups in neurological development or temperament during the first two years of life [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A small series reported no structural or signal abnormalities on neonatal magnetic resonance imaging (MRI) in seven infants exposed in utero to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      substitution therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A small series reported no abnormalities on electroencephalography (EEG) (n = 9 neonates) or cranial ultrasound (n = 10 neonates) born to addicted women on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      substitution therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Concerns about the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    on the developing visual system have been raised;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    exposure does not appear to confer this risk [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/29/4570?source=see_link&amp;anchor=H21#H21\">",
"     \"Methadone maintenance therapy during pregnancy\", section on 'Other effects on the neonate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1520006\">",
"    <span class=\"h3\">",
"     Maternal treatment retention",
"    </span>",
"    &nbsp;&mdash;&nbsp;An analysis of data from three randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/8,9,11\">",
"     8,9,11",
"    </a>",
"    ] found no difference between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    for maternal retention in treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/7\">",
"     7",
"    </a>",
"    ]. On the other hand, each of the three trials reported lower rates of illicit drug use during pregnancy among participants assigned to methadone. Thus, although use of buprenorphine may lower neonatal resource utilization (eg, days in neonatal intensive care) and cost [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/11\">",
"     11",
"    </a>",
"    ], it may not achieve the primary objective of effective substitution therapy for all women. Of note, in men and non-pregnant women, methadone maintenance is associated with greater treatment retention than buprenorphine substitution therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link&amp;anchor=H267421331#H267421331\">",
"     \"Treatment of opioid abuse and dependence\", section on 'Methadone versus buprenorphine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1520013\">",
"    <span class=\"h2\">",
"     Switching from methadone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the lack of strong evidence to recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    for initial management of pregnant women using opioids, there is no compelling reason to switch women already on methadone to buprenorphine either before or during pregnancy. Transition from methadone to buprenorphine introduces the possibility for destabilization [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/24\">",
"     24",
"    </a>",
"    ]. Transfer from methadone or other long-acting opioids can induce withdrawal and cause transient dysphoria, although transfer from short-acting opioids appears to be safe [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/25\">",
"     25",
"    </a>",
"    ]. We agree with the ACOG recommendation against transitioning women from methadone to buprenorphine during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/1\">",
"     1",
"    </a>",
"    ]. If a woman desires to switch, this should be managed by physicians with appropriate expertise and preferably prior to conception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26359775\">",
"    <span class=\"h2\">",
"     Switching to methadone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no compelling reason to switch women from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    who are stable on treatment and who conceive or are trying to conceive. According to the World Health Organization (WHO) guidelines for pharmacological treatment of opioid dependence, &ldquo;If women are being successfully treated with buprenorphine, then the benefit of staying with a treatment that is working should also be taken into consideration&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/26\">",
"     26",
"    </a>",
"    ]. Continued opioid withdrawal symptoms or opioid",
"    <span class=\"nowrap\">",
"     craving/recidivism",
"    </span>",
"    may suggest a poor response to buprenorphine. In these women, switching from buprenorphine to methadone may be beneficial.",
"   </p>",
"   <p>",
"    One potential reason for switching therapy is if a surgical procedure, such as a cesarean delivery is planned. It is easier to manage acute pain with a woman on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    as compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    since buprenorphine causes almost full blockade of mu-opioid receptors, thus interfering with the action of other opioid analgesics. However, pain can be managed effectively in patients on buprenorphine. (See",
"    <a class=\"local\" href=\"#H16284264\">",
"     'Management of pain during labor, delivery, and postpartum'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16284373\">",
"    <span class=\"h1\">",
"     BUPRENORPHINE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16284340\">",
"    <span class=\"h2\">",
"     Pharmacology",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    acts as a partial agonist at the mu-opioid receptor and has a prolonged duration of action due to its high affinity for the receptor. It is also an antagonist at the kappa opioid receptor. Pharmacological effects are similar to full opioid agonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    ), but with a &ldquo;ceiling effect&rdquo; at high doses across a range of pharmacodynamic measures [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/27\">",
"     27",
"    </a>",
"    ]. This may lower the potential for adverse effects from overdose (eg, respiratory depression), but could also mean that opioid-dependent patients will find buprenorphine less satisfying than full mu agonists, such as methadone [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    suppresses withdrawal for 24 to 48 hours; typical dosing for opioid dependence is every 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/28\">",
"     28",
"    </a>",
"    ]. Administration is sublingual due to significantly greater bioavailability compared with oral administration [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Peak plasma levels occur at approximately 90 minutes, and increase linearly with increasing dose. The drug is highly lipophilic, 96 percent bound to plasma proteins, and metabolized by the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lower maximum plasma",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    concentrations and total 24-hour plasma levels have been demonstrated during pregnancy compared with the postpartum period [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/30\">",
"     30",
"    </a>",
"    ]. In one study, some opioid-dependent women excreted a higher percentage of their daily buprenorphine dose during pregnancy than postpartum, indicating possible enhanced renal elimination antenatally [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/31\">",
"     31",
"    </a>",
"    ]. Most of the study participants were prescribed a higher buprenorphine dose as pregnancy progressed.",
"   </p>",
"   <p>",
"    In vitro assessment of transplacental transfer of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    using dually perfused placental lobules from non-opioid dependent women demonstrated low transfer to the fetal circulation, with a concentration &lt;10 percent of that in the maternal circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/32\">",
"     32",
"    </a>",
"    ]. Significant sequestering of buprenorphine by placental tissue was also reported in this study, along with quantitatively minor (less than 5 percent) placental metabolism.",
"   </p>",
"   <p>",
"    However, in a study of opioid-dependent women receiving maintenance doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    , mean buprenorphine concentration in the fetal circulation was higher: &lt;50 percent of maternal levels [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transplacental transfer and metabolism do not appear to differ significantly in preterm placentas [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16284347\">",
"    <span class=\"h2\">",
"     Safety, side effects, drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because it is a partial agonist at the mu-opioid receptor, initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    may lead to withdrawal symptoms in opioid-dependent patients, particularly if it is given within 6 hours of heroin use or within 24 hours of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    administration (see",
"    <a class=\"local\" href=\"#H16284354\">",
"     'Initiation of buprenorphine and subsequent management'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like other opioids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    may cause respiratory depression, particularly when taken with benzodiazepines or other central nervous system (CNS) depressants. Respiratory depression can be delayed in onset, more prolonged than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    -related respiratory depression, and difficult to reverse with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/36\">",
"     36",
"    </a>",
"    ]. Acute hepatotoxicity has been reported rarely in opioid-dependent patients treated with buprenorphine.",
"   </p>",
"   <p>",
"    Close monitoring is recommended for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    -maintained patients who are started on CYP3A4 inducers (eg, rifampicin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ), as dose increases may be required. In contrast, dose reduction may be required if CYP3A4 inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    , gestodene,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    and some human immunodeficiency virus [HIV] protease inhibitors) are used concomitantly with buprenorphine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5755731\">",
"    <span class=\"h3\">",
"     Risk of congenital anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Animal studies, which assessed the effects of exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    during organogenesis in rats and rabbits, did not demonstrate any embryotoxic or teratogenic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Published data are available on approximately 250 human pregnancies exposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    in the first trimester. The rate of congenital anomalies varied from 0 to 5.9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/5,33,38,39\">",
"     5,33,38,39",
"    </a>",
"    ]. These data, although reassuring, are insufficient to determine whether gestational buprenorphine exposure is associated with an increased risk of congenital anomalies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16284354\">",
"    <span class=\"h2\">",
"     Initiation of buprenorphine and subsequent management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation of opioid-dependent women is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/29/4570?source=see_link&amp;anchor=H4#H4\">",
"     \"Methadone maintenance therapy during pregnancy\", section on 'Initial evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    can only be prescribed by physicians who have undergone appropriate credentialing. A directory of providers licensed to prescribe buprenorphine is available online at",
"    <a class=\"external\" href=\"file://buprenorphine.samhsa.gov/bwns_locator\">",
"     file://buprenorphine.samhsa.gov/bwns_locator",
"    </a>",
"    . It is not a complete listing because physicians can request not to be listed. Initiation of buprenorphine during pregnancy should only be managed by physicians with appropriate certification and experience.",
"   </p>",
"   <p>",
"    There is no consensus on the optimal method of induction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/6,7,24\">",
"     6,7,24",
"    </a>",
"    ]. As discussed above (see",
"    <a class=\"local\" href=\"#H16284347\">",
"     'Safety, side effects, drug interactions'",
"    </a>",
"    above), initiation of buprenorphine may lead to withdrawal symptoms in opioid-dependent patients. To minimize this risk, it should be initiated when a woman begins to show objective, observable signs of moderate withdrawal, usually six hours or longer after the last dose of a short-acting opioid, and potentially longer (24 hours to 48 hours) following the use of long-acting opioids [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/6,24\">",
"     6,24",
"    </a>",
"    ], but before severe withdrawal symptoms occur. Bothersome mild withdrawal symptoms during this time can be treated with a variety of over-the-counter and prescription medications, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    for aches, antacids for indigestion,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    for diarrhea, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    for anxiety and restlessness [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=see_link&amp;anchor=H9#H9\">",
"     \"Opioid withdrawal in the emergency setting\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug dosing is similar to that in nonpregnant women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link&amp;anchor=H17#H17\">",
"     \"Treatment of opioid abuse and dependence\", section on 'Buprenorphine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some authors have suggested that unlike",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    , women maintained on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    typically do not require large dose adjustments during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/6\">",
"     6",
"    </a>",
"    ]. However, data from three randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/8,9,11\">",
"     8,9,11",
"    </a>",
"    ] demonstrated the need for buprenorphine dose adjustments throughout pregnancy; the average increase was 3 mgs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5754600\">",
"    <span class=\"h2\">",
"     Missed doses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women may present to labor and delivery requesting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    because of a &ldquo;lost&rdquo; or &ldquo;stolen&rdquo; dose. We recommend that the management of a missed dose be left to the patient&rsquo;s buprenorphine provider. If the provider cannot be reached and assistance from a physician with experience in this area (eg, psychiatrist) is not available, a careful history should be obtained to look for any suggestion of drug diversion or illicit opioid use. A physical examination should be performed to evaluate for signs of",
"    <span class=\"nowrap\">",
"     intoxication/overdose",
"    </span>",
"    or withdrawal (Clinical Opiate Withdrawal Scale [COWS] score) and urine toxicology should be sent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=see_link&amp;anchor=H4#H4\">",
"     \"Opioid intoxication in adults\", section on 'Clinical features of overdose'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1191?source=see_link&amp;anchor=H3#H3\">",
"     \"Opioid detoxification during treatment for addiction\", section on 'Symptoms of opiate withdrawal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of evidence of opioid intoxication,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    can generally be replaced safely. The woman should only be given a single dose and then referred to her usual buprenorphine provider for further management. A period of brief observation may be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5754806\">",
"    <span class=\"h2\">",
"     Buprenorphine versus buprenorphine plus naloxone",
"    </span>",
"    &nbsp;&mdash;&nbsp;A form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    , the combination of buprenorphine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    in a 4:1 ratio (Suboxone), is not recommended for use during pregnancy due to lack of data on the safety of naloxone alone or naloxone combination products in pregnancy. The naloxone combination product is intended to deter intravenous abuse of the sublingual formulation because crushing and injecting the combination formulation causes withdrawal symptoms, which don&rsquo;t occur when the tablet is taken sublingually [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/1\">",
"     1",
"    </a>",
"    ]. Pregnant patients on the combination of buprenorphine and naloxone (Suboxone) should be switched to buprenorphine alone. However, for the occasional woman who refuses to switch, Suboxone can be continued with appropriate counseling.",
"   </p>",
"   <p>",
"    In the United States,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    tablets were removed from the market in March 2013 and replaced with a sublingual film preparation containing the same drugs; various dose combinations are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5755566\">",
"    <span class=\"h1\">",
"     PREGNANCY MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women should be reassured that they will be treated without prejudice despite a history of opioid-dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. This discussion may reduce negative interactions with providers and improve patient satisfaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16284236\">",
"    <span class=\"h2\">",
"     Antenatal fetal surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are insufficient data on which to base recommendations for antenatal fetal surveillance during initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    or during periods of withdrawal. For women who consistently demonstrate good compliance by negative urine drug screens, routine antenatal fetal surveillance is probably unnecessary. However, for women with evidence of recidivism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    polysubstance abuse, or women who have other indications for fetal surveillance (eg, preeclampsia, fetal growth restriction), weekly or twice weekly testing during the third trimester is reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1522972\">",
"    <span class=\"h3\">",
"     Effect on fetal heart rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioid narcotics, like other central nervous system (CNS) depressants, can affect the fetal heart rate, resulting in decreased variability and fewer accelerations [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/42\">",
"     42",
"    </a>",
"    ]. The effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    on fetal testing are well-established. Methadone results in decreased fetal heart rate reactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/43-45\">",
"     43-45",
"    </a>",
"    ] or increased time to reactivity and increased time to complete the biophysical profile [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/44\">",
"     44",
"    </a>",
"    ]. In contrast, fetuses whose mothers received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    showed increased fetal heart rate variability, more frequent accelerations, and better coupling between accelerations and fetal movement early in gestation (24 to 28 weeks), and longer, more frequent movements later in gestation (32 to 36 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Compared with fetal testing post-methadone dosing, post-buprenorphine dosing nonstress tests are more likely to be reactive (adjusted odds ratio [aOR] 0.13, 95% CI 0.04-0.48) and biophysical profile scores are likely to be higher (8.7 versus 8.2; p&lt;.02) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16284264\">",
"    <span class=\"h2\">",
"     Management of pain during labor, delivery, and postpartum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuraxial",
"    <span class=\"nowrap\">",
"     analgesia/anesthesia",
"    </span>",
"    is a common approach to pain management during labor and delivery in the general obstetric population, and a good option for women taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    . For women taking buprenorphine who decline neuraxial",
"    <span class=\"nowrap\">",
"     analgesia/anesthesia",
"    </span>",
"    intrapartum or who are postpartum, pain management with opioids can be especially challenging. The goal of peripartum pain management is to provide adequate analgesia while avoiding both overmedication and withdrawal. Theoretically, tight binding of buprenorphine to the mu-opioid receptor blocks the analgesic effects of full opioid agonists, so higher doses of opioids might be required. Although acceptable pain control can be achieved in clinical practice without excess CNS or respiratory depression, these patients should be closely monitored because of the risk, though unlikely, of CNS and respiratory depression.",
"   </p>",
"   <p>",
"    There is a tendency for physicians to under-medicate pain with opioid analgesics; this tendency is exaggerated when treating opioid-dependent women [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Undertreatment stems from four common misconceptions [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      &lsquo;Maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      provides analgesia&rsquo; &mdash; Although buprenorphine provides analgesia for four to eight hours, long-term opioid exposure leads to tolerance (increasing amount of drug to achieve the same response) and opioid-induced hyperalgesia (increased sensitivity to pain) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/41,48\">",
"       41,48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      &lsquo;The use of opioids for analgesia may result in relapse&rsquo; &mdash; There is no evidence that exposure to opioid analgesics in the setting of acute pain increases rates of relapse in opioid-dependent women [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      &lsquo;The additive effect of maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      and opioid analgesics results in CNS depression&rsquo; &mdash; The risk of respiratory and CNS depression is only theoretical; tolerance develops to both the analgesic effect and the respiratory and CNS depressive effects.",
"     </li>",
"     <li>",
"      &lsquo;Complaints of pain are drug-seeking behavior&rsquo; &mdash; Patients who report acute pain with objective findings are less likely to be exhibiting drug-seeking behavior.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several other variables complicate pain management in opioid-dependent women. Smoking is common in this population (up to 90 percent) and is associated with increased postoperative narcotic requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/50\">",
"     50",
"    </a>",
"    ]. Psychological conditions, which are prevalent in patients with addiction disorders, independently predict poor pain control [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/48,51,52\">",
"     48,51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1521308\">",
"    <span class=\"h3\">",
"     Labor and delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women admitted in labor should continue to receive their full daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    dose. Likewise, they should be instructed to take their full daily dose of buprenorphine in the morning prior to a scheduled cesarean delivery. Discontinuation can precipitate withdrawal during re-introduction of buprenorphine in patients receiving opioid analgesics for pain control [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    maintenance therapy is usually dosed once daily; women taking divided doses should continue taking their buprenorphine as prescribed. Dosages of buprenorphine and other prescribed opioids should be verified when possible; however, when dose verification is not possible, such as in an emergency, the reported daily opioid dose can be given in two to four divided doses while monitoring for sedation and respiratory depression [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/41\">",
"     41",
"    </a>",
"    ]. This approach may also be useful when there is concern about whether the woman is taking her prescribed dosage in full [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial evaluation of any opioid-dependent patient on the labor and delivery unit should include a medication history; inquiry about continued illicit substance abuse, alcohol, and smoking; urine toxicology; and human immunodeficiency virus (HIV) testing (when indicated based on prior testing, area prevalence, and risk factors).",
"   </p>",
"   <p>",
"    Neuraxial",
"    <span class=\"nowrap\">",
"     analgesia/anesthesia",
"    </span>",
"    is a good option for pain management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38633?source=see_link&amp;anchor=H18#H18\">",
"     \"Pharmacologic management of pain during labor and delivery\", section on 'Neuraxial analgesia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of neuraxial analgesia, narcotics, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , can be used safely in early labor. We give 6 to 10 mg of morphine intravenously (IV) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    25 mg IV for painful contractions to women who are dilated less than 6 cm. Alternatively, patient controlled analgesia (PCA) can be used. Opioid antagonists or agonist-antagonists can precipitate acute withdrawal and should be avoided [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/51,54\">",
"     51,54",
"    </a>",
"    ]. Examples of these drugs are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/45/14038?source=see_link\">",
"     nalbuphine",
"    </a>",
"    hydrochloride,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/48/29446?source=see_link\">",
"     pentazocine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9543?source=see_link\">",
"     butorphanol",
"    </a>",
"    tartrate, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"     naloxone",
"    </a>",
"    . If any of these drugs are given inadvertently, withdrawal can be reversed with any full opioid agonist [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute intrapartum pain should not be treated with additional doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    . Likewise, we recommend not using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    for acute pain management, especially in women maintained on buprenorphine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1521336\">",
"    <span class=\"h3\">",
"     Postpartum",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    dose was increased during pregnancy, the need to continue on this increased dosage should be assessed postpartum.",
"   </p>",
"   <p>",
"    No randomized trials of pain management in opioid-addicted women or women maintained on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    have been performed. Current protocols are supported by the results of small series [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/53,55-57\">",
"     53,55-57",
"    </a>",
"    ] and expert opinion [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/40,41,48,51\">",
"     40,41,48,51",
"    </a>",
"    ]. Results are very similar to those observed in women maintained on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/52,54\">",
"     52,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goal of postpartum pain control is subjective pain relief without excessive side effects. Women should be informed that while individual experience varies, antenatal opioid use may interfere with postpartum pain control and increase postpartum opioid requirements, particularly after cesarean delivery. Opioid requirements may be 30 to 100 percent higher than those in opioid-na&iuml;ve patients; sometimes even greater increases are required [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/51,55\">",
"     51,55",
"    </a>",
"    ]. Significant inter-patient variability in opioid dose requirements makes it impossible to precisely predict the opioid dose necessary to control postpartum pain [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/41,51\">",
"     41,51",
"    </a>",
"    ]. The additional difficulty of continued illicit substance abuse may prevent providers from having a full appreciation of a woman&rsquo;s total opioid dose [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Double concentration PCA for 24 hours postpartum is the standard at some institutions. Concerns that opioid-dependent women may self-administer excessive amounts of opioids are unfounded [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/40,41,51\">",
"     40,41,51",
"    </a>",
"    ]. However, scheduled administration of analgesics, especially non-narcotic analgesics, may reduce narcotic requirements and improve pain control compared to &lsquo;as needed&rsquo; dosing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nonopioid analgesics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/62/35808?source=see_link\">",
"     ketorolac",
"    </a>",
"    ) may be adequate for routine postpartum pain after a vaginal delivery, but opioid analgesia should be made available, if required [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/52,56,57\">",
"     52,56,57",
"    </a>",
"    ]. Our patients have had good results with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    . We prefer giving opioids without acetaminophen since the opioid dose required often exceeds the safe upper limit for acetaminophen in combined preparations. Non-pharmacologic measures (application of heat and cold, massage, etc) and non-opioid analgesics should also be used. Use of ketorolac (15 to 30 mg intravenously) or other nonsteroidal antiinflammatory drugs (NSAIDs) may decrease opioid requirements. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=see_link&amp;anchor=H17#H17\">",
"     \"Management of postoperative pain\", section on 'Ketorolac'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As discussed above, postpartum pain should not be treated with additional doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    . Likewise, we recommend not using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"     methadone",
"    </a>",
"    for acute pain management, especially in women maintained on buprenorphine.",
"   </p>",
"   <p>",
"    A detailed list of pain management options is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef87721 \" href=\"UTD.htm?25/53/26460\">",
"     table 3",
"    </a>",
"    ). Some examples of drugs and doses are illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Post vaginal birth:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      500",
"      <span class=\"nowrap\">",
"       mg/",
"       <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"        oxycodone",
"       </a>",
"      </span>",
"      5 mg every 4 to 6 hours (moderate to severe pain) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      400 to 600 mg (mild to moderate pain), as needed for pain relief [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/56\">",
"       56",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Post cesarean delivery: acetaminophen 325",
"      <span class=\"nowrap\">",
"       mg/oxycodone",
"      </span>",
"      5 mg (two tablets) and ibuprofen 400 mg every 4 hours for 48 hours plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      2 to 5 mg every 2 hours, as needed for breakthrough pain [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A retrospective study using data collected as part of the Maternal Opioid Treatment: Human Experimental Research (MOTHER) trial analyzed 37 women with 40 deliveries (19 with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      , 21 with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/52\">",
"       52",
"      </a>",
"      ]. On the first postpartum day after vaginal delivery, the ranges for cumulative daily analgesia doses in the opioid substitution group were:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      (385 to 1000 mg),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      (25 to 50 mg); no patient required opioids. After cesarean delivery, these ranges were: acetaminophen (385 to 2000 mg), diclofenac (25 to 150 mg), and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"       tramadol",
"      </a>",
"      hydrochloride (50 mg).",
"      <br/>",
"      <br/>",
"      There were no differences in pain management between the two opioid substitution groups. Additionally, no differences were seen between the opioid substitution group and non-opioid dependent controls, although following cesarean delivery, the opioid substitution group required more frequent and higher doses of opioids.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1521022\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     Buprenorphine",
"    </a>",
"    does not interfere with regional or local anesthetics. Sedatives, tranquilizers, opioids (including intrathecal), and general anesthetics should be administered cautiously since these drugs can potentiate the CNS depressant and analgesic effects of buprenorphine. Buprenorphine is primarily metabolized by the liver, so severe hepatic dysfunction is a contraindication to buprenorphine use. Lesser degrees of hepatic dysfunction may impair buprenorphine metabolism; in these women, a reduction in dose or the frequency of administration may be necessary. In women with a history of hepatitis, liver enzymes should be monitored because buprenorphine can cause significant elevations in aspartate aminotransferase and alanine aminotransferase [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authors suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    doses do not need to be adjusted in patients with renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/58,59\">",
"     58,59",
"    </a>",
"    ], however, manufacturers suggest caution when dosing patients with severe renal failure (CrCl &lt;30",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    or slow titration of doses until dose stabilization [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/35,60,61\">",
"     35,60,61",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16284280\">",
"    <span class=\"h1\">",
"     BREASTFEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several guidelines from national organizations have considered use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"     buprenorphine",
"    </a>",
"    compatible with breastfeeding as levels of buprenorphine in breast milk are low [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/1,62-64\">",
"     1,62-64",
"    </a>",
"    ]. Furthermore, the drug&rsquo;s poor bioavailability when taken orally means it is unlikely that significant absorption will occur from intake of breast milk. However, breastfed infants should be monitored for sedation, appropriate feeding, and attainment of developmental milestones, especially in younger, exclusively breastfed infants [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/64\">",
"     64",
"    </a>",
"    ]. A single case of infant withdrawal symptoms after sudden cessation of breastfeeding has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?5/45/5850/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1522691\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnant women with substance dependence (",
"      <a class=\"graphic graphic_table graphicRef50295 \" href=\"UTD.htm?11/26/11692\">",
"       table 1",
"      </a>",
"      ) are candidates for opioid substitution therapy. (See",
"      <a class=\"local\" href=\"#H16284333\">",
"       'Candidates for opioid-substitution therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       Methadone",
"      </a>",
"      remains the standard treatment for opioid dependence during pregnancy. We prefer methadone to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      because of the lack of data on pregnancy outcomes after first trimester buprenorphine exposure, along with the paucity of information on long-term neurodevelopmental outcomes after in utero exposure. The available evidence supports the use of buprenorphine as an alternative treatment and some organizations are advocating that buprenorphine be used as a potential first-line medication for pregnant opioid-dependent women who are new to treatment. Factors to consider in making this choice include program availability, availability of comprehensive obstetrical and substance abuse care, and patient preference. (See",
"      <a class=\"local\" href=\"#H1519984\">",
"       'Buprenorphine or methadone?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Neonatal withdrawal syndrome appears to be less severe with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      substitution than with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      maintenance therapy. (See",
"      <a class=\"local\" href=\"#H1519999\">",
"       'Neonatal abstinence syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maternal treatment retention appears to be greater with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       methadone",
"      </a>",
"      than with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H1520006\">",
"       'Maternal treatment retention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       Buprenorphine",
"      </a>",
"      can only be prescribed by physicians who have undergone appropriate credentialing. (See",
"      <a class=\"local\" href=\"#H16284354\">",
"       'Initiation of buprenorphine and subsequent management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To minimize the risk of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      -induced withdrawal symptoms, it should only be initiated when a woman shows objective, observable signs of moderate opioid withdrawal, usually 6 hours or longer after the last dose of a short-acting opioid, and potentially longer (24 to 48 hours) following the use of long-acting opioids. (See",
"      <a class=\"local\" href=\"#H16284354\">",
"       'Initiation of buprenorphine and subsequent management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drug dosing for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      is similar to that in nonpregnant women. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=see_link&amp;anchor=H17#H17\">",
"       \"Treatment of opioid abuse and dependence\", section on 'Buprenorphine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35207?source=see_link\">",
"       naloxone",
"      </a>",
"      (Suboxone) is not recommended for use during pregnancy due to safety reasons. (See",
"      <a class=\"local\" href=\"#H5754806\">",
"       'Buprenorphine versus buprenorphine plus naloxone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who consistently demonstrate good compliance with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      therapy, routine antenatal fetal surveillance is probably unnecessary. However, for women with evidence of recidivism",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      polysubstance abuse, or women who have other indications for fetal surveillance (eg, preeclampsia, fetal growth restriction), weekly or twice weekly testing during the third trimester is reasonable. (See",
"      <a class=\"local\" href=\"#H16284236\">",
"       'Antenatal fetal surveillance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Usual",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       buprenorphine",
"      </a>",
"      dosing should be maintained intrapartum and postpartum. (See",
"      <a class=\"local\" href=\"#H16284264\">",
"       'Management of pain during labor, delivery, and postpartum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of peripartum pain management is to provide adequate analgesia while avoiding both overmedication and withdrawal. (See",
"      <a class=\"local\" href=\"#H16284264\">",
"       'Management of pain during labor, delivery, and postpartum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Opioids, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      , can be used safely in early labor and postpartum. Higher doses may be required to achieve good pain control. Opioid antagonists or agonist-antagonists can precipitate acute withdrawal and should be avoided. (See",
"      <a class=\"local\" href=\"#H1521308\">",
"       'Labor and delivery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1521336\">",
"       'Postpartum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pain control, we suggest opioids without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      rather than combined preparations (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The opioid dose required for pain control often exceeds the safe upper limit for acetaminophen in combined preparations. (See",
"      <a class=\"local\" href=\"#H1521336\">",
"       'Postpartum'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/53/41816?source=see_link\">",
"       Buprenorphine",
"      </a>",
"      use is acceptable in nursing mothers. (See",
"      <a class=\"local\" href=\"#H16284280\">",
"       'Breastfeeding'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/1\">",
"      ACOG Committee on Health Care for Underserved Women, American Society of Addiction Medicine. ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012; 119:1070.",
"     </a>",
"    </li>",
"    <li>",
"     Center for Substance Abuse Treatment. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Treatment Improvement Protocol (TIP) Series 43. DHHS Publication No. (SMA) 05-4048. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/3\">",
"      Bell JR, Butler B, Lawrance A, et al. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009; 104:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/4\">",
"      Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs buprenorphine in France. JAMA 2001; 285:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/5\">",
"      Kakko J, Heilig M, Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008; 96:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/6\">",
"      Young JL, Martin PR. Treatment of opioid dependence in the setting of pregnancy. Psychiatr Clin North Am 2012; 35:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/7\">",
"      Jones HE, Heil SH, Baewert A, et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction 2012; 107 Suppl 1:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/8\">",
"      Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/9\">",
"      Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006; 101:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/10\">",
"      Minozzi S, Amato L, Vecchi S, Davoli M. Maintenance agonist treatments for opiate dependent pregnant women. Cochrane Database Syst Rev 2008; :CD006318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/11\">",
"      Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010; 363:2320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/12\">",
"      Newman RG, Gevertz SG. Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy. J Addict Dis 2011; 30:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/13\">",
"      Coyle MG, Salisbury AL, Lester BM, et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction 2012; 107 Suppl 1:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/14\">",
"      Kacinko SL, Jones HE, Johnson RE, et al. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther 2008; 84:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/15\">",
"      Hytinantti T, Kahila H, Renlund M, et al. Neonatal outcome of 58 infants exposed to maternal buprenorphine in utero. Acta Paediatr 2008; 97:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/16\">",
"      Kahila H, Saisto T, Kivitie-Kallio S, et al. A prospective study on buprenorphine use during pregnancy: effects on maternal and neonatal outcome. Acta Obstet Gynecol Scand 2007; 86:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/17\">",
"      Lejeune C, Simmat-Durand L, Gourarier L, et al. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend 2006; 82:250.",
"     </a>",
"    </li>",
"    <li>",
"     Whitham J, Prenatal exposure to buprenorphine or methadone 2012.",
"    </li>",
"    <li>",
"     Salo S., Kivist&ouml; K., Korja R., Biringen Z., Tupola S., Kahila H., Kivitie-Kallio S. Emotional Availability, Parental Self-Efficacy Beliefs, and Child Development in Caregiver-Child Relationships with Buprenorphine-Exposed 3-year-olds. Parent Sci Pract 2009; 9:244.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/20\">",
"      Kahila H, Kivitie-Kallio S, Halmesm&auml;ki E, et al. Brain magnetic resonance imaging of infants exposed prenatally to buprenorphine. Acta Radiol 2007; 48:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/21\">",
"      Kayemba-Kay's S, Laclyde JP. Buprenorphine withdrawal syndrome in newborns: a report of 13 cases. Addiction 2003; 98:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/22\">",
"      Whitham JN, Spurrier NJ, Sawyer MG, et al. The effects of prenatal exposure to buprenorphine or methadone on infant visual evoked potentials. Neurotoxicol Teratol 2010; 32:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/23\">",
"      Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008; :CD002207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/24\">",
"      Jones HE, Martin PR, Heil SH, et al. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat 2008; 35:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/25\">",
"      Jones HE, Johnson RE, Jasinski DR, Milio L. Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone. Drug Alcohol Depend 2005; 78:33.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/27\">",
"      Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994; 55:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/28\">",
"      Bullingham RE, McQuay HJ, Porter EJ, et al. Sublingual buprenorphine used postoperatively: ten hour plasma drug concentration analysis. Br J Clin Pharmacol 1982; 13:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/29\">",
"      Kuhlman JJ Jr, Lalani S, Magluilo J Jr, et al. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 1996; 20:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/30\">",
"      Concheiro M, Jones HE, Johnson RE, et al. Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women. Ther Drug Monit 2011; 33:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/31\">",
"      Kacinko SL, Jones HE, Johnson RE, et al. Urinary excretion of buprenorphine, norbuprenorphine, buprenorphine-glucuronide, and norbuprenorphine-glucuronide in pregnant women receiving buprenorphine maintenance treatment. Clin Chem 2009; 55:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/32\">",
"      Nanovskaya T, Deshmukh S, Brooks M, Ahmed MS. Transplacental transfer and metabolism of buprenorphine. J Pharmacol Exp Ther 2002; 300:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/33\">",
"      Bartu AE, Ilett KF, Hackett LP, et al. Buprenorphine exposure in infants of opioid-dependent mothers at birth. Aust N Z J Obstet Gynaecol 2012; 52:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/34\">",
"      Fokina VM, Patrikeeva SL, Zharikova OL, et al. Transplacental transfer and metabolism of buprenorphine in preterm human placenta. Am J Perinatol 2011; 28:25.",
"     </a>",
"    </li>",
"    <li>",
"     RB Pharmaceuticals Limited. Summary of Product Characteristics- Subutex 0.4 mg, 2 mg and 8 mg Sublingual Tablets. www.medicines.ie. (Accessed on January 07, 2013).",
"    </li>",
"    <li>",
"     Martindale: The Complete Drug Reference. [Online] London: Pharmaceutical Press. file://www.medicinescomplete.com.proxy.library.rcsi.ie/ (Accessed on December 11, 2012).",
"    </li>",
"    <li>",
"     Reckitt Benckiser Pharmaceuticals Inc. Prescription Drug Label- BUPRENEX (buprenorphine hydrochloride): Daily Med. file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b086772e-d15a-4d13-b1a2-38bfbde1f18c. (Accessed on February 23, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/38\">",
"      Welle-Strand GK, Skurtveit S, Jones HE, et al. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009. Drug Alcohol Depend 2013; 127:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/39\">",
"      Lacroix I, Berrebi A, Garipuy D, et al. Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study. Eur J Clin Pharmacol 2011; 67:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/40\">",
"      Mehta V, Langford RM. Acute pain management for opioid dependent patients. Anaesthesia 2006; 61:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/41\">",
"      Huxtable CA, Roberts LJ, Somogyi AA, MacIntyre PE. Acute pain management in opioid-tolerant patients: a growing challenge. Anaesth Intensive Care 2011; 39:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/42\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 106: Intrapartum fetal heart rate monitoring: nomenclature, interpretation, and general management principles. Obstet Gynecol 2009; 114:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/43\">",
"      Archie CL, Lee MI, Sokol RJ, Norman G. The effects of methadone treatment on the reactivity of the nonstress test. Obstet Gynecol 1989; 74:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/44\">",
"      Cejtin HE, Mills A, Swift EL. Effect of methadone on the biophysical profile. J Reprod Med 1996; 41:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/45\">",
"      Levine AB, Rebarber A. Methadone maintenance treatment and the nonstress test. J Perinatol 1995; 15:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/46\">",
"      Jansson LM, Dipietro JA, Velez M, et al. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicol Teratol 2011; 33:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/47\">",
"      Salisbury AL, Coyle MG, O'Grady KE, et al. Fetal assessment before and after dosing with buprenorphine or methadone. Addiction 2012; 107 Suppl 1:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/48\">",
"      Carroll IR, Angst MS, Clark JD. Management of perioperative pain in patients chronically consuming opioids. Reg Anesth Pain Med 2004; 29:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/49\">",
"      Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med 2006; 144:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/50\">",
"      Creekmore FM, Lugo RA, Weiland KJ. Postoperative opiate analgesia requirements of smokers and nonsmokers. Ann Pharmacother 2004; 38:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/51\">",
"      Mitra S, Sinatra RS. Perioperative management of acute pain in the opioid-dependent patient. Anesthesiology 2004; 101:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/52\">",
"      H&ouml;flich AS, Langer M, Jagsch R, et al. Peripartum pain management in opioid dependent women. Eur J Pain 2012; 16:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/53\">",
"      Kornfeld H, Manfredi L. Effectiveness of full agonist opioids in patients stabilized on buprenorphine undergoing major surgery: a case series. Am J Ther 2010; 17:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/54\">",
"      Meyer M, Wagner K, Benvenuto A, et al. Intrapartum and postpartum analgesia for women maintained on methadone during pregnancy. Obstet Gynecol 2007; 110:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/55\">",
"      Jones HE, Johnson RE, Milio L. Post-cesarean pain management of patients maintained on methadone or buprenorphine. Am J Addict 2006; 15:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/56\">",
"      Jones HE, O'Grady K, Dahne J, et al. Management of acute postpartum pain in patients maintained on methadone or buprenorphine during pregnancy. Am J Drug Alcohol Abuse 2009; 35:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/57\">",
"      Meyer M, Paranya G, Keefer Norris A, Howard D. Intrapartum and postpartum analgesia for women maintained on buprenorphine during pregnancy. Eur J Pain 2010; 14:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/58\">",
"      Bryson EO, Lipson S, Gevirtz C. Anesthesia for patients on buprenorphine. Anesthesiol Clin 2010; 28:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/59\">",
"      Gevirtz C, Frost EA, Bryson EO. Perioperative implications of buprenorphine maintenance treatment for opioid addiction. Int Anesthesiol Clin 2011; 49:147.",
"     </a>",
"    </li>",
"    <li>",
"     UK data sheet. file://www.medicines.org.uk/emcmobile/medicine/26614/spc#POSOLOGY. (Accessed on March 04, 2013).",
"    </li>",
"    <li>",
"     Irish data sheet. file://www.medicines.ie/document.aspx?documentId=1658#POSOLOGY. (Accessed on March 04, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/45/5850/abstract/62\">",
"      Wong S, Ordean A, Kahan M, Society of Obstetricians and Gynecologists of Canada. SOGC clinical practice guidelines: Substance use in pregnancy: no. 256, April 2011. Int J Gynaecol Obstet 2011; 114:190.",
"     </a>",
"    </li>",
"    <li>",
"     Center for Substance Abuse Treatment (CSAT). Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. DHHS Publication No. (SMA) 04-3939. Rockville (MD): Substance Abuse and Mental Health Services Administration (SAMHSA), 2004.",
"    </li>",
"    <li>",
"     Lactmed. Buprenorphine: National Library of Medicine. file://toxnet.nlm.nih.gov (Accessed on January 23, 2013).",
"    </li>",
"    <li>",
"     Elladki H, Thill P. Buprenorphine withdrawal in an infant after cessation of breastfeeding: A case report and review of the literature. Pharmacotherapy 2011; 31:435e.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87238 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.137.129.113-48EA216BE4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_45_5850=[""].join("\n");
var outline_f5_45_5850=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1522691\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16284319\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16284333\">",
"      CANDIDATES FOR OPIOID-SUBSTITUTION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1519984\">",
"      BUPRENORPHINE OR METHADONE?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1520638\">",
"      Comparative outcome data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1519999\">",
"      - Neonatal abstinence syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1520507\">",
"      - Other neonatal outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1520006\">",
"      - Maternal treatment retention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1520013\">",
"      Switching from methadone therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26359775\">",
"      Switching to methadone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16284373\">",
"      BUPRENORPHINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16284340\">",
"      Pharmacology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16284347\">",
"      Safety, side effects, drug interactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5755731\">",
"      - Risk of congenital anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16284354\">",
"      Initiation of buprenorphine and subsequent management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5754600\">",
"      Missed doses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5754806\">",
"      Buprenorphine versus buprenorphine plus naloxone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5755566\">",
"      PREGNANCY MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16284236\">",
"      Antenatal fetal surveillance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1522972\">",
"      - Effect on fetal heart rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16284264\">",
"      Management of pain during labor, delivery, and postpartum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1521308\">",
"      - Labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1521336\">",
"      - Postpartum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1521022\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16284280\">",
"      BREASTFEEDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1522691\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/87238\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/87238|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/26/11692\" title=\"table 1\">",
"      Criteria substance dependence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/20/3405\" title=\"table 2\">",
"      Pros and cons of buprenorphine substitution therapy in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/53/26460\" title=\"table 3\">",
"      Pain management strategies for buprenorphine maintained women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/29/4570?source=related_link\">",
"      Methadone maintenance therapy during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/57/39833?source=related_link\">",
"      Neonatal opioid withdrawal (Neonatal abstinence syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1191?source=related_link\">",
"      Opioid detoxification during treatment for addiction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/51/3897?source=related_link\">",
"      Opioid intoxication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/5/28758?source=related_link\">",
"      Opioid withdrawal in the emergency setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=related_link\">",
"      Overview of illicit drug use in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38633?source=related_link\">",
"      Pharmacologic management of pain during labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29514?source=related_link\">",
"      Treatment of opioid abuse and dependence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_45_5851="Rx chancroid";
var content_f5_45_5851=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment options for chancroid*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drugs of choice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azithromycin 1 g oral once",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftriaxone 250 mg IM once",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Alternatives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciprofloxacin&bull; 500 mg oral twice daily for three days",
"        <strong>",
"         OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythromycin&Delta; 500 mg oral four times daily for seven days",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All regimens, especially single-dose ceftriaxone, are less effective in HIV-infected patients.",
"     <br>",
"      &bull; Not recommended in pregnancy.",
"      <br>",
"       &Delta; Erythromycin ethylsuccinate 800 mg may be substituted for erythromycin base 500 mg; erythromycin estolate is contraindicated in pregnancy.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Drugs for sexually transmitted diseases. Treat Guidel Med Lett 2004; 2:67.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_45_5851=[""].join("\n");
var outline_f5_45_5851=null;
var title_f5_45_5852="Temperature and blood gas";
var content_f5_45_5852=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The effect of temperature on blood gas measurements",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Temperature",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        pH",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        PCO2",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"        PO2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &ordm;C",
"       </td>",
"       <td class=\"subtitle2\">",
"        &ordm;F",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td colspan=\"1\">",
"        68",
"       </td>",
"       <td>",
"        7.65",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td colspan=\"1\">",
"        86",
"       </td>",
"       <td>",
"        7.50",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        51",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35",
"       </td>",
"       <td colspan=\"1\">",
"        95",
"       </td>",
"       <td>",
"        7.43",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        36",
"       </td>",
"       <td colspan=\"1\">",
"        97",
"       </td>",
"       <td>",
"        7.41",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        37",
"       </td>",
"       <td colspan=\"1\">",
"        98",
"       </td>",
"       <td>",
"        7.40",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        38",
"       </td>",
"       <td colspan=\"1\">",
"        100",
"       </td>",
"       <td>",
"        7.39",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        85",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td colspan=\"1\">",
"        104",
"       </td>",
"       <td>",
"        7.36",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        97",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Shapiro, Peruzzi, Kozelowski-Templin: Clinical Application of Blood Gases, ed 5. St. Louis, Mosby-Year Book, 1994, p. 128.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_45_5852=[""].join("\n");
var outline_f5_45_5852=null;
var title_f5_45_5853="Agents with systemic toxicity after skin exposure";
var content_f5_45_5853=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F79115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F79115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Agents associated with systemic toxicity following dermal exposure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td>",
"            Organophosphate and carbamate insecticides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nerve agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Local anesthetics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Lidocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Prilocaine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nitrates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Organochlorines",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Lindane",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hydrofluoric acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Heavy metals",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Organic mercury",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Thallium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Arsenic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Camphor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Alkyl halides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Carbon tetrachloride",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Trichloromethane",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Trichloroethylene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Dichloroethane (ethylene chloride)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Vinyl chloride",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td>",
"            Salicylates (eg, methylsalicylate)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ethanol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Isopropanol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Aromatic hydrocarbons",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Hexachlorobenzene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Benzene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Nitrobenzene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Toluene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Xylene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paraquat and diquat",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methyl bromide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Podophyllin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toluidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfides and sulfites",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Silver sulfadiazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfamylon",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cyanide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Formaldehyde",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acrylamide",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            n-Hexane",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_45_5853=[""].join("\n");
var outline_f5_45_5853=null;
var title_f5_45_5854="Contents: Hematologic disease";
var content_f5_45_5854=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?43/6/44141\">",
"       Geriatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Hematologic disease",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Hematologic disease",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         General",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/31/1530\">",
"           An overview of amyloidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/0/22538\">",
"           Anemia in the older adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/14/1258\">",
"           Anticoagulation in older adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/12/3274\">",
"           Approach to the patient with lymphocytosis or lymphocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/59/15290\">",
"           Diagnosis of monoclonal gammopathy of undetermined significance",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hematologic malignancy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/60/4041\">",
"           Clinical course and management of monoclonal gammopathy of undetermined significance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/13/35034\">",
"           Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/61/27610\">",
"           Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/6/24680\">",
"           Epidemiology and clinical manifestations of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/18/15658\">",
"           Initial evaluation and staging of non-Hodgkin lymphoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/12/35017\">",
"           Overview of the complications of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/42/29352\">",
"           Overview of the treatment of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/13/6362\">",
"           Selection of initial therapy for symptomatic or advanced chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/6/15466\">",
"           Staging and prognosis of chronic lymphocytic leukemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/29/29146\">",
"           Treatment of acute myeloid leukemia in older adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Myelodysplastic syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/57/41882\">",
"           Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/26/19880\">",
"           Overview of the treatment of myelodysplastic syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/39/34425\">",
"           Prognosis of the myelodysplastic syndromes in adults",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-03E87F8FA4-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f5_45_5854=[""].join("\n");
var outline_f5_45_5854=null;
var title_f5_45_5855="Digoxin structure";
var content_f5_45_5855=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Structure of digoxin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_45_5855=[""].join("\n");
var outline_f5_45_5855=null;
